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ABSTRACT
The local and systemic immune response to rotavirus was investigated, both
in previously exposed adult sheep and gnotobiotic lambs.
Vaccines were used parenterally to boost the local and systemic humoral
immune response of adult sheep. The response was evaluated by assays for rotavirus
(RV)-specific IgA and IgG antibodies and vims neutralising activity (VNT) in
serum, nasal secretions, and intestinal scrapings. Sheep vaccinated (n=12)
parenterally with a standard rotavirus vaccine (IFA and inactivated rotavirus lysate
(low dose)) showed a significant (p<0.05) increase in RV IgA antibodies in nasal
secretions and intestinal scrapings 2 weeks after vaccination. Sheep vaccinated (n=4)
parenterally with different adjuvants and antigen doses showed both dose-related and
adjuvant-related effects in RV IgG antibodies in serum and nasal secretions 2 weeks
after vaccination. At a low virus dose, ISCOMs and IFA induced a significantly
(p<0.05) higher humoral immune response compared with microspheres, however at
a high dose (inactivated purified virus), ISCOMs and microspheres induced a
significantly (p<0.05) higher humoral immune response compared with IFA. The
immune response after parenteral vaccination is dose- and adjuvant-dependent.
Sheep vaccinated (n=4) orally with live virus, with different adjuvants and
antigen doses showed no significantly increased humoral immune response. No dose
effect or adjuvant effect was observed.
More extensive techniques were used to characterise the primary immune
response in gnotobiotic lambs after infection with a lamb-passaged rotavirus strain
K923. Lambs (n=10) were infected at 6 days of age and killed over a 7 week time
interval together with controls (n=6). RV antibodies and VNT were determined in
serum, nasal secretions, and intestinal scrapings. RV antibody producing cells were
enumerated in blood. Lymphocyte populations in blood and GALT were analysed.
Lymphocyte proliferations were determined in blood and GALT and cytokine
expression was analysed in JPPs and MLNs.
Infected lambs cleared the virus by 8-9 days post-infection without showing
any clinical signs. RV IgA antibody-secreting cells (ASC) in blood and RV IgA
antibodies in serum and nasal secretions were detected from 7 days after infection
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followed at 10 days after infection by RV IgG ASC and antibodies. RV IgA
antibodies dominated after an infection with rotavirus. RV IgA antibodies were not
detected in intestinal scrapings in the first 10 days after infection, however at 52 days
after infection rotavirus-specific IgA antibodies were observed. Lymphocyte
proliferation was seen in JPPs at 52 days after infection. No significant changes were
observed in lymphocyte sub-populations. IFNy transcripts were expressed in JPPs
and MLNs in both groups and infection had no effect on the expression of IFNy. IL-4
transcripts increased with time but the infected group showed a higher expression at
3 and 52 days after infection. The first evidence of an immune response was seen in
the increased level of IL-4 3 days after infection, which preceded the presence of RV
IgA and IgG antibodies in serum and mucosal surfaces. IL-6 transcripts were
expressed and increased with time in the infected groups. No clear evidence for
CD8+ T cell or rotavirus-specific secretory antibody involvement in viral clearance
was found suggesting that other mechanisms may play a role.
Vaccines composed of either rotavirus mixed with ISCOMs or recombinant
VP6 incorporated into ISCOMs were used to examine if one oral dose could induce a
mucosal immune response and protection against subsequent challenge. Gnotobiotic
lambs were vaccinated orally either with PBS/ISC, inactivated rotavirus (IRV)/ISC,
recombinant VP6/ISC, or IRV alone, challenged 3 weeks later with a live lamb-
passaged strain, and killed 8-9 days after challenge. The immune response was
measured as described above. The rotavirus-vaccinated groups had RV IgG ASC and
antibodies in blood from 7 and 11 days respectively. After challenge, rotavirus-
vaccinated groups cleared the virus in a reduced period (7.0 days vs 9.0 days),
however this was only significant (p<0.05) in the IRV/ISC group. RV IgA antibodies
were observed in serum and nasal secretions from 4 days after challenge. In intestinal
scrapings, these were significantly (p<0.05) higher in the IRV/ISC and IRV groups.
RV IgG antibodies were significantly (p<0.05) increased in nasal secretions and
intestinal scrapings in the IRV/ISC and IRV groups. Lymphocytes from JPPs
proliferated significantly against rotavirus in the IRV/ISC and IRV groups. CD45R+
cells were significantly increased in blood in the IRV/ISC group before challenge,
however no differences were found in other lymphocyte sub-populations either in
blood or GALT. A down-regulation of IFNy transcripts was observed in JPPs and
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MLNs in the IRV/ISC group while the VP6/ISC group had a higher expression
compared with the PBS/ISC and IRV groups. IL-4 transcripts were low in MLNs in
all groups but in JPPs the rotavirus-vaccinated groups had a higher expression. IL-6
transcripts in JPPs were higher in the IRV/ISC and VP6/ISC groups but in MLNs all
rotavirus-vaccinated groups had a higher level of expression. One oral dose of
inactivated rotavirus alone, mixed with ISCOMs, or recombinant VP6 incorporated
into ISCOMs can induce priming and partial protection. These results suggest also









TABLE OF CONTENTS viii
CHAPTER 1
INTRODUCTION - REVIEW OF THE LITERATURE
1.1 INTRODUCTION 1
1.2 VIRAL ENTERIC INFECTIONS 2
1.2.1 History 2
1.2.2 Viruses associated with diarrhoeal diseases 3
1.3 ROTAVIRUS 4
1.3.1 Rotavius structure and classification 4
1.3.2 Pathogenicity, pathology, and clinical signs 5
1.3.3 Epidemiology 5
1.4 THE MUCOSAL IMMUNE SYSTEM 6
1.4.1 History 7
1.4.2 Gut-associated lymphoid tissues 8
1.4.2.1 Peyer's patches 9
1.4.2.2 Mesenteric lymph nodes 17
1.4.2.3 Lamina propria 19
1.4.2.4 Intraepithelial lymphocytes 22
1.5 MUCOSAL IMMUNITY TO VIRUSES 23
1.5.1 Cellular antiviral immune mechanims at mucosal surfaces 24
1.5.1.1 Natural killer cells 24
1.5.1.2 Cytotoxic CD8+ T cells 24
1.5.1.3 Helper CD4+ T cells 25
viii
1.5.2 Humoral antiviral immune mechanisms at mucosal surfaces 25
1.5.2.1 Mucosal IgA antibodies 25
1.5.2.2 IgG antibodies 28
1.6 MUCOSAL IMMUNITY TO ROTAVIRUS 28
1.6.1 Cellular antirotavirus immune mechanisms at mucosal surfaces 28
1.6.2 Humoral antirotavirus immune mechanisms at mucosal surfaces 30
1.6.2.1 Monogastrics 30
1.6.2.2 Ruminants 30
1.7 VACCINE STUDIES 31
1.7.1 Oral vaccination 31
1.7.2 Parenteral vaccination 33
1.7.3 Current trends in vaccine development 33
1.7.4 Vaccination against rotavirus 35




2.2 VIRUS, GROWTH, PURIFICATION, INACTIVATION, AND TITRATION 39
2.2.1 Virus 39
2.2.2 Virus growth 39
2.2.3 Virus purification 40
2.2.4 Virus inactivation 40
2.2.5 Virus titration 41
2.3 ANIMALS 42
2.4 SAMPLES 43




2.4.5 Intestinal scrapings 45
IX
2.5 ASSAYS 45
2.5.1 Rotavirus-specific IgA antibody ELISA 45
2.5.2 Total immunoglobulin A ELISA 46
2.5.3 Rotavirus-specific IgG antibody ELISA 47
2.5.4 Total immunoglobulin G ELISA 47
2.5.5 Virus neutralisation assay 47
2.6 VIRAL RNA EXTRACTION AND DETECTION 48
2.7 LYMPHOID TISSUE AND LYMPHOCYTES 48
2.7.1 Collection of gut-associated lymphoid tissues 48
2.7.2 Isolation of lymphocytes 49
2.7.2.1 Peripheral blood lymphocytes 49
2.7.2.2 Mesenteric lymph nodes and Peyer's patches 50
2.7.2.3 Small intestine 50
2.8 LYMPHOCYTE ASSAYS 53
2.8.1 Lymphocyte proliferation assays 53
2.8.2 Immunofluorescent labelling 54
2.8.3 ELISPOT 55
2.9 RNA EXTRACTION, REVERSE TRANSCRIPTASE, POLYMERASE CHAIN
REACTION, AND HYBRIDISATION 57
2.9.1 RNA extraction 57
2.9.2 Reverse transcriptase (RT) 58
2.9.3 Polymerase chain reaction (PCR) 58




STIMULATION OF MUCOSAL ROTAVIRUS-SPECIFIC IMMUNITY IN SHEEP
BY A STANDARD PARENTERAL VACCINATION PROTOCOL
3.1 INTRODUCTION 63
3.2 EXPERIMENTAL DESIGN 64
3.2.1 Animals 64
3.2.2 Vaccines 64
3.2.3 Sample collection 64
3.3 RESULTS 65
x
3.3.1 Standardisation ELISA 65
3.3.2 Antibody responses after parenteral vaccination 67
3.3.2.1 Rotavirus-specific antibodies 67
3.3.2.2 Neutralising titres against rotavirus 73
3.3.2.3 Total immunoglobulin A and G concentrations 73
3.4 DISCUSSION 74
CHAPTER 4
EFFECTS OF DIFFERENT ADJUVANTS AND ANTIGEN DOSES IN
PARENTERAL VACCINES ON ROTAVIRUS-SPECIFIC IMMUNITY IN SHEEP
4.1 INTRODUCTION 78
4.2 EXPERIMENTAL DESIGN 79
4.2.1 Animals 79
4.2.2 Vaccines 79
4.2.3 Sample collection 80
4.3 RESULTS 81
4.3.1 Antibody responses after a low dose of rotavirus antigen 81
4.3.1.1 Rotavirus-specific antibodies 81
4.3.1.2 Neutralising titres against rotavirus 85
4.3.1.3 Total immunoglobulin A and G concentrations 85
4.3.2 Antibody responses after a high dose of rotavirus antigen 87
4.3.2.1 Rotavirus-specific antibodies 87
4.3.2.2 Neutralising titres against rotavirus 91
4.3.2.3 Total immunoglobulin A and G concentrations 91
4.3.2.4 Summarised results of rotavirus-specific antibody responses 93
4.4 DISCUSSION 93
CHAPTER 5
EFFECTS OF DIFFERENT ADJUVANTS AND ANTIGEN DOSES IN ORAL
VACCINES ON ROTAVIRUS-SPECIFIC IMMUNITY IN SHEEP
5.1 INTRODUCTION 97
5.2 EXPERIMENTAL DESIGN 98
5.2.1 Animals 98
5.2.2 Vaccines 98
5.2.3 Sample collection 99
xi
5.3 RESULTS 100
5.3.1 Rotaviras-specific antibodies 100
5.3.2 Neutralising titres against rotavirus 104
5.3.3 Total immunoglobulin A and G concentrations 104
5.4 DISCUSSION 106
CHAPTER 6
CHARACTERISATION OF THE PRIMARY LOCAL AND SYSTEMIC IMMUNE
RESPONSE TO ROTAVIRUS IN GNOTOBIOTIC LAMBS
6.1 INTRODUCTION 110




6.3.1 Viral clearance 112
6.3.2 Rotavirus-specific antibody secreting cells and antibodies 112
6.3.3 Neutralising titres against rotavirus I 18
6.3.4 Total immunoglobulin A and G concentrations 119
6.3.5 Proliferation of lymphocytes in blood and GALT 123
6.3.6 Phenotypic analysis of lymphocytes in blood and GALT 125
6.3.7 Cytokine expression of lymphocytes in JPPs and MLNs 128
6.4 DISCUSSION 131
CHAPTER 7
INDUCTION OF THE MUCOSAL IMMUNE RESPONSE IN GNOTOBIOTIC
LAMBS BY VACCINATION WITH INACTIVATED ROTAVIRUS OR
RECOMBINANT ROTAVIRUS ANTIGENS MIXED WITH OR INCORPORATED
INTO ISCOMS
7.1 INTRODUCTION 141





7.3.1 Response after vaccination 143
xii
7.3.1.1 Rotavirus-specific antibody secreting cells and antibodies 143
7.3.1.2 Total immunoglobulin A and G concentrations 145
7.3.2 Response after challenge 148
7.3.2.1 Viral clearance 148
7.3.2.2 Rotavirus-specific antibody secreting cells and antibodies 149
7.3.2.3 Neutralising titres against rotavirus 155
7.3.2.4 Total immunoglobulin A and G concentrations 155
7.3.2.5 Proliferation of lymphocytes in blood and GALT 159
7.3.2.6 Phenotypic analysis of lymphocytes in blood and GALT 161








INTRODUCTION - REVIEW OF THE LITERATURE
1.1 INTRODUCTION
Diarrhoeal diseases have a world-wide impact on both human and animal
health and are a major cause of morbidity and mortality. Analyses indicate that
diarrhoeal diseases are responsible for a large proportion of the total reported
childhood deaths in developing countries, accounting for as many as 15-34% of all
deaths annually among children younger than 5 years of age in certain countries
(World Health Organization, 1973; Martines et al, 1991). It was estimated that the
annual toll in Asia, Africa, and Latin America was 3-5 billion cases of diarrhoea and
3.0-3.2 million deaths associated with diarrhoea (Bern and Glass, 1994; Glass et al,
1996).
In farm animals, diarrhoeal diseases are responsible for up to 18% of the
deaths in pigs and calves under 3 weeks of age. Economic losses in North America
alone due to neonatal diarrhoea were estimated at $700 million annually in calves
and suckling pigs (Saif, 1990). In Wyoming (North America), diarrhoeal diseases
were responsible for 10-25% of the deaths in shed-lambs under 4 weeks of age (Theil
et al, 1996). On a world-wide basis, this translates into considerable economic losses
in animal production.
Diarrhoea can be caused by many different agents including viruses such as
rotavirus, coronavirus, adenovirus, astrovirus, calicivirus, and other small round
structured viruses (Norwalk viruses), bacteria such as Escherichia coli,
Campylobacter jejuni, Vibrio, Yersina, Shigella, and Salmonella species, parasites
like Entamoeba histolytica and Giardia lamblia, and toxins produced by Vibrio,
Escherichia coli, and Shigella species (Bern and Glass, 1994). This thesis will focus
on diarrhoeal diseases caused by viruses and by rotaviruses in particular.
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1.2 VIRAL ENTERIC INFECTIONS
1.2.1 History
The search for important aetiologic agents of severe viral diarrhoea was
unrewarding until the 1970s. This frustration ended in 1972 with the discovery of a
27-nm small round virus (Norwalk virus) and its association with gastroenteritis in
older children and adults followed by the discovery in 1973 of the human 70-nm
rotavirus, and its association with severe diarrhoea in infants and young children
(Kapikian et al, 1972; Bishop et al, 1973; Flewett et al, 1973). It soon became
apparent that the 70-nm particle was an important aetiologic agent of infantile
diarrhoea, causing 35-50% of hospital admissions for this condition during the first
two years of life (Estes et al, 1983; Holmes, 1983; Kapikian et al, 1989). However,
the first work on what was probably rotavirus gastroenteritis was done in 1943.
Filtrates of stools from infants with gastroenteritis produced diarrhoea in newborn
calves (Light and Hodes, 1943; 1949).
Although the human rotaviruses were discovered in 1973, it should be noted
that in 1957 and 1963, virus-like particles were detected in intestinal tissue of mice
infected with epizootic diarrhoea of infant mice (EDIM) (Kraft, 1957; Adams and
Kraft, 1967; Bishop et al, 1973). In the 1960s, what came to be recognised as
rotavirus strains SA-11 (simian agent 11) and O (Offal) were isolated from a rectal
swab from a healthy vervet monkey and from the mixed washings of intestines of
cattle and sheep respectively (Malherbe and Harwin, 1963; Malherbe and Strickland-
Cholmley, 1967; Stuker et al, 1979; 1980). In 1969, 70-nm virus particles were
detected in calves with diarrhoea and this agent could be passaged serially in calves
with the production of disease (Mebus et al, 1969; Woode et al, 1974). In 1971, the
Nebraska calf diarrhoea virus (NCDV) was successfully cultivated in primary bovine
cell cultures (Mebus et al, 1971a,b). NCDV was found to resemble the reoviruses
morphologically but to be distinct antigenically (Fernelius et al, 1972). The murine,
simian, O, and bovine agents were later found to share a group antigen with other
rotaviruses (Lecatsas, 1972; Much and Zajac, 1972; Flewett et al, 1974a,b; Kapikian
et al, 1974).
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Rotaviruses have also been isolated from many other mammalian and avian
species including foals (Flewett et al, 1975), sheep (Snodgrass et al, 1976a,b, 1977),
goats (Scott et al, 1978), rabbits (Bryden et al, 1976), pigs (Lecce et al, 1976), deer
(Tzipori et al, 1976), pronghorn antelopes (Reed et al, 1976), apes (Ashley et al,
1982), impala, Thompson's gazelles, and addax (Eugster et al, 1978), dogs (Eugster
and Sidwa, 1979), kittens (Snodgrass et al, 1979), turkeys (Bergeland et al, 1977),
chickens (Jones et al, 1979), and pigeons (Minamoto et al, 1988).
1.2.2 Viruses associated with diarrhoeal diseases
Rotavirus is the most common endemic agent of severe diarrhoea in children
and young animals world-wide. Virtually all children and animals are infected in the
first 5 years and few weeks of life respectively and repeated infection is common, but
repeated episodes of disease are not. Most rotavirus infections are mild, but one-third
of gastroenteritis hospitalisations world-wide are due to rotavirus and an estimated
870,000 children die from rotavirus diarrhoea each year (Kapikian and Chanock,
1990; Saif et al, 1994).
Enteric adenovirus is also a cause of endemic gastroenteritis in children
younger than 2 years and in young animals. It is detected at a frequency of about
one-quarter to one-third that of rotavirus. In developed countries, enteric adenovirus
is responsible for 4-12% of diarrhoea in hospitalised children and in 2-7% of
hospitalised children in developing countries (Wadell et al, 1994).
Astrovirus and classical calicivirus are endemic agents of gastroenteritis,
infecting every child in the first few years of life and young animals. Both viruses
appear to cause predominantly mild disease in childhood, with detection rates of less
than 5% in inpatient studies. However, immunity to these agents appears to wane
with age and both have been implicated as agents of epidemic gastroenteritis among
the institutionalised elderly (Cubitt, 1994; Kurtz, 1994).
Norwalk virus, a calicivirus, is an epidemic viral agent. In developed
countries, immunity is acquired later in life and outbreaks generally involve older
children and adults. In developing countries, however, it may play a role as a cause
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of endemic childhood diarrhoea, as antibodies are acquired in the first 4 years of life
(Kapikian, 1994).
Coronaviruses are important intestinal pathogens in newborn animals and
mortality is variable between animal species and time of infection. In humans,
coronavirus is as common in healthy children as in children with diarrhoea (Caul,
1994; Pensaert et al, 1994).
1.3 ROTAVIRUS
1.3.1 Rotavirus structure and classification
The rotaviral genome consists of 11 segments of double-stranded RNA
(dsRNA) and is contained within the virus core capsid. These 11 genome segments
encode for structural and non-structural proteins. The structural proteins can be
divided into core and inner capsid proteins viral protein (VP)1, VP2, VP3, and VP6
and outer capsid proteins VP4 and VP7. Rotaviruses comprise seven distinct
(common VP6 protein) serological groups (A-G). Group A rotaviruses have been
clearly established as causing significant diarrhoea in the young. Further serological
sub-classification of group A rotavirus is based on the surface proteins VP4 and VP7.
Rotavirus types based on VP4 have been designated as P types, whereas types based
on VP7 have been referred to as G types. The current serotype classification scheme
distinguishes over 20 different P types and 14 different G types. Some G types are
associated with a certain P type, for example human strains of G 1, 3, and 4
specificity belong to P serotype 1A and those of G 2 specificity belong to P serotype
IB (Estes and Cohen, 1989; Snodgrass et al, 1992; Prem and Lyoo, 1993; Hoshino
and Kapikian, 1994; Midthun and Kapikian, 1996).
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1.3.2 Pathogenicity, pathology, and clinical signs
Rotavirus in the homologous host infects mature small intestinal villous
epithelial cells in mid and upper small intestine. Crypt cells are not infected. The
virus has also been found in goblet cells, epithelial endocrine cells, and macrophages
in the lamina propria (Suzuki and Konno, 1975; Philips, 1981; 1989) but it is a
strictly mucosal infection with no evidence of systemic spread. Rotaviruses
selectively infect mature villous absorptive cells through the binding with specific
receptors on the cell surface. Animal rotaviruses have been shown to bind to sialic
acid-containing compounds but specifically recognise the neutral glycosphingolipid
gangliotetraosylceramide (asiolo-GMl or GA1) (Fukudome et al, 1989; Willoughby
et al., 1990). A previous study has shown that GA1 is not the critical receptor but
that several sialoglycoproteins like sialoglycoprotein glycophorin A also mediate
viral attachment to epithelial cells (Mendez et al, 1993). VP4 has been shown to be
the viral attachment protein (Bass et al, 1991). Rotavirus infections destroy mature
villous absorptive cells, resulting in loss of their normal functions relating to
digestion and absorption. The destroyed mature villous epithelial cells are replaced
by immature squamous to cubical cells lacking a brush border (Saif, 1990). These
cells are not fully functional but they lead to the regeneration of a normal villous
epithelium and the end of the disease.
After an incubation period of 11 -96 hours, dependent on the host species, the
predominant signs of rotavirus infection present as depression, occasional vomiting
in infants and piglets followed shortly by the onset of watery diarrhoea, and
dehydration. Fever is common in the majority of children but not in animals (Flewett,
1982).
1.3.3 Epidemiology
All humans are infected frequently during the entire course of their lives with
their first encounter with rotavirus in the first 5 years of life (Martines et al, 1991). In
a five year study (1990-1994) in England and Wales, 88% of identified rotavirus
infections were in children <5 years old (Ryan et al, 1996).
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Bovine rotaviruses have a world-wide distribution and have been consistently
detected in a high percentage (30-83%) of scouring calves, 1-3 weeks old, on both
beef and dairy farms (Snodgrass et al, 1986; Fijtman et al, 1987; Bellinzoni et al,
1987; 1989).
Porcine rotaviruses are enzootic in pig herds around the world. Antigen
detection methods have indicated that 60% or more of swine herds are infected and
serologically nearly 100% of the swine herds have been infected (Bohl et al, 1978;
Rubenstein and Miller, 1982; Bohl et al, 1984).
Ovine rotaviruses are ubiquitous enteropathogens and persist in the
environment. In a survey in Scotland, ovine rotavirus was detected in 25% of the
diarrhoeic lambs and 56% of neonatal lambs had rotavirus-specific antibodies
(Snodgrass et al, 1977).
Canine rotaviruses have been detected in 2-22% of diarrhoeic dogs and the
percentage of positive serum samples ranged between 42-84% (McNulty et al, 1978;
Hammon and Timoney, 1983; Mochizuli and Ata, 1986).
Equine rotaviruses have been reported all over the world. Rotavirus shedding
has been detected in 11-62% of the foals with diarrhoea (Dwyer et al, 1988;
Browning et al, 1991). In a three year study (1991-1994) in the United Kingdom,
diarrhoea was associated with rotavirus in 17% of all foals (Netherwood et al, 1996).
1.4 THE MUCOSAL IMMUNE SYSTEM
The gastrointestinal, upper respiratory, and urogenital tracts are all lined by
mucosal tissues. The total mucosal surface in humans is an area larger than 400m2
(compared with 1.8m of the skin). This represents the primary site of entry of most
viral, bacterial, parasitic pathogens, and of potentially harmful antigenic substances
from the environment (Brandtzaeg et al, 1989; McGhee and Kiyono, 1993; Shalaby,
1995). Mucosal lymphoid tissues contain more immunocytes such as B and T
lymphocytes, plasma cells, and monocytes/macrophages than any other tissue in
humans and animals (Beagley and Elson, 1992). In humans, the small intestine
contains 1010 plasma cells per meter and makes this organ the richest lymphoid tissue
in the body. The human gastrointestinal tract produces more immunoglobulin (Ig)
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than the bone marrow, spleen, and lymph nodes together (Brandtzaeg et al, 1989;
Childers et al, 1989). The predominant immunoglobulin class (60-100%) produced
in the gastrointestinal tract and in other mucosal tissues is secretory IgA (Tomasi and
Bienenstock, 1968; Brandtzaeg et al, 1989; Childers et al, 1989; Beagley and Elson,
1992; McGhee and Kiyono, 1993).
Environmental antigens are most commonly encountered by either inhalation
or ingestion and are taken up by specialised lymphoreticular tissues in the upper
respiratory (bronchus-associated lymphoid tissues (BALT)) and gastrointestinal tract
(gut-associated lymphoid tissues (GALT)) (Craig and Cebra, 1971; Rudzik et al,
1975; Mestecky, 1987). This thesis will focus on the gut-associated lymphoid tissues
(GALT).
1.4.1 History
The first evidence of a mucosal immune system was reported in rabbits after
oral infection/immunisation with enterobacteriaceae (killed Shiga bacillus). The
experimental animals were protected against fatal dysentery by "coproantibodies"
(local immunity) that seemed to appear independently of serum antibodies (systemic
immunity) and this was of great importance in the general resistance of the animal to
infections originating in the gastrointestinal tract and at other mucosal sites
(Besredka, 1919). In 1922, Davies obtained evidence that specific antibodies could
be found in the faeces of patients suffering from dysentery caused by Bacillus
dysenteriae; he noted that bacterial agglutinins could appear in dysentery stools
earlier than in peripheral blood (Davies, 1922).
In the late 1940s, Burrows and co-workers demonstrated a correlation
between coproantibody and protection against experimental infection with cholera in
guinea pigs. Studies in irradiated animals further highlighted the independent
behaviour of serum and faecal antibodies by demonstrating that the faecal antibody
response to cholera vaccine was inhibited whereas serum antibody levels remained
essentially unchanged (Burrows et al, 1947; Burrows and Havens, 1948; Burrows et
al, 1950a,b).
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The independence of serum and local antibodies in other secretions such as in
saliva and mucus has also been demonstrated (Bull and McKee, 1929; Sugg and
Neill, 1931; Walsh and Cannon, 1936; Fazekas de St. Groth, 1951).
The recognition of the existence of a secretory system at the different
mucosal sites has depended on the recognition of the heterogenecity of antibodies
and the definition of various immunoglobulins. Most important was the discovery of
the yA class of immunoglobulins (antibodies) which is now identified as the
predominant class in secretions (Heremans et al, 1959). The observation that many
different external secretions like saliva, milk, tears, bronchial mucus, and intestinal
mucus contain a marked predominance of yA, now called secretory IgA or slgA
(Chodirker and Tomasi, 1963). This together with the finding of a predominance of
yA-containing plasma cells locally in secretory glands (Tomasi et al, 1965) formed
the basis of the evidence for a more or less distinct immunological system
characteristic of external secretions.
1.4.2 Gut-associated lymphoid tissues
The lymphoid cells in the gut are present in organised lymphoid aggregates
such as Peyer's patches (PP) and mesenteric lymph nodes (MLNs) or in non-
organised elements in the epithelium like intraepithelial lymphocytes (IELs) and
lamina propria lymphocytes (LPLs) (Holmgren et al, 1992; Abreu-Martin and
Targan, 1996).
These lymphoid tissues can be divided into inductive and effector sites.
Inductive sites such as the PP are where immune cells first encounter environmental
antigens and initial B and T cell triggering occurs. After this, both B and T cells
drain via lymphatics to the regional MLNs where further clonal expansion and
differentiation occurs. Then, they are transported through the thoracic duct into the
blood circulation (Holmgren et al, 1992). Many of these cells will return eventually
to the effector sites such as the LP where the terminal differentiation to effector cells
(plasma cells and cytotoxic T-lymphocytes (CTL) etc.) takes place and the




Peyer's patches were first described by Johann Peyer in 1677, and have a
follicular structure. In monogastric animals, PP occur with increased frequency more
distally in the small intestine. There are relatively fewer PP in the distal duodenum
and proximal jejunum, with more and larger PP in the ileum, especially in the
terminal ileum. In humans, there are usually between 20-30 PP in the intestine. They
are oval, usually 1-4 cm long and 1-2 cm wide. They contain an average of 10-60
follicles but have been noted to contain several hundred in the terminal ileum of man.
The size of individual follicles does not vary greatly among species, but the number
of follicles aggregated within each patch increases with the size of the animal. The
mouse for example, has only 4-6 follicles per patch (Carlson and Owen, 1987).
In ruminants, separate jejunal and ileal PP exist (Plate 1.1-1.4). However, the
ileal PP involute at a young age while the jejunal PP persist in adult animals
(Carlens, 1928; Reynolds and Morris, 1983). Jejunal PP have long interfollicular
areas, and their follicles are small and pearshaped compared to the long sac-like
follicles of the ileal PP. Jejunal PP have the same shape as PP from monogastrics but
the ileal PP is constituted by one continuous long PP (Landsverk et al, 1991).
The PP in monogastric animals and the jejunal PP in ruminants are seen as
secondary lymphoid organs, while the ileal PP in ruminants is seen as a primary
lymphoid organ where B cell lymphopoiesis occurs in the early stages of life (Larsen
and Landsverk, 1986; Hein et al, 1989; Landsverk et al, 1991).
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Plate 1.1: The jejunal Peyer's patch obtained from a gnotobiotic lamb 37 days after
infection with rotavirus.
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Plate 1.2: The follicle of a jejunal Peyer's patch (j) (Haematoxylin and eosin
(H&E); X100).
10
Plate 1.3: A portion of the ileal Peyer's patch obtained from a gnotobiotic lamb 37
days after infection with rotavirus.
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Plate 1.4: The ileal Peyer's patch (i) and villous epithelium (v) (H&E; XI00).
The PP follicles can be divided into three distinct regions: the specialised
dome, the B cell zone, and the parafollicular T cell zone.
The dome epithelium consists of a specialised follicle-associated epithelium
(FAE) (Plate 1.5) that has a cell composition distinct from the villous epithelium:
mucus-producing goblet cells are rare, but absorptive cuboidal epithelial cells are
present, as are specialised phagocytic (antigen-sampling) cells called microfold (M)
cells. The proportion of M cells in the FAE ranges from 10% in humans and mice, to
50% in rabbits and 100% in pigs and calves (Siebers and Finlay, 1996). These M
cells are located between the absorptive cells in the follicle-associated epithelium and
migrate from the adjacent crypt epithelium (Keren, 1992). In ruminants, the ileal PP












licle-associated epithelium (f) from the jejunal Peyer's patch obtained
from a gnotobiotic lamb 37 days after infection with rotavirus (H&E; X400).
Morphologically, M cells are characterised by the absence of overlying
mucus, a poorly developed glycocalyx (the surface coat of glycoproteins and
glycolipids), sparse microvilli that are irregular in size, shape, and arrangement, lack
an organised terminal web of microfilaments, and the presence of an invaginated
basolateral membrane containing T lymphocytes, B lymphocytes, macrophages, and
dendritic cells (Neutra et al, 1996). Most M cells lack the long regular microvilli of
the adjacent absorptive cells (Carlson and Owen, 1987; Keren, 1992; Giannasca and
Neutra, 1994).
The structural specialisation of M cells brings the apical and basolateral
membrane to within a few microns and shortens the distance that transcytotic
vesicles must travel to cross the epithelial barrier. Endocytic or phagocytic uptake of
foreign antigens or particles is followed by rapid transcytosis to the intraepithelial
pocket, with little or no retention in M cell lysosomes (Neutra et al, 1996). It is
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thought that endocytosis does not result in significant antigen digestion presumably
due to the lack of fusion with lysosomes (Neutra and Kreahenbuhl, 1992). Recent
studies in rats suggest that some level of processing may be taking place due to the
presence of lysosomal markers on apical vesicles and the expression of major
histocompatibility complex (MHC) class II determinants on endosomal-lysosomal
compartments on the basolateral membrane (Allan et al, 1993). In contrast to
absorptive cells, soluble antigens and even whole viruses (reovirus types 1 and 3,
poliovirus, and rotavirus) and bacteria (Escherichia co/;'-RDEC, Vibrio cholerae,
Shigella, and Salmonella) can pass relatively intact through the M cells (Wolf et al,
1981; Inman and Cantey, 1983; Kohbata et al, 1986; Owen et al, 1986; Dharakul et
al, 1988; Wassef et al, 1989; Sicinski et al, 1990).
The adjacent absorptive epithelial cells synthesise a 60kDa glycoprotein
called secretory component (SC). This is an important molecule that is present on the
basal-lateral surfaces of the absorptive epithelial cells. SC combines through
disulfide bridges with polymeric IgA (plgA) that is secreted by the plasma cells in
the lamina propria and is collected into vesicles, which aggregate at the apical border
of the cell. Polymeric IgA consists of dimers of IgA molecules joined with each other
by the J (joining) chain through disulfide bridges (Mestecky and McGhee, 1987).
These polymeric IgA-SC complexes are then secreted into the intestinal lumen. The J
chain is not essental for IgA transport but is necessary for the stable association of
plgA with SC (Hendrickson et al, 1996). In the intestine, the SC is thought to protect
the plgA from digestive enzymes. M cells do not make SC, nor do they express SC
to bind plgA. As a result, the follicle-associated epithelium does not transport IgA
into the intestinal lumen (Brandtzaeg and Bjerke, 1990). This may be an important
mechanism to facilitate transport of antigens into the dome area of the GALT. Since
secretory IgA is thought to bind to and prevent uptake of luminal antigens, the lack
of such a mechanism over the dome regions should facilitate attachment of antigens
to these sites (Keren, 1992).
Since M cells are clearly responsible for the initial uptake of antigens by the
intestinal lumen, it would be logical to believe that they also present the antigen but
this is likely to be limited to their physical isolation from the majority of the T cells.
However, the adjacent follicle-associated epithelium does express surface MHC class
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II, as does the absorptive villous epithelium (Bjerke and Brandtzaeg, 1988). Thus,
the role of M cells may merely be the initial antigen uptake and transport to the
underlying follicle, or to adjacent B lymphocytes within the epithelium (Jarry et al,
1989). B lymphocytes are known to be capable of antigen processing and
presentation as they bind soluble antigens through their cell-surface immunoglobulin.
They internalise the antigens bound by their surface immunoglobulin receptors and
then display peptide fragments of these antigens as peptide-MHC Class II complexes
on their surface where they can interact with CD4+ T cells. However, the role of B
cells in priming naive T cells in natural immune responses is still unclear (Ashwell,
1988; Kurt-Jones et al, 1988; Panja and Mayer, 1994).
Although M cells are known to be the major antigen-sampling cell of the
intestine, other cells have been implicated in this function as well. One of the more
intriguing candidates is the Paneth cell (Erlandsen and Chase, 1972; Kern et al,
1987). These are poorly characterised cells found in the base of crypts in the small
intestine. Although their location at the base of the crypt does not suggest an
important role in sampling luminal antigens, these cells have phagocytic capabilities
in vivo and in vitro. Further, as with other phagocytic cells they contain lysozyme.
However their role in processing antigens for a mucosal immune response is still
unclear.
After the initial uptake of antigens by M cells, the antigens are transported
into the underlying follicular areas, where antigen-presenting cells (APCs) such as
macrophages and dendritic cells determine which antigens are presented to T and B
lymphocytes. Dendritic cells are not unique in the PP being found in other lymphoid
organs. They are also found in the skin where they are called Langerhans cells. In the
murine PP they are found in the sub-epithelial dome, just beneath the FAE, and
throughout the follicle sparing the germinal centres (Kelsall and Strober, 1996).
Dendritic cells are stellate and irregularly shaped and occur at a frequency of less
than 1%. They are capable of antigen uptake and processing these antigens into
peptides. These peptides are presented with MHC Class I or Class II molecules on
their surface where they can interact with CD8+ and CD4+ T cells respectively
(Steinman and Nussenzwieg, 1980; Mayrhofen et al, 1983; Spalding et al, 1983; Liu
and McPherson, 1994; Panja and Mayer, 1994; Kelsall and Strober, 1996).
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APCs internalise exogenous antigens through phagocytosis. Within the
endosome, proteolysis takes place resulting in antigen fragments. When these antigen
fragments bind with MHC Class II molecules (produced in the Golgi-system) in
multivesicular bodies, they are targeted to the surface to interact with CD4+ T
lymphocytes. Endogenous antigens (e.g., viral proteins) are processed in the
cytoplasm. MHC Class I molecules formed in the endoplasmic reticulum (ER)
associate with cytoplasmic peptides that are carried to the ER by peptide transporters.
These MHC Class I-peptide complexes traffic to the membrane, where they can be
recognised by TcRs on CD8+ T cells. MHC Class I molecules are expressed on
virtually all nucleated cells (Panja and Mayer, 1994).
Macrophages and dendritic cells when stimulated by antigens presented by M
cells produce a T cell-stimulating factor (TSF) or interleukin (IL)-12. IL-12 has a
stimulating effect on natural killer (NK) cells as well as on CD4+ and CD8+ T cells
(Germann and Rude, 1995; Orange and Biron, 1996; Heufler et al, 1996).
The B-cell zone, below the dome, contains germinal centres believed to be
the site where B-cells receive triggering signals from the antigen to develop into IgA
precursors and affinity maturation (Butcher et al, 1982; Weinstein and Cebra, 1991).
The B-cell activation is induced by T helper cells and these T cells express a typical
phenotype CD3+, CD4+, CD5+, and CD8". In mice, based on in vitro work with T cell
clones, these T helper cells can be divided into Thl- and Th2-cells, however these
subsets have never been identified in sheep (Mosmann et al, 1986). Thl - T cells can
produce IL-2, interferon gamma (IFNy), and lymphotoxin (tumor necrosis factor-p)
(TNFp). Th2- T cells can produce IL-4, IL-5, IL-6, and IL-10 (Mosmann et al, 1986;
Mosmann and Coffman, 1989). Thl- T cells provide help for the elimination of
intracellularly infected host cells via activation of macrophages and direct cytolytic
activity through activation of cytotoxic CD8+ T cells. In addition, Thl- T cells
regulate delayed-type hypersensitivity (DTH) responses and downregulate Th2- cell
function. Maximal B cell help is provided by Th2- T cells although Thl - T cells can
also provide helper activity through IL-2. Th2- T cells inhibits Thl-cells through IL-
10 (Mosmann and Moore, 1991; Street and Mosmann, 1991).
Cognate interactions between B cells and T helper cells then leads to
immunoglobulin isotype switching in B cells. Soluble factors do not mediate this
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effect (Kawanishi et al, 1983a; 1983b; 1985). Transforming growth factor-[3 (TGF(3)
is an important cytokine for isotype switching to IgA. TGF(3 enhances the IgA
production by lipopolysaccharide-stimulated murine B lymphocytes (Coffman et al,
1989). TGFP causes a switch in the immunoglobulin heavy-chain-constant region
genes from mainly IgM+ cells to IgA+ cells. IL-2 and/or IL-5 can increase secretion
of IgA, which is important for clonal expansion. IL-2 and IL-5 cause the terminal
differentiation of IgA-committed B cells (Coffman et al, 1989; Sonoda et al, 1989;
Lebman et al, 1990). The IgA enhancing activity of IL-5 is further increased by IL-4
or IL-2 (Lebman et al, 1987; Murray et al, 1987). IL-6 induces levels of IgA two- to
threefold higher than IL-5, suggesting that IL-6 plays an important role in the
terminal differentiation of IgA4" cells and other isotypes. It would appear that both
IL-5 and IL-6 are involved in the regulation of IgA synthesis and the terminal
differentiation of IgA4" B cells. This fit well with the finding that gut epithelial cells
secrete high levels of IL-6 (Beagley et al, 1989; Beagley and Elson, 1992). Thus, the
predominance of IgA in mucosal secretions could be explained by a higher
predominance of Th2-type cells in mucosal sites.
Adjacent to the B-cell zone is the T-cell dependent areas in which both CD4+
T cells and CD8+ T cells can be detected. After antigen presentation in these two
regions B cells undergo partial differentiation and proliferation, followed by
transport to the regional MLNs via lymphatics. More then 95% of lymphocytes that
leave the PP do so via the lymph (Reynolds and Pabst, 1984). While it is believed
that when T cells migrate out of the PP, they are fully differentiated and primed to
perform their regulatory tasks, B cells require further differentiation in the MLNs. It
is believed that up to 20% of PP-derived cells home to mucosal tissue outside the
intestine (Butcher, 1986).
1.4.2.2 Mesenteric lymph nodes
MLNs lie within the mesentery and drain the lymphatics, which originate
from the intestinal mucosa and PP. They are structurally identical to peripheral
lymph nodes, with well-defined thymus-dependent areas (TDA), primary or
secondary follicles, germinal centres, and medullary structures (Plate 1.5).
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Unlike PP (T cells 20-35%; B cells 40-50%), T cells predominate in MLNs
(60-70%; B cells 30-40%), but, similarly to PP, show the same preponderance of
cells with the helper T cell phenotype (60-70% of all T cells). T cells with Fc
receptors for IgA are relatively common and many B cells carry IgA on their surface
(Arnaud-Battandier et al, 1980; Durkin et al, 1981; Stevens et al, 1982; Kraal et al,
1983; Gibson et al, 1984).
The lymphocytes primed in the PP may lodge in the MLNs for a period
before continuing their migration to the different mucosae. In the MLNs, a further
differentiation of mainly B lymphocytes occurs. The MLNs contain helper T cells,
mainly of the Th2-type which can induce terminal differentiation of B cells
previously committed to IgA production following interaction with isotype-specific
PP T cells (Kawanishi et al, 1983a).
After further differentiation in the MLNs, the lymphocytes enter the systemic
circulation via the thoracic duct and preferentially "home" to sites within the
secretory immune system. It is postulated that disseminated lymphocytes possess
surface proteins such as the 04(37 ligand that can act as homing receptor and interact
with adressins (e.g., MAdCAM-1) on endothelial cells in mucosal glandular and
lymphoid tissues (Kagnoff, 1996). Within the intestine, lymphocytes enter the lamina
propria and the inter-epithelial spaces. B and mainly T helper cells migrate to the
lamina propria and suppressor/cytotoxic T cells migrate to the epithelium, where
they are known as intraepithelial lymphocytes (IELs). B cells in the lamina propria
undergo the final differentiation into IgA-secreting plasma cells.
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Plate 1.5: The mesenteric lymph node obtained from a gnotobiotic lamb 37 days after
infection with rotavirus showing a B cell follicle (b), a germinal centre (g), a T cell
area (t), and an afferent lymphatic (a) (H&E; XI00).
1.4.2.3 Lamina propria
The lamina propria (LP) (Plate 1.6) is heavily infiltrated by a wide variety of
lymphoid cells including lymphocytes, plasma cells, macrophages, eosinophils,
basophils and mast cells.
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Plate 1.6: The intestine obtained from gnotobiotic lamb 37 days after infection with
rotavirus showing enterocytes (e), intraepithelial lymphocytes (—»), and the lamina
propria (lp) (H&E; X400).
The LP contains both T and B lymphocytes. The B cell compartment of the
LP in mice, rat, and cattle constitutes 20-40% of all the cells (Lyscom and Brueton,
1982; Tseng, 1982; Nagi and Babiuk, 1987) and comprises small lymphocytes and
terminally differentiated plasma cells, the majority of which are committed to IgA
synthesis. Most IgA antibody commited "conventional" B cells derive from PP
precusors which enter the blood circulation from intestinal lymphatics and relocate in
the LP (Husband and Gowans, 1978). However a small population of B cells arise
from B cell precusors orginating in the peritoneal cavity, the so-called B-l cells
(Kroese et al, 1989; Solvason et al, 1991). B-l cells have a distinctive surface
phenotype (possess the pan-T-cell glycoprotein Ly-1 (CD5 in humans), a unique
anatomical localisation (enrichment in the peritoneal cavity), and an extensive
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capacity for self-renewal compared to "conventional" B cells which are activated in
the PP. They preferentially produce IgM of low affinity and broad specificity for
polysaccharides, lipids, and proteins compared to "conventional" B cells, which
produce IgA of high affinity and narrow specificity. However, TGF(3, IL-4, IL-5, and
IL-10 can activate B1-cells and induce class switching from IgM to IgA. After
invasion of the mucosa by a pathogen they immediately produce low-affinity IgM
and, subsequently, with the help of Th2- cells, generate high affinity IgA (Murakami
and Honjo, 1995).
The LP is the only tissue in which large numbers of plasma cells are present
continuously under normal conditions (Mowat, 1987). IgA plasma cells account for
70-90% of the total with most of the remainder being IgM-producing cells. IgG and
IgE plasma cells are found less often while IgD plasma cells are extremely rare
(Lamm, 1976). Most of the small B lymphocytes are predominantly IgM bearing
cells (sIgM+). Thus, the LP contains not only actively secreting IgA plasma cells, but
also the precursors of these cells.
The significance of the local production of other Ig isotypes is a matter of
some controversy. Polymeric IgM bound to secretory component can be transported
across the epithelium in the same way as IgA, and in individuals with selective IgA
deficiency the mucosa is populated with IgM plasma cells (Hobbs and Hepner,
1968). IgG plasma cells frequently increase in number as a result of intestinal
inflammation.
T lymphocytes constitute 40-60% of the LP population in mice, rats, humans,
and cattle. 60% of these T cells are CD4+ (both Th 1 - and Th2-type), and one third are
CD8+ (Selby et al, 1981; Lyscom and Brueton, 1982; Parrot et al, 1982; Nagi and
Babiuk, 1987; Beagley and Elson, 1992; Staats et al, 1994). Macrophages,
eosinophils, and mucosal mast cells make up approximately 10%, 5%, and 1-3%
respectively of the LP (Bull and Bookman, 1979; Staats et al, 1994).
The LP is a major site of T cell-dependent B cell differentiation. T
lymphocytes in the LP are enriched for Th2- T cells. Thus, the predominance of IgA
plasma cells can be explained by a predominance of the Th2- T cells, which produce
IL-5 and IL-6, relative to Thl- T cells (Taguchi et al, 1990).
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1.4.2.4 Intraepithelial lymphocytes
The epithelium is the layer of the intestine in closest contact with antigen and
might therefore be expected to have a wide range of immune effector cells to deal
with the constant antigenic exposure. The IELs reside within this epithelium (Plate
1.7).
Plate 1.7: The intestine obtained from a gnotobiotic lamb 37 days after infection with
rotavirus showing intraepithelial lymphocytes (—>) (H&E; X400).
IELs in mice, guinea-pigs, cattle, and humans make up approximately 5-20%
of lymphocytes in the normal intestinal epithelium (Arnaud-Battandier et al, 1980;
Selby et al, 1981; 1983; Nagi and Babiuk, 1987; Goodman and Lefrancois, 1988).
80-90% of IELs can be subdivided into two classes based on their T cell receptor
(TcR): those expressing a(3TcRs (known to recognise foreign antigen presented in
the context of class I and II MHC molecules) and those expressing y8 TcRs (shown
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to have cytotoxic activity usually of a non-MHC restricted nature) (Goodman and
Lefrancois, 1988). 80% of IELs bear the CD8 surface marker while 5-15% express
the CD4 surface marker irrespective of their TcR expression in mice and humans
(Goodman and Lefrancois, 1989; Cerf-Bensussan and Guy-Grand, 1991). This is
quite different from the CD4:CD8 ratio found in the LP (Mowat, 1990). In
ruminants, a higher percentage of CD4 CD8" y8+ T cells are present within the
epithelium compared to mice and humans (Clevers et al, 1990; Hein and MacKay,
1991). The precise functions of this cell population are still unclear. IELs participate
in the defense of the epithelium through either cytotoxic activity or the secretion of
lymphokines. In a study in mice, cytotoxic IELs protected the mucosa against
reovirus by eliminating infected epithelial cells through lysis (London et al, 1989).
IELs produce ILNy, TNPa, IL-2, IL-5, and TGL(3 but the role of these cytokines in
the mucosal immune response is still unclear. ILNy could be a cell growth inhibitor
and TNLa could be involved in recruitment and activation of lamina propria
macrophages and neutrophils able to release cytotoxic factors (Cerf-Bensussan and
Guy-Grand, 1991; Lefrancois, 1994).
1.5 MUCOSAL IMMUNITY TO VIRUSES
Mucosal immunity to viruses involves the cellular and humoral immune
system acting to limit the extent of virus replication, to clear virus, and to prevent
reinfection. The secretory IgA system provides the main protection of mucosal
surfaces, however significant contributions are also made by the cellular arm of the
immune system and through diffusion of antiviral IgG antibodies onto mucosal
surfaces (Murphy, 1994).
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1.5.1 Cellular antiviral immune mechanisms at mucosal surfaces
From the cellular immune system natural killer (NK) cells, MHC class I-
restricted cytotoxic CD8+ T cells, and MHC class Il-restricted helper CD4+ T cells
can all act as antiviral effector cells.
1.5.1.1 Natural killer cells
NK cells are a population of T cell-receptor-negative (CD3~) lymphocytes
that spontaneously mediate the lysis of virus-infected cells. Morphologically, they
are similar to large granular lymphocytes. NK cells do not have to recognise special
receptors on the infected cell unlike cytotoxic CD8+ cells.
The important early role of NK cells in limiting the extent of certain mucosal
viral infections was shown in humans with an inherited deficiency in NK cells who
experienced more severe herpesvirus infection then normal individuals (Biron et al,
1988; Abraham and Ogra, 1994).
1.5.1.2 Cytotoxic CD8+ T cells
Cytotoxic CD8+ T cells appear to be the major T cell effector with antiviral
activity (Offit and Dudzik, 1990). Cytotoxic CD8+ T cells recognise a short viral
peptide produced endogenously, together with the MHC class I (32-microglobulin
heterodimer which is expressed on the surface of every infected cell (Madden et al,
1991).
Since viral infection of a cell is generally required for antigen presentation by
the MHC class I (32-microglobulin heterodimer, cytotoxic CD8+ T cells which are
located close to epithelial cells cannot prevent infection but can eliminate cells
already infected or restrict virus replication in infected cells. The net effect is the
prevention of further spread of virus (MacKenzie et al, 1989; Godson et al, 1992).
Cytotoxic CD8+ T cells are most efficient during primary infection when a
sufficient antibody response is still lacking. Immunisation with antigens that induce
predominantly cytotoxic CD8+ T cell activity in the absence of antibody is less
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successful in restricting replication of virus and preventing illness than immunisation
that induces a sustained antibody response (Andrew et al, 1987; Webster et al, 1991).
Cytotoxic CD8+ T cells kill the infected target cells by lysis and two
lymphocytotoxicity mechanisms are involved. The secretory lytic pathway when
pore-forming protein (perforin) and a series of granule serine proteinases
(granzymes) are released into the localised environment of the effector and target
cell, causing lysis of the target cell, but sparing the effector cell. The non-secretory
lytic pathway when apoptosis-inducing cell-surface molecules, such as Fas
molecules, interact with FasL molecules on the effector cell and could crosslink the
intracellular "death domain" of Fas and initiate intracellular signals that culminate in
apoptosis of the target cell (Berke, 1995).
1.5.1.3 Helper CD4+ T cells
Helper T cells provide help to B cells, but in addition may have a direct
antiviral activity cells (Taylor and Askonas, 1986; McDermott et al, 1987). They are
less effective than cytotoxic CD8+ T cells. This is due to the more limiting
distribution of its restricting element, the MHC class II a(3 heterodimer, which is
present predominantly on B cells and antigen presenting cells such as macrophages
and dendritic cells (Taylor and Askonas, 1986; McDermott et al, 1987).
1.5.2 Humoral antiviral immune mechanisms at mucosal surfaces
1.5.2.1 Mucosal IgA antibodies
Although cellular immune mechanisms and passively acquired IgG
antibodies contribute to the mucosal immune response to viruses, the major
mediators of resistance to viral infection on mucosal surfaces are IgA antibodies. IgA
antibodies play a significant role in the clearance of viral infections, modification of
the severity of disease on reinfection, and the prevention of infection on re-exposure
to virus (Murphy, 1994; Maxson et al, 1995). Effector mechanisms of IgA are: 1)
immune exclusion, preventing viral attachment and penetration; 2) intra-epithelial
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cell neutralisation; and 3) excretion of antigens from the lamina propria (Mazanec et
al, 1993).
The major viral antigens that induce a protective antibody response are the
surface glycoproteins of viruses. IgA recognises the same viral antigens as IgG
antibodies. The specificity of the neutralising activity of IgA and IgG antibodies for
antigenically related variant viruses appears to be similar; the mucosal IgA antibody
response possesses similar breadth of specificity as the systemic IgG antibody
response. The main advantage of IgA antibodies in protecting mucosal surfaces
appears to be their ability to be transported selectively across mucosal surfaces, and
not an inherently greater antiviral activity (Renegar and Small, 1991). In contrast to
this, protection of piglets against transmissible gastroenteritis (TGE) virus is more
effective by milk/colostral IgA than IgG (Bohl and Saif, 1975; Saif and Bohl, 1979;
Bohl et al, 1972; Saif et al, 1972).
The mucosal IgA response to viral infections (e.g., Sendai virus) is rapid after
first infection and can be detected as early as day 3 following infection (Blandford
and Heath, 1972). The primary response peaks within 6 weeks and can decrease to a
low often barely detectable level by 3 months. Reinfection results in a secondary
response, indicating immunological memory characterised by a rapid rise in IgA titre
to a higher peak titre and maintenance of detectable levels over a longer period
(Bishop et al, 1990; Coulson et al, 1990; 1992). Frequent reinfection causes an active
mucosal antibody (IgA) response and stimulates memory IgA plasma cells as these
are short-lived.
Evidence for the existence of a common mucosal immune system comes from
the observation lhat immunisation of a mucosal site often leads to detectable immune
responses at distant mucosal sites (Mestecky, 1987). For example, sows first infected
with the respiratory variant of TGEV, porcine respiratory coronavirus (PRCV) which
is antigenically related, are protected against intestinal TGEV (De Diego et al, 1994).
This seeding of distant mucosal sites is likely to be the result of trafficking of locally
stimulated mucosal B lymphocytes to distant sites, where they reside as IgA plasma
cells actively producing antibody or as memory B cells (Rudzik et al, 1975;
Czerkinsky et al, 1987; Mestecky, 1987). Although this common mucosal system
exists, it appears to be relatively inefficient at protecting sites not directly stimulated
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with antigen (Ogra and Karzon, 1969; Nedrud et al, 1987). The local nature of the
mucosal antibody response comes from the finding that the concentration of virus-
specific IgA producing B cells at the site of antigenic stimulation is much higher than
that at more distant sites (Dharakul et al, 1988).
1.5.2.2 IgG antibodies
The majority of IgG antibodies present at mucosal surfaces are derived from
plasma through passive diffusion. IgG antibodies produced by the mucosa also
contribute to the total antiviral activity in mucosal secretions (Ogra et al, 1974).
Further, in IgA-deficient patients, mucosal production and secretion of IgG and IgM
antiviral antibodies can compensate for the deficiency of production and secretion of
IgA antibodies (Ogra et al, 1974).
The activity of IgG antibodies against viruses that replicate at mucosal
surfaces is derived from three different sources: 1) antibodies produced by the host at
the mucosal site (Ogra et al, 1974); 2) maternally derived antibodies through the
feeding of colostrum (Puck et al, 1980; Snodgrass et al, 1980; Reuman et al, 1983;
1987); and 3) passively transferred polyclonal antibodies through the transudation of
serum antibodies (Offit et al, 1986; Besser et al, 1988).
The impact of the IgG antiviral antibodies varies at different mucosal
surfaces. In the lung, serum antibodies can diffuse readily across the alveolar wall
and therefore have an impact against respiratory viruses (Prince et al, 1985).
Diffusion of IgG across the gastrointestinal tract is poorer and the hostile luminal
environment and the dilution effect further limit the effectiveness of antibodies of
this class. The antiviral activity of IgG antibodies in vivo is related to direct
neutralisation of virus infectivity.
Many viruses infect mucosal surfaces in the first few months of life when
maternal IgG antibodies may still be present. These maternal IgG antibodies can
significantly modify the immune response to viruses that replicate at mucosal
surfaces. The magnitude of the mucosal and systemic antibody response to a viral
infection, in the presence of maternal IgG antibodies, can be reduced significantly
despite a high level of virus replication (Kimman et al, 1987). However, a secondary
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IgG response is seen when rechallenged with virus (Reuman et al, 1983). Individuals
in which the IgG response is suppressed by passively derived IgG antibodies still
show a well developed IgA antibody response (Kimman and Westenbrink, 1990).
1.6 MUCOSAL IMMUNITY TO ROTAVIRUS
1.6.1 Cellular antirotavirus immune mechanisms at mucosal surfaces
In monogastric animals, a primary rotavirus infection produces increases in
both rotavirus-specific CD4+ T helper cells (Offit et al, 1992; 1993) and cytotoxic
CD8+ T cells (Offit and Dudzik, 1990). An increase in cytotoxic T cells is also found
after oral infection with vaccinia virus recombinants expressing rotavirus outer
capsid protein VP7 (Offit et al, 1994). Shedding of rotavirus was ablated after
passive transfer of CD8+ lymphocytes to mice with severe combined
immunodeficiency (SCID mice) (Dharakul et al, 1990). Rotavirus-specific cytotoxic
T cells seem to be important in the lysis of rotavirus-infected villous epithelial cells,
restricting rotavirus growth, and in protection against reinfection (Offit and Dudzik,
1989; Offit et al, 1989; Dharakul et al, 1990).
(32-microglobulin knockout mice (deficient in MHC-class I-restricted CD8+ T
cells), either treated with anti-CD8 antibody, or not treated, shed the virus for 1-4
days longer than normal control mice did but they completely resolved the primary
infection and they all were resistant to reinfection. Clearance of rotavirus infection in
these knockout mice correlated with the development of an intestinal rotavirus-
specific IgA response. This suggests that cytotoxic T lymphocytes mediate rotavirus
clearance but are not essential for this function and that they are not necessary for the
development of immunity to rotavirus reinfection.
JhD knockout mice (B-cell-deficient) had similar virus-shedding curves
compared to normal control mice and completely resolved infection. However, when
treated with anti-CD8 antibody they became chronically infected after primary
infection. Upon rechallenge, JhD mice who had cleared the primary infection were
all susceptible to reinfection but shed the virus in smaller quantities and for fewer
days than naive mice. This suggests that B cells also play a role in clearance of
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primary infection but are absolutely necessary for development of immunity against
rotavirus reinfection and that CD8+ T cells can actively mediate almost complete
short-term and partial long-term protection from reinfection (Franco and Greenberg,
1995; Franco et al, 1997a).
fiMT knockout mice (B-cell-deficient) gradually resolved primary infection
and when depleted of CD8+ T cells no difference was observed in viral clearance.
This suggests that other effector mechanisms may operate like cytotoxic CD4+ T
cells or NK cells which play protective roles in other viral infections (Yasukawa and
Zarling, 1984; Karupiah et al, 1990; McNeal et al, 1995).
Mechanisms involving the release of antiviral cytokines such as IFNy and
TNF-a may also play roles in resolution of virus shedding (Ramsay et al, 1993).
Type 1 interferons have been shown to be produced in response to infection with
rotavirus and could mediate the antirotavirus effect (La Bonnardiere et al, 1981;
Lecce et al, 1990). JhD knockout mice become chronically infected when depleted of
CD8+ T cells. When JHD knockout mice are depleted of IFNy they clear the primary
infection like normal control mice. IFNy knockout mice clear primary infection
efficiently but this is delayed when depleted of CD8+ T cells. This suggests the
antirotaviral activity of CD8+ T cells is not dependent on killing of the host-infected
cells by the secretion of IFNy (Franco et al. 1997b). Non-immunological
mechanisms such as depletion of villous epithelial cells susceptible to rotavirus
infection could also play a role in the resolution of viral shedding (McNeal et al,
1995).
A similar picture is seen in ruminants infected orally with rotavirus. The
number of cytotoxic T cells is increased in the epithelium (IEL) and lamina propria
in the mid and lower small intestine (the site of rotavirus infection) (Parsons et al,
1993). In CD8+ T cell-depleted gnotobiotic calves significantly increased levels of
virus excretion were detected and no effect on serum and faecal antibody levels was
seen. In CD4+ T cell-depleted gnotobiotic calves reduced levels of faecal and serum
antibody levels were found and no effect on virus excretion was seen (Oldham et al,
1993).
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1.6.2 Humoral antirotavirus immune mechanisms at mucosal surfaces
1.6.2.1 Monogastrics
In monogastric animals, after a primary rotavirus infection, increased levels
of serum antirotavirus IgM followed by antirotavirus IgA and IgG were found. In the
duodenal fluid, saliva, and faeces a similar picture was seen for secretory IgM and
IgA (Hjelt et al, 1985a; Grimwood et al, 1988; Conner et al, 1991; Coulson et al,
1992). This intestinal antirotavirus IgA is found only when an animal is infected
orally. Because the antirotavirus IgM response is short-lived, serum IgA and IgG are
more sensitive markers of a previous rotavirus infection (Grimwood et al, 1988).
After reinfection, antirotavirus faecal (intestinal) IgA is increased which is a
more reliable marker of reinfection than seroconversion. With frequent reinfection of
rotavirus, an increased faecal IgA antibody level was observed. Frequent reinfection
causes an active mucosal antibody (IgA) response and stimulates memory IgA
plasma cells (Merchant et al, 1991; Coulson et al, 1992; Shaw et al, 1993).
Colostrum derived from women previously exposed to rotavirus showed a
predominant antirotavirus IgA response produced in the breast tissue (Hjelt et al,
1985b; Rahman et al, 1987).
The mechanism of protection by mucosal antibody has not been determined,
but it may not be through classic neutralisation. Passively transferred monoclonal
IgA antibodies (non-neutralising) against the VP6 protein of rotavirus were capable
of preventing primary and resolving chronic murine rotavirus infection. This could
support the hypothesis that a possible mechanism of host defense to rotavirus
infection is the intracellular inactivation of rotavirus by secretory IgA during
transcytosis (Burns et al, 1996).
1.6.2.2 Ruminants
In ruminants a similar picture is seen for both the primary and secondary
response except that IgA persists for a much shorter period (1-3 weeks) in serum
than in faeces and nasal secretions (Vonderfecht and Osburn, 1982; Saif, 1987).
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Colostrum derived from dams previously exposed to rotavirus showed a
predominant antirotavirus IgG which diffused from serum and selectively
concentrated in the mammary gland (Wells et al, 1978; Newby et al, 1982).
1.7 VACCINE STUDIES
Many attempts are being made to vaccinate animals in order to develop
protection against pathogens in the environment. Because mucosal surfaces are the
most frequent portals of entry for common viral, bacterial, and parasitic infectious
diseases, it is therefore clearly important to try to stimulate the mucosal immune
system.
If successfully manipulated, GALT could confer long-term mucosal as well
as systemic immunity against a variety of toxins and pathogens (Holmgren, 1991;
Shalaby, 1995). There are several potential routes of vaccination but this thesis will
focus on the oral and parenteral vaccination routes.
1.7.1 Oral vaccination
Oral vaccines are often more desirable than parenteral types due to their ease
of production and quality control. They are also easier (and safer) to administer to
large numbers of recipients because they do not require medically trained personnel
or sterile supplies, and the protective barrier of the skin will not be breached during
administration (e.g., poliovirus vaccine). With oral vaccination the antigen delivery
can be at the site of natural infection (Holmgren, 1991). However orally administered
vaccines are still limited due to the poor long-term efficacy and the requirement for
multiple doses to stimulate and maintain a mucosal immune response. Furthermore
repeated oral vaccination could induce oral tolerance which could result in a non-
responsiveness of the immune system with a subsequent infection (Mowat, 1994).
There are three general barriers that may influence the effectiveness of oral
vaccination. Firstly, the harsh environment of enzymatic digestion and pH changes
(e.g., gastric acidity) can alter the antigenic structure which could result in markedly
decreased immunogenicity due to loss of critical epitopes. Conformational changes
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may result in precipitation in the gut lumen, loss of binding affinity to M cell
surfaces, or presentation of inappropriate epitopes to the PP. Conformational changes
can arise in both freely dispersed or surface bound macromolecules (surface
molecules on bacteria or viral vaccines). So feeding during oral vaccination can be
important in buffering the harsh environment to minimise the loss of important
epitopes.
Secondly, variation in contact exposure time between antigens and PP could
influence the efficacy of oral vaccines. The variability in contact exposure time is
attributed to the gastric-emptying time which in humans can be as short as 2 hours
(fasted state) or as long as 16 hours (fed state) (Mojaverian et al, 1985). Prolonged
residence in the stomach could have significant drawbacks in terms of proteolytic
digestion by pepsin or protein denaturation due to low pH. The residence time in the
small intestine is less variable ranging from 3 to 5 hours irrespective of feeding state
(Davies et al, 1986). Oral vaccines which empty as a bolus from the stomach, such
as in a fasted state, will have a shorter period of contact with the PP than in a fed
state where the vaccine is released from the stomach in conjunction with the meal. So
feeding conditions are important while giving an oral vaccine. Whether a brief
contact exposure time is sufficient to stimulate an immune response will depend on
the dose and on the third general barrier which is the efficiency of antigen uptake by
the PP. In any event, changes in the total exposure time and the adhesion between the
antigen and PP add an element of variability which could influence overall efficacy
(Shalaby, 1995).
The ideal vaccine would be one that would provide 90% efficacy within a
few weeks of a single administration. Furthermore, the mucosal protection would be
of long duration without the need for reimmunising on a regular basis. The vaccine
would be low cost, safe, cause no adverse side reactions such as immunosuppression,
no interference with immunity to other vaccines given simultaneously, and be
genetically and thermally stable (Babiuk and Campos, 1993).
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1.7.2 Parenteral vaccination
Parenteral vaccines do not have the advantage of antigen delivery at the site
of natural infection; they can have possible side effects, and are less easy to give to
large numbers of people or animals.
Parenteral vaccines with various antigens usually do not stimulate a secretory
IgA immune response in mucosal secretions but can stimulate a systemic immune
response consisting primarily of IgM and IgG antibodies. Serum or slgA is
infrequently induced. However in individuals previously exposed to the antigen by
the mucosal route (e.g., by natural infection), a secretory IgA response could be
detected in external secretions (Mestecky, 1987; Ogra et al, 1976; Mestecky et al,
1986).
In a previous study on cholera vaccine, in unexposed individuals (lactating
Swedish women) parenteral immunisation with cholera vaccine did not consistently
induce secretory IgA antibodies in either saliva or milk. In contrast, parenteral
immunisation in previously exposed individuals (lactating Pakistani women) to
Vibrio cholerae induced specific IgA antibodies in both these external secretions
(Svennerholm et al, 1980)
An increase in secretory IgA by parenteral immunisation is therefore
dependent on the initial mucosal exposure (Mestecky, 1987). A systemic immune
response is always triggered by parenteral immunisation.
1.7.3 Current trends in vaccine development
Chemical modification of antigens has been studied in an effort to improve
immunogenicity through enhanced uptake by PP. Certain molecules such as cholera
toxin-binding subunit B (CTB) are taken up preferentially by M cells. Both CTB and
the heat-labile toxin (LT) of E.coli exhibit increased affinity largely because of
binding to the GM-1 ganglioside receptor on M cells and enterocytes (Holmgren,
1991; Frey et al, 1996). Furthermore, these molecules are resistant to enzyme-
catalysed hydrolysis. Thus, chemical modification with CTB or LT could improve
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immunogenicity either by facilitating uptake by M cells or by providing a steric
barrier to enzymatic degradation (Shalaby, 1995).
Certain bacteria and viruses have high specificity for PP, and in some cases
can colonise PP without mucosal invasion. This would enable the recombinant
vectors of these bacteria or viruses to provide sustained expression of endogenous as
well as foreign antigens to underlying follicles. Vectors which have been studied
include Salmonella typhi, Salmonella typhimurium, Yersinia, Vaccinia, Bacillus
Calmette-Guerin (BCG), and adenovirus (Holmgren, 1991; Dogget and Curtiss,
1992; Sutter and Moss, 1992; Stover et al, 1992; 1993; Shalaby, 1995). However,
this area is still in its infancy with regard to practical human vaccine application and
must overcome a number of obstacles such as safety of the proposed vector, pre¬
existing immunity to vector, and development of appropriate formulations to
preserve the viability and immunogenicity of the vector (Holmgren, 1991).
Mucosal adjuvants have been used to enhance the immunogenicity of certain
antigens. One potent adjuvant is cholera toxin (CT) that has a high binding affinity
for M cells and intestinal epithelium. CT also appears to enhance the antigen-
presenting capacity of macrophages, modulate growth of B cells (promotion of
isotype differentiation leading to increased IgA formation), and T cells (increased
levels of CD4+ T cells against CT-induced disease) (Lycke and Holmgren, 1986;
Owen et al, 1986; Bromander et al, 1991; Hornqvist et al, 1991; Umesaki and
Setoyama, 1992; Vjady and Lycke, 1993; Holmgren et al, 1993). LT seems to have a
similar effect to CT (Holmgren et al, 1993).
A unique feature of polymeric delivery systems is that they can be designed
to meet the specific physical, chemical, and immunogenic requirements of a
particular antigen. The delivery system can be manipulated to incorporate variable
amounts of antigen and/or adjuvants, used to minimise antigen digestion by enzymes,
chemically modified at the surface to improve site specificity, designed to be
biodegradable, and finally, to provide selective uptake by the PP and sustained
antigen release following uptake by the PP. Thus, many of the immunological and
physiological barriers encountered with oral vaccine development may be addressed
using polymeric delivery systems. Several different polymeric antigen delivery
systems which can be taken up by PP and enhance mucosal immune response are
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being studied. These include microspheres made from a variety of biodegradable
polymers such as poly (lactic)/glycolic acid (PLGA), polyphosphazene, and
polyanhydrides (Eldridge et al, 1989; 1990; McGhee and Kiyono, 1993; Nakaoka et
al, 1995; Shalaby, 1995; Singh et al, 1997), liposomes which are made from
biodegradable materials such as phospholipids (Haan et al, 1995; Zhou et al, 1995),
and immunostimulating complexes (ISCOMs) which are non-covalently bound
complexes of Quil-A adjuvant, cholesterol and amphipathic antigen (Hoglund et al,
1989; Morein et al, 1990; Morein and Akerblom, 1992; McGhee and Kiyono, 1993;
Sundquist et al, 1996). However, further study is required to optimise these
polymeric matrixes (especially microspheres and liposomes) because the uptake in
PP is still not efficient enough (Shalaby, 1995). Current studies involve addition of
CT or CTB to their surfaces to enhance uptake in the gastrointestinal tract.
In the last few years, research has been initiated on DNA vaccination. Direct
inoculation of plasmid DNAs encoding for specific viral proteins allows the
expression of immunising proteins by the host cells and presentation to MHC class I
molecules, eliciting CD8+ T cell responses. DNA vaccines have been administered
by several routes including intramuscular, intravenous, and intradermal inoculations,
and by gene-gun delivery of DNA-coated particles into the epidermis. Inoculation of
DNA has generated immune responses and protective immunity for influenza A virus
in mice and ferrets, lymphocytic choriomeningitis virus and rabies virus in mice, and
rotavirus in mice (Fynan et al, 1993; Ulmer et al, 1993; Webster et al, 1994; Xiang et
al, 1994; Zarozinski et al, 1995; Herrmann et al, 1996; Chen et al, 1997).
1.7.4 Vaccination against rotavirus
A safe and effective oral rotavirus vaccine for young children has yet to be
achieved but progress with live oral reassortant vaccines may lead to the first
licensed vaccine. Previous work has been done on vaccinating infants with
heterologous rotavirus strains using bovine NCDV (Lincoln [RIT 4237]) (serotype
6), bovine WC3 (serotype 6), or rhesus MMU18006 (serotype 3). Although
neutralising antibodies were detected after vaccination they were specific only
against 1 or 2 human rotavirus strains (serotypes). Vaccination with NCDV, WC3, or
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rhesus MMU18006 was protective against human rotavirus serotype 1, 1 and 3, and 3
respectively (Vesikari et al, 1983; 1985; Anderson et al, 1986; Clark et al, 1986;
Kapikian et al, 1989; 1991; Vesikari, 1993; Ukae et al, 1994; Ward and Bernstein,
1994; Midthun and Kapikian, 1996). A previous natural rotavirus infection or
rotavirus vaccination, regardless of serotype, is necessary to induce a heterotypic
response (Ukae et al, 1994).
In developed countries, these vaccines had efficacy against rotavirus
diarrhoea, however in developing countries a lack in efficacy was reported using
NCDV (DeMol et al, 1986; Hanlon et al, 1987). Reasons for vaccine failure could
be the following: higher rotavirus challenge doses may be common in developing
countries overwhelming vaccine-induced immunity; other enteric micro-organisms
present in the gut may interfere with vaccine replication; higher levels of breast milk
or placentally derived antibodies in infants may neutralise vaccine virus and thereby
prevent replication; and vaccine-induced immunity may be poor in malnourished
infants (Saif and Jackwood, 1990).
The difference in protection following natural infection with human rotavirus
versus vaccination with heterologous strains could be due to differences in epitopes
or to the relatively inefficient replication of heterologous rotaviruses in humans
which could translate into generally poor immune responses. Therefore new
approaches have been tried such as humanxanimal reassortant vaccines containing
10 genes derived from animal rotavirus (bovine or rhesus rotavirus) and one gene
(encoding for VP7) from a human rotavirus (strain DS-1) or quadrivalent vaccines
consisting of mixtures of serotype 1, 2, and 4 reassortants and rhesus rotavirus.
(Perez-Schael et al, 1990; Kapikian et al, 1989; 1991; Vesikari et al, 1992; Bishop,
1993; McNeal et al, 1994).
Trials have been conducted using a quadrivalent vaccine composed of three
rhesus-human (DS-1) reassortants, each with 10 rhesus rotavirus genes and 1 human
rotavirus gene that encodes VP7 serotype 1, 2, or 4 specificity and the rhesus
rotavirus itself provides coverage for VP7 serotype 3. The quadrivalent vaccine has
been evaluated in two trials in the USA and was 80-82% protective against severe
diarrhoea and 49-57% protection against any rotavirus diarrhoea (Bernstein et al,
1995; Kapikian et al, 1996).
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Trials have also been conducted using a multivalent bovine rotavirus (WC3)
reassortant vaccine composed of bovine rotavirus genes and at least one human
rotavirus gene for either of the virion surface proteins (VP4 or VP7). The
monovalent WC3 reassortant (WI79-9) containing VP7 serotype 1 of a human
rotavirus was 64-100% protective in three trials against all rotavirus disease, with no
clinical events (Clark et al, 1990; Treanor et al, 1995; Clark et al, 1996a,b). A
multivalent vaccine consisting of three reassortants of serotype 1, 2, and 3 combined
with a separate reassortant bearing the VP4 of a human rotavirus P8 yielded 67%
protection (Clark et al, 1996a,b).
Some animal rotavirus vaccines are available, and successful vaccination has
been achieved by maternal parenteral vaccination with subsequent passive transfer of
immunity via milk to the offspring. This has been particularly successful in cattle
stimulating the secretion of specific antibodies in colostrum and milk to take
advantage of the fact that rotavirus antibody present in the lumen of the neonatal
intestine is an effective mediator of protection.
In monogastrics with primary rotavirus immunisation, an antirotavirus IgG
antibody response in serum and milk was detected after parenteral vaccination (Offit
and Clark, 1985; Conner et al, 1993). Intestinal antirotavirus IgG was also found but
this is mainly through transfer of circulating serum IgG into the lumen (Yolken et al,
1990). However, in the case of a secondary immunisation in monogastrics previously
exposed to rotavirus, a significant IgA increase in milk was found. In serum there
was a predominantly IgG response with some IgA detected (McGuire and Crawford,
1973; Browning et al, 1991; Snodgrass et al, 1995).
In ruminants after a primary or secondary parenteral immunisation, an
increase in IgG antibodies was found in milk and serum (Wells et al, 1978;
Snodgrass et al, 1980; Fahey et al, 1981; Saif et al, 1983; Crouch, 1985; van Zaane
et al, 1986).
Development of animal vaccines must take account of differences in mucosal
immunity between monogastric animals and ruminants, particular in their different
antibody response in milk.
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1.8 AIMS OF THIS STUDY
No detailed characterisation of the mucosal immune response against a pathogen is
yet available. Rotavirus is used as model to investigate the mucosal immune
response. This study aims:
I) to establish assays to monitor the immune response at humoral, cellular, and
cytokine level (chapter 2).
II) to study if sheep vaccinated parenterally with a standard rotavirus vaccine can
boost the immune response to rotavirus (chapter 3).
III) to compare the effect of different adjuvants and antigen doses in parenteral
vaccines on the immune response in sheep (chapter 4).
IV) to compare the effect of different adjuvants and antigen doses in oral vaccines on
the immune response in sheep (chapter 5).
V) to characterise the primary immune response to rotavirus in gnotobiotic lambs
(chapter 6).
VI) to induce immunological priming and protection to a subsequent challenge in





In this study, MAI04 cells were used for virus growth, virus titration, and
virus neutralisation tests. MA104 cells are an epithelial-like continuous cell line,
derived from embryonic rhesus monkey kidney (Stormont, Ireland). The cells were
prepared in our tissue culture unit by Mrs. K. Hall and Mrs. K. Quinn. They were
grown in Iscove's Modified Dulbeco Medium (IMDM) (Hyclone, UK) containing
1% (v/v) 0.1M glutamine and 10% (v/v) inactivated Foetal Bovine Serum (FBS)
(Sigma, UK) (FBS was inactivated by a 30 minutes incubation at 56°C). For
investigative purposes (virus titration and virus neutralisation tests) cells were seeded
at a concentration of 2x10 /ml, with 10% inactivated FBS.
2.2 VIRUS, GROWTH, PURIFICATION, INACTIVATION, AND
TITRATION
2.2.1 Virus
In this study two different strains of rotavirus were used. These were a bovine
strain UK G6P5 (Bridger and Woode, 1975) and an ovine strain K923 G10P14
(Snodgrass et al, 1976a; Fitzgerald et al, 1995). Both strains were plaque-purified
and adapted to in vitro propagation in MA104 cells. K923 was also used as a
gnotobiotic lamb passaged isolate.
2.2.2 Virus growth
Virus lysate was treated with trypsin (Sigma, UK) for 1 hour at 37°C at a
concentration of lOjlg/ml. Flasks (150cm2) with confluent monolayers of MA104
cells were washed twice with PBS and 1ml of inoculum was added to the MA 104
cells and incubated for 1 hour at 37°C. After incubation, 50mls of 199 M/M medium
which was treated for 1 hour at 37°C with 1 (tg/ml of trypsin was added to each flask
and incubated at 37°C on a roller. When there was a full cytopathic effect (between
1-5 days), flasks were stored at -70°C to lyse the cells and release the virus. Flasks
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were thawed and virus lysate was collected and stored at -20°C. When used for in
vivo studies, rotavirus lysate was extracted with 1,1,2-trichlorotrifluoroethane
(arcton) (BDH, UK). This was mixed together in equal amounts, shaken vigorously
for 5 minutes, and centrifuged for 10 minutes at 250xg (Beckman TJ-6 centrifuge).
The top layer was collected and stored at -20°C.
2.2.3 Virus purification
After virus growth, virus lysate was centrifuged at 17,000xg (Beckmann J6;
SW40 rotor) for 1 hour to pellet cell debris. Supernatant fluids were collected and
spun at 100,000xg (Beckman J6; SW40 rotor) to pellet the virus. Virus pellets were
resuspended in 3mls of a 20mM Tris-buffer pH 7.5 and layered on 4mls of a 40%
(w/v) sucrose solution and spun down for 2 hours at 100,000xg (Beckman J6, SW40
rotor). Pellets were resuspended in lOmls of sterile PBS and stored at -20°C until
further use.
2.2.4 Virus inactivation
Virus was inactivated by three different methods:
a) by addition of 1.25% (v/v) of a formaldehyde solution (38% w/v) (Fisons, UK) to
the virus lysate or the purified virus pellet and incubated for 1 hour at 37°C and then
left overnight at 4°C. This method was used to prepare virus for parenteral
vaccination. As this is a standard method of rotavirus inactivation (Fontaine et al,
1974), the effectiveness of the method was not confirmed.
b) by addition of 5% (v/v) binary ethylene imine (BEI). 2-bromideethylamine
hydrobromide salt (0.1M) (Sigma, UK) was dissolved in a pre-warmed 0.2 N sodium
hydroxide solution and kept for 1 hour at 37°C (Girard et al, 1977), and added to the
virus lysate or the purified virus pellet and left at 37°C for 24 hours. After
inactivation with BEI at 5% (v/v), virus was passaged three times through MA104
cells and no virus was detected (Table 2.1). This method of inactivation was used
when the virus was given by oral vaccination.
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Table 2.1: Infectivity of inactivated bovine rotavirus strain UK (arcton extracted)
with 1% (v/v) and 5% (v/v) of BEI.
Material Time ffu1 Material Time ffu
Virus + 1% (v/v) BEI Oh 10V8/ml Virus + 5% (v/v) BEI Oh 10b'8/ml
2h ND 2h 1053/ml
4h ND 4h 104'3/ml
6h 1058/ml 6h 103'3/ml
8h ND 8h 1023/ml
lOh ND lOh 1013/ml
12h 1058/ml 12h <1013/ml
14h ND 14h <1013/ml
16h ND 16h <1013/ml
18h 1053/ml 18h <1013/ml
20h ND 20h <1013/ml
22h ND 22h <1013/ml
24h 1048/ml 24h <1013/ml
ND=Not done; ffu = fluorescent focus units
c) by addition of 5x10" mg of psoralen to lOmls of purified virus suspension and
exposing this for 20 minutes to UVB-light at a distance of 7.5cm (Groene and Shaw,
1992). Before further use the protein concentration was determined by a BCA™
protein assay (Pierce, USA). This method was used to inactivate purified virus for
use in in vitro assays. Psoralen itself had no influence on the proliferation of mouse
lymphocytes in vitro (Bruce et al, 1994)
2.2.5 Virus titration
Each passage of every rotavirus strain was titrated in MA 104 cell monolayers
grown in 96-well plates (Nunc, Denmark) which were infected with 10-fold dilutions
of the virus in duplicate. Sealed plates were centrifuged for 1 hour at 150xg
(Beckmann J-6 M/E centrifuge) at 20°C. After virus inoculation, plates were
incubated overnight at 37°C. After incubation, the cells were fixed with diluted
acetone for 2-5 minutes. Plates were washed twice with PBS and 50pl of a lamb anti-
rotavirus strain UK serum (Lab. No. #3625) diluted 1/200 in PBS was added to the
wells and incubated for 25 minutes at 37°C. Plates were washed twice with PBS and
50|ll of a donkey anti-sheep/goat IgG fluorescein-labelled, (FITC) (SAPU, UK)
diluted 1/320 in PBS was added to the wells. Plates were incubated for a further 25
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minutes at 37°C, then washed twice with PBS. Air dried plates were examined for
fluorescence by UV microscopy (Ortholux 2, Leitz, Germany). The titre of the virus
was calculated by the Karber formula (Karber, 1931, cited by Cruickshank R. et al.
1965).
2.3 ANIMALS
Animals used in this study for a ruminant model of rotavirus infection, were
multiparous mature crossbred sheep and gnotobiotic male and female cross-Suffolk
lambs. Sheep were chosen as the supply of sheep and availability of reagents were
greater than for cattle. The sheep were purchased from the Moredun flock, housed in
pens and fed ad libitum on hay and water with a regulated supply of concentrates.
Gnotobiotic lambs were delivered aseptically by hysterectomy, held in positive-
pressure plastic film isolators (Plate 2.1) (isolators were provided by Moredun
Isolators) and fed evaporated milk (Carnation®; Nestle, UK), diluted 1:3 in sterile
water, according the following feeding regime (Table 2.2). This reduced regime was
used as gnotobiotic lambs developed diarrhoea when fed normally. The amount of
milk given to these gnotobiotic lambs was 50% reduced compared to the normal diet.
This study would like to investigate if rotavirus was able to induce diarrhoea and not
influenced by diet. Lambs increased in weight with time when fed with this reduced
regime (no weight graphs shown).
Table 2.2: Feeding regime for gnotobiotic lambs
Day first feed second feed third feed fourth feed
Day of birth 60mls glucose 150mls milk 150mls milk 200mls milk
Day 1 - Day 4 240mls milk 240mls milk 240mls milk X
Day 5 - Day 11 350mls milk 300mls milk 350mls milk X
Day 12 450mls milk 300mls milk 450mls milk X
termination
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Plate 2.1: Isolator with three gnotobiotic lambs.
2.4 SAMPLES
2.4.1 Nasal secretions
Nasal secretions were collected by tampons (Lil-lets, Smith & Nephew Ltd.,
UK), size 2cm x 0.5cm, which were inserted into the ventral nasal meatus,
withdrawn after 10 minutes and squeezed out with a syringe. The tampons were
carefully examined and those with blood present were excluded from the assays. The
nasal secretions were stored at -20°C until use.
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2.4.2 Blood
Blood (lOmls) was collected from the jugular vein in vacutainers with or
without 200|il preservative-free heparin (lOOOunits/ml) (Sigma, UK) for the
collection of peripheral blood lymphocytes (see 2.7.2) or serum respectively.
Blood samples were left overnight at room temperature to coagulate. The
next day, blood samples were centrifuged for 5 minutes at 250xg (Beckman TJ-6
centrifuge) and the serum fractions were collected. The serum samples were stored at
-20°C until use.
2.4.3 Saliva
Saliva (1ml) was collected from under the tongue with a syringe. The saliva
was centrifuged for 5 minutes at maximum speed with a micro-centrifuge (Damon,
IEC CentraM-centrifuge, USA). The saliva supernatants were harvested and stored at
-20°C until use.
2.4.4 Faeces
Faeces was collected from the rectum with a swab (lambs) or by manual
stimulation (sheep). Faecal swabs were stored in bijoux for viral RNA extraction and
examination.
Faeces were also collected for the detection of rotavirus-specific and total
antibody levels. 4mls of a 50mM ethylenediaminetetraacetic acid (dihydrate)
(EDTA) (Sigma) and O.lmg/ml of trypsin inhibitor Type II-S: Soybean (Sigma)
solution was added to 0.5g of faeces. This suspension was processed in a Colwarth
Stomacher (Seward Faboratory, Fondon) for 2 minutes and centrifuged for 5 minutes
at maximum speed with a micro-centrifuge. The samples were kept on ice during




The intestinal secretions were collected by scraping gently along the length of
a longitudinally incised piece (20cm) of small intestine with the edge of a glass
microscope slide. The scraping was placed into universals (Sterilin) containing 5mls
of an enzyme inhibition buffer. This contained ImM phenyl methyl-sulphonyl
fluoride (PMSF) (Sigma), ImM iodoacetate (sodium salt) (Sigma), 0.lmg trypsin
inhibitor (soybean type I-S) (Sigma), and lOmM EDTA dissolved in lOOmls of
distilled water. A few drops of 95% ethanol were required to dissolve the PMSF. The
suspension was sonicated for 30 seconds at amplitude of 20 microns (MSE) and then
centrifuged for 5 minutes at maximum speed with a micro-centrifuge. The
supernatants were collected and stored at -20°C until use.
2.5 ASSAYS
2.5.1 Rotavirus-specific IgA antibody ELISA
Maxisorp plates (Nunc, Denmark) were coated, except column 1 for blanking
the ELISA-reader (Dynatech 500), with lOOpl monoclonal mouse anti-rotavirus VP6
UK/1 (Lab No. #5328) diluted 1/5000 in ELISA coating buffer and incubated
overnight at 4°C in a humid box. The ELISA coating buffer contained 0.795g
disodium carbonate (Fisons, UK) and 1.465g sodium hydrogen carbonate (Fisons,
UK) dissolved in 500mls of distilled water and adjusted to pH 9.6. Plates were
washed three times with PBS containing 0.05% (v/v) polyoxyethylene-sorbitan
monolaurate (Tween-20) (Sigma) (wash buffer). Rows A, C, E, and G were
incubated with 1 OOjllI of a rotavirus strain K923, diluted 1/10 in PBS containing
0.05% (v/v) Tween-20, and 2% (v/v) dried skimmed milk (Marvel, UK) (PTS) and
rows B, D, F, and H with negative MA104-cells, diluted 1/10 in PTS as a negative
control. Plates were incubated for 1 hour at 37°C in a humid box. Plates were washed
3 times with wash buffer and lOOpl of samples and standards, 8 doubling dilutions of
a bovine colostral whey (Lab. No. W3640/3) diluted in PTS were added in duplicate
to positive and negative wells. Plates were incubated for 1 hour at 37°C in a humid
45
box. Plates were washed three times with wash buffer and lOOpl of monoclonal
mouse IgG a bovine IgA-horseradish peroxidase (HRP) (Lab. No. B/84/1/5)
(monoclonal mouse IgG anti-bovine IgA was a gift from Dr. C. Stokes, University of
Bristol and this was purified and conjugated to HRP by Mr. D. Harkins, Moredun
Research Institute) diluted 1/1000 in PTS was added. Plates were incubated for 1
hour at 37°C in a humid box. After incubation plates were washed three times with
wash buffer and lOOpl of the substrate G-phenylenediamine dihydrochloride (OPD)
(Sigma) was added. Colour development was stopped with 50pl of 2M H2SO4. Plates
were read with a Dynatech500 ELISA-reader at 492nm. OD values of negative wells
were subtracted from positive wells. OD means of each duplicate were compared to
the OD values of standards and expressed as units/lOOmls or units/ml. The standard
was assigned an arbitrary value of 50,000 units.
2.5.2 Total immunoglobulin A ELISA
Maxisorp plates (Nunc, Denmark) were coated, except column 1 for blanking
ELISA-reader (Dynatech MR500), with lOOpl of pig anti-sheep IgA serum (gift from
Dr. W.D. Smith, Moredun Research Institute), diluted 1/4000 in ELISA coating
buffer and incubated overnight at 4°C in a humid box. Plates were washed three
times with PBS containing 0.05% (v/v) Tween-20. 100(ll of samples and standards, 8
doubling dilutions of standard IgA, this was purified from clarified lung fluid of a
sheep infected with ovine retrovirus (Jaagsiekte) (JSRV) (gift from Ms. P. Dewar
and purified by Mr. D. Harkins, Moredun Research Institute), diluted in PTS and
were added in duplicate to rows A, C, E, and G. In rows B, D, F, and H 1 OOjllI of PTS
was added as a negative control. Plates were incubated for 1 hour at 37°C in a humid
box. Plates were washed three times with wash buffer and lOOpl of monoclonal
mouse IgG anti-bovine IgA-horseradish peroxidase diluted 1/1000 in PTS was
added. After an incubation of 1 hour at 37°C, plates were treated and developed in
the same way as described in the rotavirus-specific IgA ELISA. OD means were
expressed in mg/lOOmls.
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2.5.3 Rotavirus-specific IgG antibody ELISA
The assay is similar to the rotavirus-specific ELISA except specific reagents
were: a hyperimmune lamb anti-rotavirus serum (Lab. No. #3625) was used as the
standard and the detection conjugate was a donkey anti-sheep IgG HRP (The
Binding Site, UK) diluted 1/1000. The standard was assigned an arbitrary value of
800,000 units.
2.5.4 Total immunoglobulin G ELISA
The assay is similar to the total IgA ELISA except specific reagents were:
rabbit anti-sheep immunoglobulins (Ig) (DAKO, UK) diluted 1/2000 was used as the
coating antibody, a hyperimmune lamb anti-rotavirus serum (Lab. No. #3625) with
9,600mg IgG/L (determined by a sheep IgG calibration kit (Serotec, UK)) was used
as the standard, and the detection conjugate was a rabbit anti-sheep IgG-HRP
(Pierce, USA) diluted 1/20,000.
2.5.5 Virus neutralisation assay
Neutralisation tests were performed using the microtitre fluorescent focus
reduction method (Ojeh et al, 1984). MA 104 cells monolayers were prepared by
addition of lOOpl of 2xl05 MA 104 cells/ml diluted in IMDM containing 10% (v/v)
inactivated FBS, 1% (v/v) 0.1M glutamine, 1% (v/v) 2.5M hepes (Sigma, UK), and
1M NaOH (pH 7.0) to a 96 well plate (Nunc, Denmark). Plates were sealed (Greiner,
UK) carefully and incubated overnight at 37°C.
All sera and other body fluids were diluted in 199 M/M media to 1/10 and
inactivated at 56°C for 30 minutes before use. Using transfer plates (Nunc,
Denmark), doubling two-fold dilutions of sera were made in 199 M/M. The stock
antigen was diluted to a titre of approximately 50 fluorescent focus forming units per
well and equal amounts were added to every well except cell controls. For antigen
control, virus was added to 199 M/M. The loaded transfer plates were sealed and
incubated at 37 °C for 1 hour. After incubation, the MAI04 cells monolayers were
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inoculated with the virus/serum mixture, plates were sealed (Greiner, UK) and
centrifuged at 150xg for 1 hour at 20°C.
After an overnight incubation at 37°C, plates were treated the same as
described in virus titration (see 2.2.5). Titres were expressed as the reciprocal of the
highest serum dilution giving a 60% reduction of fluorescent foci when compared to
the virus control wells. As the quality control, a rabbit anti-rotavirus strain UK serum
(Lab. No. #5877) was used.
2.6 VIRAL RNA EXTRACTION AND DETECTION
Analysis for the presence of viral RNA in faeces was based on a previous
described method (Herring et al, 1982). Double-stranded RNA was extracted from
the faeces by placing the faecal swabs in a plastic tube with 0.75mls of SDS-
extraction buffer (appendix) and 1ml of Tris saturated phenol/chloroform (Sigma,
UK). This was mixed using the vortex mixer and centrifuged for 10 minutes at 250xg
(Beckman, TJ-6 centrifuge). The top aqueous phase was collected and stored at -
20°C. Samples were run on a 7.5% polyacrylamide continuous gel for 1.5 hours and
double-stranded RNA was visualised by silver nitrate staining.
2.7 LYMPHOID TISSUE AND LYMPHOCYTES
2.7.1 Collection of gut-associated lymphoid tissue
Sheep or lambs were killed with 20mls or lOmls of pentibarbitone 200mg/ml
respectively (Euthatal) (Rhone Merieux Limited) by inoculation into the jugular vein.
The gut (from pylorus to rectum) was removed aseptically for collection of
mesenteric lymph nodes (MLNs), jejunal and ileal Peyer's patches (JPPs and IPPs),
and small intestine. MLNs, JPPs, IPPs, and small intestine were placed into a Hanks
Balanced Salts solution without calcium and magnesium (Gibco, BRL) containing
lOOunits/ml benzyl penicillin (sodium) (Britannia), and 0. lmg/ml streptomycin
sulphate (Gibco, BRL) until future use.
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Plate 2.2: Gut obtained from a gnotobiotic lamb 37 days after infection with
rotavirus.
2.7.2 Isolation of lymphocytes
2.7.2.1 Peripheral blood lymphocytes
Blood was centrifuged for 10 minutes at 250xg to collect buffy-coat cells.
These were resuspended and washed twice with HBSS; viable cells were counted by
the trypan blue dye exclusion technique and resuspended at the appropriate cell
concentration in IMDM containing lOOunits/ml penicillin, 0. lmg/ml streptomycin,
1% (v/v) 0.1M glutamine, and 10% (v/v) inactivated FBS until further use.
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2.7.2.2 Mesenteric lymph nodes and Peyer's patches
The collection of lymphocytes from MLNs and PPs was based on previously
described methods (Entrican et al, 1992; Bruce et al, 1995). Fat and surrounding gut
tissues were trimmed off. A cell suspension was prepared by chopping the MLNs or
the PPs with scissors in HBSS (Gibco, BRL) containing lOOunits/ml benzyl
penicillin (sodium) (Britannia), 0. lmg/ml streptomycin, 0.5|lg/ml gentamicin (Gibco,
BRL), and 2% (v/v) inactivated foetal bovine serum (FBS) (Sigma, UK). The cell
suspension was processed for 2 minutes with a Colwarth Stomacher and passed
through two layers of sterile lens tissue (Whatman Paper Ltd., Maidstone UK). Cells
were washed twice with HBSS and treated as above (see 2.7.2.1). The average yield
of lymphocytes obtained from a piece of MLN, a JPP, and a 5-10cm piece of IPP
was» 250x106, 25-45x106, and »250xl06 cells respectively.
2.7.2.3 Small intestine
The collection of lamina propria (LPLs) and intraepithelial lymphocytes
(IELs) was based on a previously described method (Nagi and Babiuk, 1987). Fat
was trimmed off and the collected small intestine was cut into pieces of 10cm to
15cm length (Plate 2.3). Each piece was inverted so that the mucosal surface was
exposed, filled with HBSS without magnesium and calcium and ends were tied
together with a non-biological string.
These pieces of small intestine were placed into a glass beaker filled with
lOOmls of HBSS containing 2mM EDTA, to release epithelial cells (including IELs)
(Plate 2.4). The pieces were stirred gently at 37°C. After 30 minutes, the first cell
suspension was collected and discarded. The beaker was filled with lOOmls of fresh
EDTA solution and stirred for 45 minutes. The second cell suspension was
centrifuged for 10 minutes at 250xg (Beckman TJ-6 centrifuge) and collected. The
beaker was filled again with lOOmls of fresh EDTA-solution for the collection of the
third cell suspension. The second and third batches of cells with IELs were pooled
for further processing.
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The fragments of small intestine were then washed for 30 minutes with a
37°C solution of RPMI containing lOOunits/ml penicillin, 0. lmg/ml streptomycin,
1% (v/v) 0.1M glutamine, and 10% (v/v) inactivated FBS (this to remove the
EDTA). Wash medium was decanted and the beaker was filled with 75mls of RPMI
containing 80units/ml collagenase XI (Sigma, UK), 0.lmg/ml deoxyribonuclease
type V (Sigma, UK), lOOunits/ml penicillin, 0.lmg/ml streptomycin, 1% (v/v) 0.1M
glutamine, and 10% (v/v) inactivated FBS to remove LPLs (Plate 2.5). The beaker
contents were stirred gently for 1 hour at 37°C and the cell suspension was collected
by centrifugation. The average yield of lymphocytes obtained from a 10cm piece of
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Plate 2.3: Small intestine before treatment (H&E; XI00).
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Plate 2.4: Small intestine after treatment with HBSS containing 2mM ED"
obtain IELs (H&E; XI00).
A to
Plate 2.5: Small intestine after treatment with RPMI containing 80units/ml
collagenase XI to obtain LPLs (H&E; XI00).
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Sterile glasswool columns in 10 or 20mls syringes were washed through with
HBSS until a neutral pH was obtained. The cell suspensions with IELs were passed
through the 20mls syringe and cell suspensions with LPLs through the lOmls
syringe. Columns were washed with HBSS. These cell suspensions were put on an
equal volume of Lymphoprep™ (Nycomed, Pharma AS, Norway) and centrifuged
for 1 hour at 250xg (Beckmann TJ-6 centrifuge). The top layers with IELs and LPLs
were collected and washed twice with HBSS and treated as described above (see
2.7.2.1).
2.8 LYMPHOCYTE ASSAYS
2.8.1 Lymphocyte proliferation assay
200p.l of a lymphocyte suspension at a concentration of lxl06/ml in IMDM
containing lOOunits/ml penicillin, 0. lmg/ml streptomycin, 1% (v/v) 0.1M glutamine,
and 10% (v/v) inactivated FBS was added to each well of a 96-well (U-bottomed)
microtiter plate (Nunc, Denmark). 20fil of inactivated purified rotavirus antigen at a
concentration of 10p,g/ml, 4p.g/ml, and 0.4|ig/ml was added to the test wells in
triplicate. Controls, all in triplicate, included unstimulated cultures (20pl of medium
only), cultures stimulated with 20|il of 10(Xg/ml concanavalin A (ConA) (Sigma,
UK), cultures stimulated with 20pl of 2.5|ig/ml pokeweed mitogen (PWM; lectin
from Phytolacca americana) (Sigma, UK), and cultures stimulated with 4p.g/ml
ovalbumin (OVA) (Sigma, UK) as proliferation and specificity controls. Plates were
placed in a humid box and kept at 37°C and in an atmosphere of 5% CO2.
Lymphocytes were cultured for four days and then pulsed with 0.1 pCi 3H
thymidine (Amersham) for a further 18 hours. Cultures were then harvested with a
Micromate™ 196 (Packard, USA) and thymidine uptake was determined by dry
scintillation counting with a Matrix™ 96 (Packard, USA).
Mean counts per minute (cpm) were determined for replicate wells and a
stimulation index (SI) was calculated as the mean cpm in stimulated cultures divided
by the mean cpm in cultures with medium only.
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2.8.2 Immunofluorescent labelling
1 OOjiil of a lymphocyte suspension at 5xl06cells/ml was added to round-
bottomed test tubes and centrifuged at 250xg for 3 minutes (Beckman CS 6R
centrifuge). Cell pellets were resuspended in 500pil of wash buffer (PBS containing
0.01M sodium azide and 2% (v/v) inactivated FBS) and centrifuged at 250xg for 3
minutes. Wash buffer was discarded and 50p,l of wash buffer was added to the first
two test tubes (controls). 50jll1 of the appropriate monoclonal mouse anti-sheep cell
surface marker (Table 2.3) (monoclonal antibodies were provided by Mr. D. Deane,
Moredun Research Institute) diluted in wash buffer was added to the remaining test
tubes and incubated for 30 minutes at 4°C.
After incubation cells were washed with 500(0.1 of wash buffer. After last
wash, 50(tl of wash buffer was added to the first test tube (control) and to the
remaining test tubes 50(rl of fluorescein-labelled rabbit anti-mouse IgG (DAKO,
UK) diluted 1/50 in wash buffer was added and incubated for 30 minutes at 4°C.
After incubation cells were washed twice with wash buffer and resuspended
in 200 (tl of a 4% (w/v) paraformaldehyde solution (BDH) and stored at 4°C until
cells were scanned and counted with a FACScan® (Becton-Dickinson Ltd). Analyses
were based on 5000-10000 cells. FACS profiles of the different monoclonal
antibodies used on the different lymphocyte populations are shown in the appendix.
Table 2.3: Monoclonal antibodies (Mab) used for FACS analysis
Mab Isotype Specificity Reference
17D IgG, Ovine CD4 (Maddox et al, 1985)
7C2 IgG2a Ovine CD8 (Maddox et al, 1985)
86D IgG, Ovine WC2 (78 T cells) (MacKay et al, 1989)
VPM8 IgG, Ovine light chain Ig (B cells) (Puri et al, 1985)
73B IgG, Ovine CD45R (B cells and
naive T cells)
(MacKay et al, 1990)
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2.8.3 ELISPOT
Maxisorp plates (Nunc, Denmark) were coated with lOOpl of the monoclonal
rabbit anti-rotavirus antibody (Lab. No. #5722) diluted 1/2000 in ELISA coating
buffer and incubated for 1 hour at 37°C in a humid box. Plates were washed four
times with PBS. Plates were coated with lOOpl of 5(tg/ml purified bovine rotavirus
(strain UK) in PBS. Plates were incubated overnight at 4°C in a humid box, and then
washed four times with PBS. Plates were incubated for 1 hour at 372C and 5% CCb
with 200|ll of IMDM containing 10% foetal calf serum (FCS). After incubation,
medium was discarded from the plates and 1 OOptl of a suspension containing 0.5x106
peripheral blood lymphocytes/ml diluted in IMDM containing 10%FCS, was added
to the wells. Plates were incubated overnight at 37°C in an atmosphere of 5% CCK
The next day, plates were washed four times with PBS/0.05% Tween-20 and lOOpl
of monoclonal mouse IgG anti-bovine IgA-HRP (Lab. No. B/84/1/5) or donkey anti-
sheep IgG-HRP affinity purified (The Binding Site, UK), diluted 1/1000 in
PBS/0.05% Tween-20 was added. Plates were incubated overnight at room
temperature and left in the dark. After overnight incubation, plates were washed four
times with PBS/0.05% Tween-20 and lOOfil of the precipitating substrate
aminoethylcarbazole (AEC) was added to each well. Plates were left until spots were
visible (Plate 2.6 and 2.7). Washing the plates with distilled water stopped the
reaction. Spots were counted and expressed as antibody secreting cells
(ASC)/1,000,000 lymphocytes.
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Plate 2.6: Rotavirus-specific IgA antibody secreting cells in blood.
Plate 2.7: Rotavirus-specific IgG antibody secreting cells in blood.
56
2.9 RNA EXTRACTION, REVERSE TRANSCRIPTASE, POLYMERASE
CHAIN REACTION, AND HYBRIDISATION
2.9.1 RNA extraction
RNA extraction was based on a previously described method (Chomczynski
o
and Sacchi, 1987). 1x10 lymphocytes were homogenised in 5mls of extraction
buffer (appendix). After homogenising, 0.5ml of a sterile 3M sodium acetate solution
pH 4.5 was added and mixed, followed by 5mls of phenol (BDH) and 1ml of
chloroform, this mixture was shaken vigorously for 5 minutes.
After shaking, the mixture was left on ice for 10 minutes and centrifuged at
maximum speed for 10 minutes with a micro-centrifuge. After centrifugation, the
aqueous phase was transferred to a sterile centrifuge tube and an equal volume of
isopropanol (propan-2-ol) (BDH) was added and mixed. This was left at -20°C for at
least 1 hour before centrifugation at maximum speed for 20 minutes with a micro¬
centrifuge. The supernatant was discarded and the pellet was washed with 70%
ethanol and centrifuged at maximum speed for 10 minutes with a micro-centrifuge.
o
Finally, the pellet was resuspended in 200(0.1 of sterile distilled water (per 1x10,
starting cells).
The RNA sample were checked on a northern gel for RNA integrity and
contaminating DNA (genomic DNA runs as a distinct band above the RNA). 0.4g
agarose was dissolved in 40mls of a lxMOPS buffer (appendix) using a microwave
and once cooled below 50°C, 2mls of a 37% formaldehyde solution was added
before pouring the gel. To 2|ol of RNA sample, 8|ol of RNA sample loading buffer
(appendix) was added. This was heated at 65°C for 10 minutes and then chilled on
ice. Sample was loaded on the gel and run for 30-60 minutes at 80V. Running buffer
was a lxMOPS buffer. RNA bands were visualised with UV-light.
RNA was quantified with a spectrophotometer at ODs of 260nm and 280nm
used as an internal control (absorption at 260nm/280nm ~ 2.0). 1 absorption unit at
260nm = 40p,g of RNA and final concentration was expressed as (ig/ml.
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2.9.2 Reverse transcriptase (RT)
cDNA was prepared from RNA by using the following protocol. RNA was
heated at 65°C for 10 minutes and cooled on ice. lpg of RNA was reverse
transcribed in a 20pl reaction mixture containing 4.0|il 5xRT buffer (Boehringer),
2.0pl lOxdNTPs (2mM) (Promega), 2.0pl lOxrandom primer pd(N)6 (62.5units/ml)
(Pharmacia Biotech), 0.25|ll (5 units) of AMV reverse transcriptase (gene product of
avian myeloblastosis virus) (Boehringer), and made up with sterile distilled water.
The AMV reverse transcriptase was added to each reaction and mixed gently. This
was incubated at 37°C in a water bath for 90 minutes. After incubation, samples were
vortexed, centrifuged and 80pl of sterile distilled water was added to each sample
making a total of lOOpl. Samples were stored at -20°C if not used straight away.
2.9.3 Polymerase chain reaction (PCR)
DNA amplification was performed by the following method. 1 Ojul of each of
the resulting reverse transcriptase reactions was used as a template in a 20 pi PCR
consisting of 2.0pl lOxPCR buffer (Boehringer), 2.0pl lOxdNTPs (2mM)
(Promega), 2.0pl of the specific upstream primer (lOpM), 2.0pl of the specific
downstream primer (lOpM), 0.2pl (1 unit) Taq DNA Polymerase (Boehringer), and
1.8|ll sterile distilled water.
Cytokine-specific primers (Table 2.4) were chosen since they spanned the
coding region of the cytokine transcripts based on the published sequences for
bovine IFNy (Cerretti et al, 1986a), bovine IL-2 (Cerretti et al, 1986b), ovine IL-4
(Seow et al, 1993), and ovine IL-6 (Ebrahimi et al, 1995). The glyceraldehyde-3-
phosphate dehydrogenase gene (GAPDH), based on the human sequence, was used
as a non-specific control (Tokunaga et al, 1987).
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Table 2.4: Nucleotide sequence of upstream (sense) and downstream (antisense) PCR
primers for target genes
Cytokine Oligonucleotide Predicted product
(bp)
GAPDH sense 5'CATAACACAGGAGCTCAAGA3' 646
anti-sense 5'TGCCAAGTTGGACCCTGAGA3'
IFNy sense 5'CATAACACAGGAGCTACCGA3' 550
anti-sense 5'TGCCAAGTTGGACCCTGAGA3'
IL-2 sense 5'ATGTACAAGATACAACTC3' 465
anti-sense 5'GTCATTGTTGAGTAGATG3'
IL-4 sense 5'ATGGGTCTCACCTCCCAGCTGATC3' 405
anti-sense 5'ACACTTTGAGTATTTCTCCCTCAT3'
IL-6 sense 5'ATGAACTCCCTCTTCACAAGCGCC3' 627
anti-sense 5'ACTTCATCCGAATAGCTCTCAGGC3'
The PCR mixture was quickly centrifuged and overlayed with 20p,l of sterile
mineral oil. Cycling parameters for all primer sets were 30 cycles of 95eC for 1
minute, 50 -C for 2 minutes, and 72 aC for 2 minutes.
4p.l of loading buffer, 0.25% (w/v) bromophenol blue in a 60% glycerol
solution, was added to each PCR and analysed on a 1.5% agarose gel. Agarose was
dissolved in 1XTBE (10XTBE buffer: 1M Tris, 1M boric acid, and lOmM EDTA,
pH 8.0) using a microwave and once cooled below 50°C, ethidium bromide
(lOmg/ml) (5(il per 40mls) was added before pouring the gel. 5 |ll of each sample
was loaded, including 5pl of a 1Kb DNA ladder (Gibco BRL) on the gel and run for
30-60 minutes at 80V in a running buffer of lxTBE buffer. DNA bands were
visualised with UV light.
2.9.4 Southern blotting
Denaturation of the gel was performed by soaking in a 0.5M sodium
hydroxide (Fisher Scientific) and 1.5M sodium chloride solution (Fisher Scientific).
After 15 minutes, the solution was poured off and a 1M ammonium actetate (BDH)
and 0.02M sodium hydroxide (Fisher Scientific) solution was added to the gel. After
15 minutes the solution was changed and replaced for a last soak of 30-60 minutes.
The Southern blot was set up by placing cling film on the bench followed by
the gel (wells side down). The gel was covered with a wet Hybond-N nylon
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membrane (Amersham) avoiding air bubbles, one piece of wet 3MM blotting paper,
and followed by two pieces of blotting paper. This was covered with layers of blue
paper roll and a glass plate and left overnight. The next day, glass plate, blue roll,
and blotting paper were removed to place nylon membrane on a piece of blue roll to
let it air-dry. When dry, DNA was fixed by exposing the nylon membrane for 3
minutes to UVB light.
2.9.5 Hybridisation
Hybridisation was based on a protocol provided with the DIG DNA labelling
and detection kit (Boehringer Mannheim, Cat. No. 1093657).
Membranes were pre-hybridised in a glass tube for 30 minutes at 55°C with
5-10mls of a pre-hybridisation buffer containing 5xSSC buffer (20xSSC buffer: 3M
sodium chloride and 300mM sodium citrate, adjusted to pH 7.0 and autoclaved),
1.0% of a lOxblocking stock solution (blocking reagent provided in kit), 0.1% N-
laurolsylsacosine, and 0.02% sodium dodecyl sulphate (SDS). Membranes were
hybridised overnight at 55 2C with lOmls of pre-hybridisation buffer containing 6pl
of the specific cytokine probe.
The probe was made, using the DIG oligonucleotide tailing kit (Boehringer
Mannheim, Cat. No. 1417231). In short, 4(tl of tailing buffer, 4(il of cobalt chloride
solution, lOOpmol of oligonucleotide (Table 2.5), l|il of DIG-dUTP solution, lpl
dATP solution, 50 units (~ 1 jj.1) terminal transferase was made up with sterile water to
20(tl in an eppendorf on ice. This was incubated for 15 minutes at 37°C and then
placed on ice.
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Table 2.5:Nucleotide sequence of upstream (sense) and downstream (antisense)
hybridisation probes
Cytokine Oligonucleotide







IL-6 sense 5 'TGCTTCCAATCTGGGTTCAATCAGGCGATT3'
After overnight incubation, membranes were washed twice with a solution
containing 0.1% SDS and 2XSSC for 5 minutes at room temperature and washed
twice with a solution containing 0.1% SDS and 0.2xSSC for 15 minutes at 55 2 C.
Membranes were washed for 1 minute at room temperature with DIG-buffer 1 (DIG-
buffer 1: 0.1M maleic acid and 0.15M sodium chloride, adjusted to pH 7.5 and
autoclaved) followed by 30 minutes at room temperature with DIG-buffer 2 (DIG-
buffer 2: lOxblocking stock solution diluted 1/10 in DIG-buffer 1). Membranes were
incubated for 30 minutes at room temperature with anti-DIG-AP conjugate diluted
1/5000 in DIG-buffer 2 in sealed plastic bags. After incubation, membranes were
washed twice with DIG-buffer 1 for 15 minutes followed by a 2 minutes wash with
DIG-buffer 3 (DIG-buffer 3: 0.1M Tris-HCl, 0.1M sodium chloride, and 50mM
magnesium chloride, pH 9.5). Membranes were developed in the dark by adding
lOmls of DIG-buffer 3 containing 45|il of NBT-solution and 35|ll of X-phosphate
solution in sealed plastic bags. Colour precipitate started to form within a few
minutes and the reaction was usually completed after 16 hours. Washing the
membranes with distilled water stopped the reactions.
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2.10 STATISTICS
Results were analysed using Minitab 9.2 (Minitab Inc.) and Genstat 5 (IACR)
software. Group differences between rotavirus-specific antibody titres and total
antibody concentrations in serum and nasal secretions were analysed using a model
for repeated measurement (Genstat 5). Group differences in rotavirus-specific
antibody titres and total antibody concentrations in intestinal scrapings, virus
neutralising titres (l0log-values), and rotavirus-specific antibody secreting cells in
blood were analysed with analysis of variance (ANOVAs) (Minitab 9.2). The
percentage of lymphocyte sub-populations in blood and GALT were compared to
pre-vaccination levels and control group respectively with analysis of variance
(ANOVAs) (Minitab 9.2). Lymphocyte proliferation results (10log-values) were
analysed using a 2-tailed t-test (Minitab 9.2). Cytokine expressions were analysed as
positive (1) versus negative (0) using a 1-sample t-test (Minitab 9.2).
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CHAPTER 3
STIMULATION OF MUCOSAL ROTAVIRUS-SPECIFIC
IMMUNITY IN SHEEP BY A STANDARD PARENTERAL
VACCINATION PROTOCOL
3.1 INTRODUCTION
Parenteral administration of inert non-replicating antigens tends to induce a
poor immune response, which can be enhanced with adjuvants. Inactivated
adjuvanted rotavirus dam vaccines are used in cattle and are based on oil-
adjuvantation.
Freunds incomplete adjuvant (IFA), an oil-based adjuvant, has been used as a
successful carrier for antigen. Increased rotavirus-specific IgG antibodies were found
in serum and colostrum when vaccinating the dam parenterally in cattle and sheep
(Wells et al, 1978; Snodgrass et al, 1980; Castrucci et al, 1984; Saif et al, 1984;
Archambault et al, 1988; Mostl and Burke, 1988; Bellinzoni et al, 1989). The
majority of these rotavirus-specific IgG antibodies present in colostrum are derived
from serum (Saif et al, 1984). The maternally derived neutralising antibodies present
in the intestine through the feeding of colostrum protect the calves and lambs against
rotavirus infection.
In general, parenterally administered vaccines are not effective at inducing a
mucosal immune response especially in naive animals. Mucosal immune responses
are not seen after parenteral vaccination in unexposed humans. In contrast, in
previously exposed humans parenteral vaccination can induce or boost an immune
response at mucosal surfaces (Svennerholm et al, 1980; Pickering et al, 1995). Naive
sows vaccinated parenterally with live attenuated TGE virus showed a virus-specific
IgG response in serum and milk (Bohl et al, 1975), however a mucosal response
(e.g., virus-specific secretory IgA in milk) was only seen in naturally infected sows
(Saif and Bohl, 1980).
Currently it is not clear if this standard rotavirus vaccination of the dam can
boost rotavirus-specific antibodies at mucosal surfaces other than from serum
transudation.
The aim of this chapter was to study whether parenteral vaccination using a
standard parenteral rotavirus vaccine can boost the mucosal humoral immune




Non-lactating multiparous crossbred sheep were used. All animals had serum
neutralising antibodies to rotavirus measured by virus neutralising assay, indicating
previous natural intestinal exposure.
In this study, two groups of sheep (n=12 for each group) were used and
vaccinated parenterally either with PBS or with inactivated rotavirus lysate (RV)
each adjuvanted with IFA (PBS/IFA and RV/IFA respectively).
3.2.2 Vaccines
Bovine rotavirus strain UK was used as a cell culture lysate (infectivity titre
of 106 8 ffu/ml) (see 2.2.2) and inactivated by formaldehyde before use (see 2.2.4).
The RV/IFA group was vaccinated with 2mls each of inactivated rotavirus
lysate emulsified (1:1) with IFA (DIFCO, UK). The PBS/IFA group was vaccinated
with 2mls each of PBS emulsified (1:1) with IFA. All sheep were vaccinated in equal
volumes in each back leg by deep intramuscular injection.
3.2.3 Sample collection
Blood, nasal secretions, saliva, and faeces were collected at intervals and
intestinal scrapings were collected at necropsy. Sheep were sampled at vaccination
(pre-bleed) and at 2, 4, 6, 8, 12, and 16 weeks after vaccination. 7 out of 12 sheep
from each group were killed 2-3 weeks after vaccination and the remaining sheep
were killed 16-18 weeks after vaccination.
Serum, nasal secretions, saliva, faeces, and intestinal scrapings were tested
for rotavirus-specific antibodies and total IgA and IgG concentrations by ELISA.




3.3.1 Standardisation of ELISAs
Each ELISA was standardised on an 8-point curve. The rotavirus-specific
antibody IgA and IgG standard curves with sample curves are shown in Fig 3.1 and
3.2 respectively. The total IgA and IgG standard curves with sample curves are given
in Fig. 3.3 and 3.4 respectively.
Fig. 3.1: Rotavirus-specific IgA ELISA
0.8 X
- - x- - Intestinal scrapings
— - A: ■ - Nasal secretions
-♦ Standard curve rotavirus-
specific IgA
■- - - Serum
0
2 3 4 5 6 7 8
Doubling dilutions






■- - - Serum
— - A - — Nasal secretions
--X-- Intestinal scrapings
0 H 1 1 ~~¥ 1 1 1
2 3 4 5 6 7 8
Doubling dilutions
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Fig. 3.3: Total immunoglobulin A ELISA
1 -r
1 2 3 4 5 6 7 8
Doubling dilutions
Standard curve total IgA
— ■- - - Serum
— -A — Nasal secretions
— - X- - Intestinal scrapings
Fig. 3.4: Total immunoglobulin G ELISA
Doubling dilutions




Each standard curve was reproducible with a linear/linear fit of r2 >0.95.
When serial dilutions of test samples produce results parallel to the standard curve, it
indicates that antibody values can be compared at a single test dilution with a
standard curve generated by serial dilutions of the standard sample.
Sample curves in all four ELISAs from serum, nasal secretions, and intestinal
scrapings were parallel to standard curves. The faecal and saliva samples were not
further analysed because faecal samples had no detectable levels of antibodies and
the sample curve of saliva was not parallel to the standard curve.
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3.3.2 Antibody responses after parenteral vaccination
3.3.2.1 Rotavirus-specific antibodies
The RV/IFA group showed a significant (p<0.05) but transient increase in
rotavirus-specific IgA antibodies (Fig.3.5 and Table 3.1) in nasal secretions 2 weeks
after vaccination together with a significant (p<0.05) difference in rotavirus-specific
IgA antibodies at the intestine at time of killing 2-3 weeks after vaccination. No
differences were observed in intestinal scrapings 16-18 weeks after vaccination (Fig.
3.6 and Table 3.2). No increase in rotavirus-specific IgA antibodies was seen in
serum at any time.
A significant increase (p<0.05) in rotavirus-specific IgG antibodies was
observed in serum (Fig. 3.7 and Table 3.3) and nasal secretions (Fig. 3.8 and Table
3.4) in the RV/IFA group from 2 weeks after vaccination. The RV/IFA group had a
significantly (p<0.05) higher level of rotavirus-specific IgG antibodies in intestinal
scrapings 2-3 weeks after vaccination but not at 16-18 weeks after vaccination (Fig.
3.9 and Table 3.5).
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Rotavirus-specific IgA antibody responses in nasal secretions of each animal




0 2 4 6 8 12 16
PBS/IFA 0.6 1.1 2.2 1.5 1.2 3.8 3.4
(0.6) (0.8) (1.2) (0.7) (0.8) (2.7) (2.5)
RV/IFA 0.7 2.4* 2.2 1.8 1.5 1.3 17
(0.5) (1.8) (0.7) (0.6) (0.7) (1.0) (26)
Results given as mean with (SD) and expressed in units/mg IgA; * p<0.05 (RV/IFA
vs PBS/IFA)
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Fig. 3.6: Rotavirus-specific IgA antibody responses in intestinal scrapings
Weeks after vaccination
Rotavirus-specific IgA antibody responses in intestinal scrapings of each
animal after parenteral vaccination with RV/IFA and PBS/IFA. Results
expressed in units/|ig IgA.
Table 3.2: Mean rotavirus-specific IgA antibody responses in intestinal scrapings
Isotype Group/Weeks after vaccination 2-3 16-18
IgA PBS/IFA 1.7 (0.7) 2.2 (2.2)
RV/IFA 6.5 (4.7)* 1.7 (2.1)
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Rotavirus-specific IgG antibody responses in serum of each animal after
parenteral vaccination with RV/IFA and PBS/IFA. Results expressed in
units/mg IgG.
Table 3.3: Mean rotavirus-specific IgG antibody responses in serum
Group/Weeks
after vaccination
0 2 4 6 8 12 16
PBS/IFA 1.5 0.7 0.6 0.6 0.9 1.0 0.9
(0.5) (0.4) (0.3) (0.4) (0.3) (0.4) (0.3)
RV/IFA 1.2 4.2* 18** 35 40 38 40
(0.6) (2.7) (9.7) (35) (63) (50) (63)
Results given as mean with (SD) and expressed in units/mg IgG; * p<0.05; **
p<0.01 (RV/IFA vs PBS/IFA)
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Rotavirus-specific IgG antibody responses in nasal secretions of each animal




0 2 4 6 8 12 16
PBS/IFA 1.0 0.9 1.0 1.0 1.1 1.5 2.8
(1.1) (0.6) (0.5) (0.3) (0.3) (0.4) (0.9)
RV/IFA 1.3 8.3* 27** 70 95** g7** 111**
(1.5) (7.0) (14) (86) (54) (45) (90)
Results given as mean with (SD) and expressed in units/mg IgG; * p<0.05; **
p<0.01 (RV/IFA vs PBS/IFA)
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Rotavirus-specific IgG antibody responses in intestinal scrapings of each
animal after parenteral vaccination with RV/IFA and PBS/IFA. Results
expressed in units/|lg IgG.
Isotype Group/Weeks after vaccination 2-3 16-18
IgG PBS/IFA 213 (166) 56 (29)
RV/IFA 550 (312)* 65 (42)
Results given as mean with (SD) and expressed in units/p.g IgG; * p<0.05 (RV/IFA
vs PBS/IFA)
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3.3.2.2 Neutralising titres against rotavirus
All animals had pre-existing serum neutralising antibodies against rotavirus.
After vaccination, significant (p<0.05) increases were observed in the RV/IFA group
from 2 weeks after vaccination which lasted until the termination of the experiment
(Table 3.6). Intestinal scrapings had a low level of neutralising activity against
rotavirus (maximum VNT=10) but no changes were observed between the groups
(data not shown).
Table 3.6: Mean neutralising titres in serum
Group/Weeks
after vaccination
0 2 4 6 8 12 16
PBS/IFA 80 80 80 80 80 80 40
(20-320) (40-320) (40-160) (20-160) (40-160) (40-160) (40-80)
RV/IFA 80 2560* 10240** 10240** 5120** 5120** 10240**
(20-320) (640- (2560- (5120- (2560- (2560- (5120-
20480) 20480) 10240) 10240) 10240) 10240)
Results given as mean with (range); * p<0.05; ** p<0.01 (RV/IFA vs PBS/IFA)
3.3.2.3 Total immunoglobulin A and G concentrations
Individual IgA concentrations varied markedly. No significant differences
were observed in serum (range: 5-168 mg/lOOmls), nasal secretions (range: 96-1140
mg/lOOmls) (Table 3.7), and intestinal scrapings (range: 1.2-40 mg/lOOmls) (data not
shown) after vaccination.
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Table 3.7: IgA concentrations in serum and nasal secretions
Sample Group/Weeks
after vaccination
0 2 4 6 8 12 16
Serum PBS/IFA 25 21 20 18 18 24 29
(13) (10) (13) (12) (14) (10) (16)
RV/IFA 29 22 27 42 34 60 51
(16) (8.7) (11) (50) (35) (61) (45)
Nasal PBS/IFA 275 357 212 204 251 174 180
(181) (302) (134) (94) (99) (154) (106)
RV/IFA 310 324 161 185 176 277 169
(210) (168) (95) (99) (84) (64) (122)
Results given as mean with (SD) and expressed in mg IgA/lOOmls
Individual IgG concentrations varied markedly. No significant differences
were observed in serum (range: 2181-11776 mg/lOOmls), nasal secretions (range: 17-
140 mg/lOOmls) (Table 3.8), and intestinal scrapings (range: 0.01-0.1 mg/lOOmls)
(data not shown) after vaccination.
Table 3.8: IgG concentrations in serum and nasal secretions
Sample Group/Weeks 0 2 4 6 8 12 16
after vaccination
Serum PBS/IFA 4765 4513 5675 5290 4479 4864 6197
(1530) (1330) (1087) (676) (1232) (1942) (2466)
RV/IFA 4578 4317 4249 6287 5381 4495 3761
(1401) (1598) (898) (2320) (2458) (830) (789)
Nasal PBS/IFA 74 84 44 55 49 34 20
(26) (52) (4) (33) (18) (16) (5)
RV/IFA 67 81 54 95 34 58 19
(23) (47) (27) (44) (12) (50) (2)
Results given as mean with (SD) and expressed in mg IgG/lOOmls
3.4 DISCUSSION
In this study, different ELISAs were used to measure rotavirus-specific
antibody and total IgA and IgG levels in serum, nasal secretions, saliva, faeces, and
intestinal scrapings. Doubling dilutions of samples were compared to an 8-point
doubling dilution standard curve. The use of measurement by single dilution was
justified when sample curves were parallel to standard curves. Serum, nasal
secretions, and intestinal washings could be tested by single dilutions.
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Saliva could not be tested, as the sample curve was not parallel to the
standard curve. This could be due to degradation by endogenous proteolytic enzymes
present in saliva during storage (Coulson et al, 1989), the method of sampling by
taking saliva from under the tongue and not at the parotid gland, or the time of
feeding which could alter the dilution factor of antibodies. Faecal samples had no
detectable antibodies. This may be due to the high dilution factor in faeces.
The standard vaccine with IFA and inactivated rotavirus lysate was
successful in stimulating rotavirus-specific IgG antibodies and neutralising activity in
serum as previously observed in animals vaccinated parenterally with rotavirus lysate
(live or inactivated) and IFA (Snodgrass et al, 1980; Castrucci et al, 1984; Saif et al,
1984; Bellinzoni et al, 1989).
Significantly increased levels of rotavirus-specific IgG antibodies were also
found in nasal secretions from 2 weeks after vaccination. Rotavirus-specific IgG
antibodies in intestinal scrapings were significantly increased 2-3 weeks but not at
16-18 weeks after vaccination. Rotavirus-specific IgG antibodies detected in nasal
secretions and intestinal scrapings in cattle and rabbits are assumed to be derived
from serum by transudation (Besser et al, 1988; Conner et al, 1993). A study on
influenza virus in humans indicated that virus-specific IgG antibodies in saliva and
nasal secretions were derived from the circulation (Murphy and Clements, 1989).
Although, 5-15% of plasma cells in mucosal tissues produce IgG but the relative
importance of this locally produced IgG in mucosal immunity is still unclear
(McGhee and Kiyono, 1993).
In this study, high rotavirus-specific IgG antibody levels were detected in
serum from 2-16 weeks after vaccination. However, this was not reflected in high
rotavirus-specific IgG antibody levels in the intestine. The significant difference
between the PBS/IFA and RV/IFA group observed in intestinal rotavirus-specific
IgG antibodies 2-3 weeks after vaccination could be related to the effect of
stimulated local rotavirus-specific IgG production or it could be due to transudation.
However, rotavirus-specific IgG antibodies were higher at 16 weeks than at 2 weeks
after vaccination. In a study with specific-pathogen (rotavirus)-free rabbits, a similar
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suggestion was made that parenteral vaccination could stimulate locally produced
rotavirus-specific IgG antibodies (Conner et al, 1993).
However, of greater significance were the observations that a single
parenteral vaccination with RV/IFA stimulated an increase in rotavirus-specific IgA
antibodies in nasal secretions and in the intestine, providing evidence that the
common mucosal immune system operates in sheep
Several possible mechanisms exist whereby parenteral vaccination in
previously exposed animals induces production of virus-specific intestinal or
respiratory antibodies. First, circulating antigen-presenting cells (APCs) carrying
rotavirus antigen can traffic to the GALT and trigger memory B cells (McGhee et al,
1992). Secondly, circulating APCs can trigger memory B cells present in blood these
may disseminate to the GALT (Coffin et al, 1995).
No rotavirus-specific IgA antibodies were detected in serum. Most work in
parenterally vaccinated ruminants has concentrated on the antibody response in
colostrum and milk, which is predominantly an IgG response (Saif et al, 1984). This
is in contrast to monogastrics in which the IgA response is predominant. In sheep
vaccinated parenterally with killed Salmonella typhimurium, the contribution of IgA
in serum was minimal while IgG was predominant (Mukkur et al, 1995). However,
rotavirus-specific IgA antibody levels were detected in the intestine and nasal
secretions. It is likely that these antibodies were produced by plasma cells in the
GALT and not derived from serum. In a previous study on influenza and cholera in
naturally exposed humans, IgA antibodies increased in serum and milk respectively
after parenteral immunisation (Svennerholm et al, 1980; Moldoveanu et al, 1995).
The significant difference seen in rotavirus-specific IgA antibodies in the
intestine 2 weeks after vaccination correlated with the significant increase seen in
rotavirus-specific IgA antibodies in nasal secretions suggesting that nasal secretions
could be an accurate reflection and a good marker for intestinal mucosal immunity.
However, more data is needed about the levels of rotavirus-specific IgA antibodies in
the intestine at other time points after vaccination. In a previous study in humans
salivary rotavirus-specific antibodies were found to be a good indicator for intestinal
rotavirus-specific antibody (Ward et al, 1992a), but this was not the case in this
study.
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No significant increases were found in total immunoglobulin levels in serum,
nasal secretions, and intestinal scrapings. Significant increases in rotavirus-specific
antibodies do not result in increases in total immunoglobulin levels. The total
immunoglobulin levels found in this study are in general higher, except for total IgA
levels in serum, than observed in a previous study in which immunoglobulin levels
were measured (Smith et al, 1975). The difference could be explained by the
different methods (ELISA vs single radial immunodiffusion) used or the history and
age of the animals.
This study showed that rotavirus-specific antibody levels in nasal secretions
could be a good reflection of intestinal anti-rotavirus antibody levels. Collecting
nasal secretions is simple and non-invasive, and could have potential in screening
and monitoring the kinetics of the mucosal immune response for example in vaccine
studies.
This study also demonstrates that parenteral vaccination can boost rotavirus-
specific IgA antibodies in the intestine and related mucosae in naturally exposed
sheep using incomplete Freunds adjuvant. Such a response should be expected to
correlate with increased protection against infection but no challenge system in
adults was available to test this.
Stimulation of IgA antibodies in the intestine and other mucosal surfaces such
as in the respiratory tract could increase protection against reinfection by a mucosal
pathogen. Finally, if mammary gland IgA and IgG antibody levels could also be
increased then this could improve passive immunity transfer to offspring in diseases
such as TGE in pigs and rotaviral enteritis in man and animals.
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CHAPTER 4
EFFECTS OF DIFFERENT ADJUVANTS AND ANTIGEN DOSES
IN PARENTERAL VACCINES ON ROTAVIRUS-SPECIFIC
IMMUNITY IN SHEEP
4.1 INTRODUCTION
IFA has been used successfully as an antigen carrier in rotavirus dam
vaccines for cattle, increasing rotavirus-specific IgG antibodies in serum and
colostrum, neutralising antibodies in serum (Snodgrass et al, 1980, Fahey et al,
1981), and rotavirus-specific IgA antibodies at mucosal surfaces (see chapter 3).
Due to the possible side effects of IFA such as the formation of granulomas
or even abscesses at the injection site and the difficulty of injection through its high
viscosity, other adjuvants are being developed and tested (Edelman, 1980; Osebold,
1982).
ISCOMs and biodegradable poly(lactic)/glycolic acid (PLGA) microspheres
have been used as an adjuvant and were selected for use in this study. Increased
rotavirus-specific antibodies were found in colostrum in baboons when vaccinating
the mother intramuscularly with a mixed rotavirus/ISCOM vaccine (Snodgrass et al,
1995). Increased specific antibody levels were observed when rhesus macaques were
vaccinated intramuscularly with micro-encapsulated vaccines containing either
staphylococcal enterotoxin B, whole formalin-inactivated simian immune deficiency
virus (SIV) or tetanus toxoid (Eldridge et al, 1991; Marx et al. 1993; Singh et al,
1997).
Most rotavirus dam vaccines available use an oil-based adjuvant (e.g., IFA)
emulsified with virus antigens in the form of tissue culture lysates. These commercial
vaccines tend to use a dose of virus antigen that can be grown in cell culture without
further concentration, which in practice incorporates a titre of approximately 106 0"6 5
ffu/ml per dose (Snodgrass, personal communication). No studies have been done to
compare the effect of purified rotavirus or a higher dose of rotavirus antigen, on the
immune response.
The aim of the work described in this chapter was to study the effect of
different adjuvants (IFA, ISCOMs and microspheres) and antigen doses (lysate and




Non-lactating multiparous crossbred sheep were used and all had serum
neutralising antibodies to rotavirus.
Sheep were divided into 9 groups of n=4 and vaccinated intramuscularly with
either inactivated rotavirus lysate (RV) (low antigen dose) or inactivated purified
rotavirus (PRV) (high antigen dose) adjuvanted with incomplete Freunds (IFA)
(RV/IFA; PRV/IFA), ISCOMs (RV/ISC; PRV/ISC), or microspheres (RV/MSPH;
PRV/MSPH). One group received no treatment.
4.2.2 Vaccines
The rotavirus used was the bovine strain UK either as a cell culture lysate
(infectivity titre of 106 8 ffu/ml) (see 2.2.2) or sucrose-purified (infectivity titre of
1088 ffu/ml) (see 2.2.3). Both preparations were inactivated by the formaldehyde
method (see 2.2.4). Protein concentrations of rotavirus lysate and purified rotavirus
were determined with a BCA™ protein assay.
The RV/IFA group was vaccinated with 2mls each of inactivated rotavirus
lysate emulsified (1:1) with IFA (DIFCO, UK). The RV/ISC group received 2mls
each containing 1ml inactivated rotavirus lysate, 500pg ISCOM matrix (Iscotec,
Sweden), and PBS making a total volume of 2mls. The RV/MSPH group received
lOmg each of microspheres (gift from Dr. A. Coombes, University of Nottingham)
adsorbed with 1.49mg of lysate protein (-28% of the amount of lysate protein used
in the RV/IFA and RV/ISC groups). 40mg of microspheres were incubated overnight
at 37°C with 4mls of inactivated rotavirus lysate (protein concentration was
5.35mg/ml). After incubation, suspension was centrifuged for 5 minutes at maximum
speed with a micro-centrifuge and washed twice with PBS. Protein concentration
was determined in supernatants to measure the adsorption of protein to the
microspheres. Adsorption percentage is (the total amount of protein adsorbed to the
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microspheres/ the total amount of protein used) xl00%. The adsorption percentage
was (4x1.49/21.4) xl00% =27.8%.
The PRV/IFA group received 2mls each of lOOug of inactivated sucrose-
purified rotavirus emulsified (1:1) with IFA. The PRV/ISC group was vaccinated
with 2mls containing 100|ig of inactivated sucrose-purified rotavirus, 500p,g ISCOM
matrix, and PBS making a total volume of 2mls. The PRV/MSPH group received
lOmg each of microspheres adsorbed with 136|lg of inactivated sucrose-purified
rotavirus. 40mg of microspheres were incubated overnight at 37°C with 3mls of
purified rotavirus (protein concentration was 482p.g/ml). After incubation,
microspheres were treated the same as above. Adsorption percentage was 37.6%.
All sheep were vaccinated with equal volumes of inocula in each back leg by
deep intramuscular injection.
4.2.3 Sample collection
Blood and nasal secretions were collected at initial vaccination and at 1 and 2
weeks after vaccination. At necropsy, 2-3 weeks after vaccination, intestinal
scrapings were collected.
Serum, nasal secretions, and intestinal scrapings were tested for rotavirus-
specific antibodies and total IgA and IgG concentrations by ELISA. Virus




4.3.1 Antibody responses after a low dose of rotavirus antigen
4.3.1.1 Rotavirus-specific antibodies
Rotavirus-specific IgA antibodies were present in nasal secretions from all
animals before initial vaccination. None of the vaccinated groups showed any
significant increase at 1 and 2 weeks after vaccination, although in the RV/IFA group
2 of 4 animals had marked individual increases (Fig. 4.1 and Table 4.1). Rotavirus-
specific IgA antibodies were not detected in serum at any stage (data not shown).
Rotavirus-specific IgA antibodies were present in intestinal scrapings taken at
necropsy in all animals (range: 1.0-27 units/pg IgA), but no difference in response
was detected between the groups (data not shown).
All animals had rotavirus-specific IgG antibodies in serum and nasal
secretions at initial vaccination. A significant (p<0.05) increase in serum antibody
responses was observed in the RV/IFA and RV/ISC groups 2 weeks after vaccination
(Fig. 4.2 and Table 4.2). In nasal secretions, the RV/IFA (4 of 4) and RV/ISC (3 of
4) groups had marked individual increases in rotavirus-specific IgG antibodies, but
the overall response was not significant (Fig. 4.3 and Table 4.3). Rotavirus-specific
IgG antibodies were observed in intestinal scrapings (range: 57-796 units/pg IgG),
but no significant differences were observed between the groups (data not shown).
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Rotavirus-specific IgA antibody responses in nasal secretions of each animal
after parenteral vaccination with a low antigen dose. Results expressed in
units/mg IgA.
Group/Weeks after vaccination 0 1 2
Non-vaccinated 2.9 (1.4) 1.5 (0.6) 2.31
RV 0.4 (0.2) 2.1 (1.0) l.l1
RV/IFA 0.7(1.1) 3.0(1.4) 4.0 (2.5)
RV/ISC 1.2(1.0) ND 1.8 (1.0)
RV/MSPH 0.8 (0.7) ND 1.7 (0.8)
Results given as mean with (SD) and expressed in units/mg IgA; one animal;
(vaccinated vs non-vaccinated); ND = not done
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Rotavirus-specific IgG antibody responses in serum of each animal after
parenteral vaccination with a low antigen dose. Results expressed in units/mg
IgG.
Table 4.2: Mean rotavirus-specific IgG antibody responses in serum
Group/Weeks after vaccination 0 1
Non-vaccinated 0.3 (0.2) 0.1 (0.1) 0.2 (0.1)
RV 0.1 (0.1) 0.2(0.1) 0.5 (0.4)
RV/IFA 0.6 (0.2) 2.2 (0.6) 5.4 (2.3)**
RV/ISC 1.2(1.3) ND 5.1 (2.8)**
RV/MSPH 1.1(1.4) ND 0.8 (0.6)
Results given as mean with (SD) and expressed in units/mg IgG; ** p<0.01
(vaccinated vs non-vaccinated); ND = not done
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Rotavirus-specific IgG antibody responses in nasal secretions of each animal
after parenteral vaccination with a low antigen dose. Results expressed in
units/mg IgG.
Group/Weeks after vaccination 0 1 2
Non-vaccinated 0.2 (0) 0.6 (0.4) 1.81
RV 0.1 (0) 0.1(0) 0.11
RV/IFA 0.3 (0.1) 2.6 (2.2) 7.2 (4.3)
RV/ISC 0.8 (0.9) ND 5.1 (2.8)
RV/MSPH 1.1 (1.2) ND 0.9 (0.8)
Results given as mean with (SD)
(vaccinated vs non-vaccinated); ND
and expressed
= not done
in units/mg IgG; 1' one animal;
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4.3.1.2 Neutralising titres against rotavirus
All animals had rotavirus neutralising responses in serum at initial vaccination. After
vaccination, the RV/IFA and the RV/ISC group showed a significant (p<0.05)
increase of neutralising antibodies in serum. (Table 4.6). The RV group showed
smaller increases but these were not statistically significant.
Table 4.6: Mean neutralising titres in serum
Group/Weeks after vaccination 0 1 2
Non-vaccinated 80 80 80
(40-160) (40-160) (40-160)
RV 40 160 320
(10-80) (40-160) (160-640)
RV/IFA 40 1280 5120
(10-80) (320-2560)* (640-10240)**
RV/ISC 80 ND 5120
(20-640) (640-10420)**
RV/MSPH 80 ND 80
(40-160) (40-160)
Results given as mean with (range); * p<0.05; ** P<0.01 (vaccinated vs non-
vaccinated); ND = not done
4.3.1.3 Total immunoglobulin A and G concentrations
Individual IgA concentrations varied markedly. No significant changes were
observed in serum (range: 6-101 mg/lOOmls), nasal secretions (range: 73-1310
mg/lOOmls) (Table 4.4), and intestinal scrapings (range: 0.1-2.4 mg/lOOmls) (data
not shown) between the groups after vaccination.
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Table 4.4: IgA concentrations in serum and nasal secretions
Sample Group/Weeks after vaccination 0 1 2
Serum Non-vaccinated 31(15) 25 (14) 30(15)
RV 54 (32) 40 (22) 36 (30)
RV/IFA 22 (8) 22(15) 26(16)
RV/ISC 16(9) ND 11(4)
RV/MSPH 20 (9) ND 27(17)
Nasal Non-vaccinated 839 (86) 1069 (364) 388'
RV 729 (376) 572 (392) 2481
RV/IFA 201(36) 363 (281) 297 (201)
RV/ISC 284 (53) ND 112(30)
RV/MSPH 369 (195) ND 279(99)
Results given as mean with (SD) and expressed in mg IgA/lOOmls; 1 one animal;
(vaccinated vs non-vaccinated); ND = not done
Individual IgG concentrations also varied markedly. No significant
differences were found in serum (range: 1851-6758 mg/lOOmls), nasal secretions
(range: 14-169 mg/lOOmls) (Table 4.5), and intestinal scrapings (0.01-0.2
mg/lOOmls) (data not shown) between the groups after vaccination.
Table 4.5: IgG concentrations in serum and nasal secretions
Sample Group/Weeks after vaccination 0 1 2
Serum Non-vaccinated 3534 (1016) 3060 (619) 4753 (1263)
RV 4067 (1057) 4313 (1277) 4886 (2115)
RV/IFA 2579 (1203) 2636 (688) 3299 (1355)
RV/ISC 4544(1190) ND 5059 (938)
RV/MSPH 4167 (206) ND 5086 (1024)
Nasal Non-vaccinated 45 (21) 95 (66) 27'
RV 72 (69) 47 (21) 871
RV/IFA 90 (46) 69 (37) 61 (20)
RV/ISC 64 (9) ND 32 (21)
RV/MSPH 74 (37) ND 89 (37)
Results given as mean with (SD) and expressed in mg IgG/lOOmls; 1 one animal;
(vaccinated vs non-vaccinated); ND = not done
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4.3.2 Antibody responses after a high dose of rotavirus antigen
4.3.2.1 Rotavirus-specific antibodies
Rotavirus-specific IgA antibodies were present in all animals before initial
vaccination. No significant increase was observed in the vaccinated groups, although
in the PRV/MSPH group 2 of 4 sheep had marked individual increases 1 week after
vaccination (Fig. 4.4 and Table 4.7). Rotavirus-specific IgA antibodies were not seen
in serum at any stage, but were present in intestinal scrapings (range: 1.0-15 units/(ig
IgA) with no significant differences between the groups (data not shown).
Rotavirus-specific IgG antibodies were found in serum and nasal secretions
in most animals at initial vaccination. Marked individual increases in serum
rotavirus-specific IgG antibodies were observed in the PRV/IFA (3 of 4), PRV/ISC
(2 of 4), and PRV/MSPH (2 of 4) groups, however this was only significant (p<0.05)
in the PRV/IFA group 2 weeks after vaccination (Fig. 4.5 and Table 4.8). None of
the vaccinated groups showed a significant increase in rotavirus-specific IgG
antibodies in nasal secretions, although in the PRV/ISC and PRV/MSPH groups 2
and 4 animals respectively had marked individual increases (Fig. 4.6 and Table 4.9).
No significant differences were observed in intestinal scrapings (range: 18-564
units/|ag IgG) at necropsy (data not shown).
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Rotavirus-specific IgA antibody responses in nasal secretions of each animal
after parenteral vaccination with a high antigen dose. Results expressed in
units/mg IgA.
Table 4.7: Mean rotavirus-specific IgA antibody responses in nasal secretions
Group/Weeks after vaccination 0 1 2
Non-vaccinated 2.9(1.4) 1.5 (0.6) 2.31
PRV 1.0 (0.7) 1.7 (0.3) 0.8 (0.2)
PRV/IFA 0.2(0.1) 2.1 (2.8) 0.9 (0.6)
PRV/ISC 2.1 (2.0) ND 0.7 (0.8)
PRV/MSPH 1.1 (1.7) 5.5 (2.8) 1.4(1.7)
Results given as mean with (SD) and expressed in units/mg IgA; one animal;
(vaccinated vs non-vaccinated); ND = not done
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Rotavirus-specific IgG antibody responses in serum of each animal after
parenteral vaccination with a high antigen dose. Results expressed in
units/mg IgG.
Table 4.8: Mean rotavirus-specific IgG antibody responses in serum
Group/Weeks after vaccination 0 1 2
Non-vaccinated 0.3 (0.2) 0.1 (0.1) 0.2 (0.1)
PRV 0.1 (0) 0.4 (0.2) 1.4(1.3)
PRV/IFA 0.3 (0.4) 1.0 (0.5) 7.7 (3.7)**
PRV/ISC 0.2(0.1) 12(14.9) 17(16)
PRV/MSPH 0.6 (0.5) 3.1 (1.5) 7.3 (6.7)
Results given as mean with (SD) and expressed in units/mg IgG; ** p<0.01
(vaccinated vs non-vaccinated)
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Rotavirus-specific IgG antibody responses in nasal secretions of each animal
after parenteral vaccination with a high antigen dose. Results expressed in
units/mg IgG.
Table 4.9: Mean rotavirus-specific IgG antibody responses in nasal secretions
Group/Weeks after vaccination 0 1 2
Non-vaccinated 0.2 (0) 0.6 (0.4) 1.81
PRV 0.1 (0) 0.2 (0.2) 0.4 (0.4)
PRV/IFA 0.2(0.1) 0.1(0) 0.1(0)
PRV/ISC 0.7 (0.6) ND 70 (91)
PRV/MSPH 3.5 (4.8) 14(17) 16(11)
Results given as mean with (SD)
(vaccinated vs non-vaccinated); ND
and expressed in
= not done
units/mg IgG; 1 one animal;
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4.3.2.2 Neutralising titres against rotavirus
All animals had serum neutralising responses at initial vaccination. After
vaccination, significant (p<0.05) increased levels of neutralising responses were
observed in the PRV/ISC and the PRV/MSPH vaccinated groups (Table 4.10).
Table 4.10: Mean neutralising responses in serum
Group/Weeks after vaccination 0 1 2
Non-vaccinated 80 80 80
(40-160) (40-160) (40-160)
PRV 80 80 80
(20-320) (40-160) (40-160)
PRV/IFA 80 40 80
(40-160) (20-160) (40-160)
PRV/ISV 80 1280 1280
(40-160) (320-5120)* (640-5120)*
PRV/MSPH 80 320 640
(20-160) (80-640)* (320-1280)*
Results given as mean with (SD); * p < 0.05 (vaccinated vs non-vaccinated)
4.3.2.3 Total immunoglobulin A and G concentrations
Individual IgA concentrations varied markedly. No significant changes were
observed in serum (range: 12-160 mg/lOOmls), nasal secretions (range: 155-1588
mg/lOOmls) (Table 4.11), and intestinal scrapings (range: 2.0-32 mg/lOOmls) (data
not shown) between the groups after vaccination.
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Table 4.11: IgA concentrations in serum and nasal secretions
Sample Group/Weeks after vaccination 0 1 2
Serum Non-vaccinated 31 (15) 25 (14) 30(15)
PRV 84 (53) 51 (20) 38 (5.5)
PRV/IFA 54(18) 30(12) 31 (9.6)
PRV/ISC 17 (3.1) 19 (5.9) 17 (3.6)
PRV/MSPH 36 (30) 31 (23) 35 (21)
Nasal Non-vaccinated 839 (86) 1069 (364) 388'
PRV 547(102) 483 (163) 435 (213)
PRV/IFA 899 (124) 1018 (811) 354 (56)
PRV/ISC 253 (166) ND 406 (314)
PRV/MSPH 549(407) 891 (721) 384 (84)
Results given as mean with (SD) and expressed in mg IgA/lOOmls; 1 one animal;
(vaccinated vs non-vaccinated); ND = not done
Individual IgG concentrations also varied markedly. No significant
differences were found in serum (range: 2038-9846 mg/lOOmls), nasal secretion
(range: 16-169 mg/lOOmls) (Table 4.12), and intestinal scrapings (range: 0.01-0.5
mg/lOOmls) (data not shown) between the groups after vaccination.
Table 4.12: IgG concentrations in serum and nasal secretions
Sample Group/Weeks after vaccination 0 1 2
Serum Non-vaccinated 3449(1016) 3310(575) 4753 (1263)
PRV 5572 (480) 6044(1608) 4352 (2647)
PRV/IFA 4641 (1543) 5178 (1920) 5418 (2224)
PRV/ISC 5180 (2569) 3564 (694) 6519 (2855)
PRV/MSPH 5105 (2427) 5719 (1837) 3861 (1091)
Nasal Non-vaccinated 45 (21) 95 (66) 27'
PRV 63 (7.0) 59 (21) 65(33)
PRV/IFA 43 (12) 59 (9.2) 54 (18)
PRV/ISC 45(25) ND 76 (21)
PRV/MSPH 79 (25) 79 (54) 52 (28)
Results given as mean with (SD) and expressed in mg IgG/lOOmls; 1 one animal;
(vaccinated vs non-vaccinated); ND = not done
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4.3.2.4 Summarised results of rotavirus-specific antibody responses
Summarised results of rotavirus-specific antibody responses after parenteral
vaccination are shown in Table 4.13.
Table 4.13: Summarised results of rotavirus-specific antibody responses after
parenteral vaccination
Rotavirus-specific antibody responses











+ = significant increase; - = no response; ? = no clear observation due to missing data
4.4 DISCUSSION
In general, parenteral vaccination was successful in raising rotavirus-specific
IgG antibodies or virus neutralising activity in serum and rotavirus-specific IgA
antibodies at mucosal surfaces in previously exposed animals. Similar responses
have been reported in pigs against transmissible gastroenteritis virus (TGEV) and in
humans against influenza virus following parenteral vaccination (Crouch, 1985;








Vaccination with virus lysate or purified virus alone was unsuccessful in
stimulating an immune response to rotavirus. Similar observations were seen with
parenteral vaccination of inactivated (Salk) poliovirus (Ogra et al, 1980).
After vaccination, serum rotavirus-specific IgA antibodies were not detected
in any of the vaccinated groups at any stage. In parenterally vaccinated ruminants,
the antibody response is predominantly an IgG response (Saif et al, 1984). A similar
observation was made in chapter 3.
Significant increases in serum rotavirus-specific IgG antibodies were
observed in the RV/IFA, PRV/IFA, and RV/ISC vaccinated animals. Smaller but
non-significant increases were also observed in the PRV/ISC and PRV/MSPH
vaccinated groups.
IFA was successful in boosting rotavirus-specific IgG antibodies, but no
difference in response was observed between the two antigen doses. Vaccination
with ISCOMs increased serum rotavirus-specific IgG antibodies. Similar increased
levels of virus-specific IgG antibodies were seen in mice and baboons vaccinated
parenterally with an influenza/ISCOM and rotavirus/ISCOM vaccine respectively
(Lovgren, 1988; Lovgren et al, 1990; Snodgrass et al, 1995). A dose effect was
observed and a high antigen dose correlated with an increased rotavirus-specific IgG
antibodies in serum compared to the response seen in animals given the lower
antigen dose. Microspheres were successful in boosting serum rotavirus-specific IgG
antibodies only when they were given with the higher antigen dose. The lack of
response at the low antigen dose is probably due to the small amount of rotavirus
antigen adsorbed to the microspheres. Similar observations were made in mice
vaccinated intramuscularly with microspheres and free rotavirus (Moser et al, 1996).
In previous studies on Mycobacterium tuberculosis and tetanus toxoid, purified
antigens encapsulated within microspheres were able to stimulate specific serum
antibodies after parenteral vaccination (Vordermeier et al, 1995; Singh et al, 1997).
Increased levels of rotavirus-specific IgA antibodies in nasal secretions were
observed in the RV/IFA, PRV/IFA, and PRV/MSPH vaccinated groups, but these
increases were not significant. This is probably due to the limitation of group size.
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The study described in chapter 3 showed significantly increased rotavirus-specific
IgA antibodies in nasal secretions using a standard parenteral rotavirus vaccine
(RV/LFA). No conclusion can be drawn for the ISCOM vaccinated animals due to
missing data. However, in previously exposed baboons rotavirus-specific IgA
antibodies were increased in milk after parenteral vaccination with a
rotavirus/ISCOM vaccine (Snodgrass et al, 1995).
Increased levels of rotavirus-specific IgG antibodies in nasal secretions were
observed in the RV/IFA, RV/ISC, PRV/ISC, and PRV/MSPH vaccinated animals.
Vaccination with IFA and a high antigen dose did not increase rotavirus-specific IgG
antibodies in nasal secretions while an increase in serum was seen, which could
suggest that no diffusion of antibodies from serum to nasal secretions takes place and
that these IgG antibodies are locally produced at the mucosal site. A similar
suggestion was made in chapter 3. The lack of response seen in the animals
vaccinated with the microspheres and the lower antigen dose is probably due to the
small amount of antigen adsorbed to the microspheres. A dose effect was also seen
when vaccinated with ISCOMs, a high antigen dose correlated with an increased
level of rotavirus-specific antibodies.
Significantly increased serum neutralising antibodies were detected in the
RV/IFA, RV/ISC, PRV/ISC, and PRV/MSPH vaccinated groups. The increase in
neutralising activity was observed with the standard rotavirus vaccine (RV/IFA),
while no increase in neutralising activity was seen in PRV/IFA group. This might be
due to the loss of presentation of neutralising epitopes when purified rotavirus is
emulsified with IFA and that the rotavirus antigens present in the cell culture lysate
are protected by other proteins. This could suggest that the significant increase
observed in rotavirus-specific IgG antibodies in serum in the PRV/IFA group is due
to an increase in non-neutralising VP6-specific antibodies. Increased neutralising
activity was seen when purified virus was used with ISCOMs or microspheres
suggesting that the purification process does not have an effect on the antigenic
structure.
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Total immunoglobulin levels were similar to those observed in chapter 3, no
significant changes occurred. Total immunoglobulin levels were in general higher,
except for serum IgA, than previously described (Smith et al, 1975).
This study demonstrates that parenteral vaccines can boost a rotavirus-
specific antibody response in serum and at mucosal surfaces. However different
adjuvants and antigen doses influence the immune response, with a low antigen dose,
TFA and ISCOMs cause significant increases in rotavirus-specific and neutralising
antibodies, while no response is observed with microspheres. However with a high
antigen dose, ISCOMs and microspheres induce increases in rotavirus-specific and
neutralising antibodies compared to IFA. The small number of animals in each group
had an influence on the outcome of the results. The standard parenteral rotavirus
vaccine (RV/IFA) as described in chapter 3 and in this study is efficient in inducing




EFFECTS OF DIFFERENT ADJUVANTS AND ANTIGEN DOSES
IN ORAL VACCINES ON ROTAVIRUS-SPECIFIC IMMUNITY
IN SHEEP
5.1 INTRODUCTION
Oral rotavirus vaccines are being developed for young children. The most
promising vaccines are a quadrivalent vaccine composed of three rhesus-human
genetic reassortants and a rhesus rotavirus strain, and a multivalent bovine rotavirus
genetic reassortant vaccine composed of bovine rotavirus genes and human rotavirus
genes (Bernstein et al, 1995; Clark et al, 1996a,b; Kapikian et al, 1996). However, in
animals, rotavirus vaccination is based on maternal vaccination with inactivated
rotavirus emulsified with an oil-based adjuvant (Snodgrass et al, 1980; Saif et al,
1984). Aimed at a passive transfer of maternal rotavirus neutralising antibodies via
colostrum and milk to the offspring. These maternal antibodies present in the lumen
of the neonatal intestine are an effective mediator of protection.
Oral vaccination has the advantage that the antigen is delivered at the site of
infection and a specific immune response at mucosal surfaces is induced. Several
studies have shown that oral vaccination can induce a mucosal immune response in
naive animals. Cholera toxin (CT) and ISCOMs have successfully been used as oral
adjuvants in increasing specific antibodies both systemically and locally in mice
against tetanus toxoid and influenza (Jackson et al, 1993; Ghazi et al, 1995).
Biodegradable microspheres have been reported to be a successful carrier for oral
antigen. For example one study, toxin-specific antibodies in serum and in mucosal
secretions were induced when mice were vaccinated orally with staphylococcal
enterotoxin B toxoid encapsulated in microspheres respectively (Eldridge et al, 1989;
1990). However, no evidence is available that oral vaccination in previously exposed
animals can boost the mucosal immune response.
The aim of the experiments described in this chapter was to study whether
oral vaccination can boost immune responses at mucosal surfaces. Two doses of





Non-lactating multiparous crossbred sheep were used and divided into
groups. All animals in these groups had serum neutralising antibodies to rotavirus
measured by virus neutralising assay, indicating previous natural intestinal exposure.
Sheep were divided into 8 groups (n=4 for each group) and vaccinated orally
with either inactivated rotavirus lysate (RV) (low antigen dose) or inactivated
purified rotavirus (PRV) (high antigen dose) adjuvanted with CT (RV/CT), ISCOMs
(RV/ISC; PRV/ISC) or microspheres (RV/MSPH; PRV/MSPH). Three groups were
used as controls, receiving either live rotavirus lysate (LRV), live passaged ovine
rotavirus isolate (LK923) or no treatment at all.
5.2.2 Vaccines
Rotavirus used was bovine strain UK or ovine strain K923. The bovine strain
was used either as a cell culture lysate (infectivity titre of 106'8 ffu/ml) (see 2.2.2) or
8 8
sucrose-purified (infectivity titre 10 ' ffu/ml) (see 2.2.3). The cell culture lysate was
used as a live rotavirus dose (LRV), or inactivated by the BEI method (see 2.2.4) and
adjuvanted. Protein concentrations of rotavirus lysate and purified rotavirus were
determined with a BCA™ protein assay. The ovine strain of rotavirus, K923 was
contained in faeces from the first gnotobiotic lamb passage of the Moredun strain of
lamb rotavirus (Snodgrass et al, 1976a).
The LRV and LK923 group received 5mls of rotavirus lysate and lg of faeces
diluted in 5mls PBS respectively. The RV/CT group received 500pg of CT (Sigma,
UK) mixed with 5mls of inactivated rotavirus. The RV/ISC group received 500|ig
ISCOM matrix (Iscotec, Sweden) mixed with 5mls of inactivated rotavirus. The
RV/MSPH group received lOmg each of microspheres (gift from Dr. A. Coombes,
University of Nottingham) adsorbed with 1.05mg of lysate protein. 40mg of
microspheres were incubated overnight at 37°C with 4mls of virus lysate (protein
concentration was 4.45mg/ml). After incubation, the suspension was centrifuged for
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5 minutes at maximum speed with a micro-centrifuge and washed twice with PBS.
Protein concentration was determined in supernatants to measure the adsorption of
protein to the microspheres. Adsorption percentage was 23.6%.
The PRV/ISC group was vaccinated with lOOpg of inactivated purified
rotavirus, 500|lg ISCOM matrix, and PBS making a total volume of 5mls. The
PRV/MSPH group received lOmg each of microspheres adsorbed with 136|lg of
purified rotavirus protein. 40mg of microspheres were incubated overnight at 37°C
with 3mls of purified rotavirus (protein concentration was 482|j,g/ml). After
incubation, microspheres were treated the same as above. Adsorption percentage was
37.6%.
5.2.3 Sample collection
Blood and nasal secretions were collected at initial vaccination, and then at 1
and 2 weeks post vaccination. The sheep were killed at 2-3 weeks after vaccination
and at necropsy intestinal scrapings were collected.
Serum, nasal secretions, and intestinal scrapings were tested for rotavirus-
specific antibodies and total IgA and IgG concentrations by ELISA. Virus





Rotavirus-specific IgA antibodies were present in nasal secretions at initial
vaccination. None of the vaccinated groups showed a significant increase although in
each of the RV/ISC, PRV/ISC, and RV/MSPH groups 1, 2, and 1 animal respectively
had marked individual increases (Fig 5.1 and Table 5.1). Rotavirus-specific IgA
antibodies were not observed in serum at any stage (data not shown) but were present
in intestinal scrapings (range: 1.0-61 units/pg IgA) with no differences between the
groups (data not shown).
Rotavirus-specific IgG antibodies were present in serum (Fig. 5.2 and Table
5.2), nasal secretions (Fig. 5.3 and Table 5.3), and intestinal scrapings (range: 4-354
units/pg IgG) (data not shown) but no significant differences were found between the
groups.
100




















Rotavirus-specific IgA antibody responses in nasal secretions of each animal
after oral vaccination. Results expressed in units/mg IgA.
Table 5.1: Mean rotavirus-specific IgA antibody responses in nasal secretion
GroupAVeeks after vaccination 0 1 2
Non-vaccinated 0.5 (0.1) 0.7 (0.1) 0.7 (0.8)
LRV 0.5 (0.4) 0.4 (0.4) 0.3 (0.3)
LK923 0.1 (0) 0.2 (0.2) 1.1(1.8)
RV/CT 0.9 (0.9) 0.4 (0.2) 0.5 (0.3)
RV/ISC 1.6(1.6) 2.1 (2.7) 4.2 (5.5)
PRV/ISC 0.3 (0.5) 3.5 (3.6) 0.3 (0.4)
RV/MSPH 0.5 (0.4) 1.0(1.1) 2.7 (3.9)
PRV/MSPH 1.4(1.8) 2.0(1.7) 1.7 (0.1)
Results given as mean with (SD) and expressed as units/mg IgA; (vaccinated vs non-
vaccinated)
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Rotavirus-specific IgG antibody responses in serum of each animal after oral
vaccination. Results expressed in units/mg IgG.
Table 5.2: Mean rotavirus-specific IgG antibody responses in serum
Group/Weeks after vaccination 0 1 2
Non-vaccinated 0.3 (0.4) 0.5 (0.7) 0.1 (0.1)
LRV 0.1 (0) 0.2 (0.1) 0.2 (0.1)
LK923 0.6 (0.2) 0.4 (0.1) 0.8 (0.4)
RV/CT 0.1 (0.1) 0.1 (0.1) 0.2(0.1)
RV/ISC 0.7(1.0) 0.3 (0.1) 0.3 (0.2)
PRV/ISC 0.3 (0.1) 0.2 (0.2) 0.3 (0.2)
RV/MSPH 1.0(1.2) 0.6 (0.6) 0.4 (0.4)
PRV/MSPH 0.2(0.1) 0.2 (0.1) 0.3 (0.2)
Results given as mean with (SD) and expressed as units/mg IgG; (vaccinated vs non-
vaccinated)
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Rotavirus-specific IgG antibody responses in nasal secretions of each animal
after oral vaccination. Results expressed in units/mg IgG.
Table 5.3: Mean rotavirus-specific IgG antibody responses in nasal secretions
Group/Weeks after vaccination 0 1 2
Non-vaccinated 0.4 (0.2) 1.0 (0.7) 0.4 (0.1)
LRV 0.7 (0.5) 1.3 (1.6) 0.5 (0.4)
LK923 0.6 (0.2) 0.7 (0.3) 0.8 (0.3)
RV/CT 0.4 (0.1) 0.6 (0.2) 1.5 (1.5)
RV/ISC 4.1 (4.0) 1.3 (0.6) 1.8 (1.2)
PRV/ISC 0.4 (0.3) 0.6 (0.5) 0.7 (0.7)
RV/MSPH 2.2 (0.4) 1.2(0.3) 1.2(0.3)
PRV/MSPH 1.3 (1.6) 0.2 (0.1) 3.2(3.3)











5.3.2 Neutralising titres against rotavirus
No significant differences were observed in serum (Table 5.4) between the
groups. In intestinal scrapings a low neutralising activity (VNT=10) (data not shown)
that was not affected by vaccination was observed.
Table 5.4: Mean neutralising titres in serum
Group/Weeks after vaccination 0 1 2
Non-vaccinated 80 (40-320) 80 (20-160) 80 (40-320)
LRV 40 (20-160) 40 (20-160) 80 (40-160)
LK923 40 (20-40) 40 (20-40) 80 (40-160)
RV/CT 160 (80-320) 80 (20-320) 80 (20-160)
RV/ISC 80 (40-320) 80 (40-320) 80 (40-320)
PRV/ISC 160 (80-640) 160 (80-640) 160 (80-640)
RV/MSPH 160 (20-640) 160 (20-640) 160 (20-640)
PRV/MSPH 320 (80-2560) 320 (80-2560) 320 (80-2560)
Results given as mean with (range); (vaccinated vs non-vaccinated)
5.3.3 Total immunoglobulin A and G concentrations
Individual IgA concentration varied markedly. No significant differences
were found in serum (range: 9-87 mg/lOOmls) (Table 5.4) and intestinal scrapings
(0.7-51 mg/lOOmls) (data not shown) between the groups. Increased IgA levels were
observed in the PRV/ISC and PRV/MSPH groups in nasal secretions (range: 110-
1977 mg/lOOmls) (Table 5.5) 2 weeks after vaccination, but these levels were not
significant.
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Table 5.5: IgA concentrations in serum and nasal secretions
Sample Group/Weeks after vaccination 0 1 2
Serum Non-vaccinated 59(18) 54 (24) 55 (17)
LRV 34 (35) 37 (27) 33(23)
LK923 17 (5.0) 15 (2.0) 17 (3.0)
RV/CT 33 (19) 33 (28) 27(18)
RV/ISC 43 (9.0) 32(11) 35(14)
PRV/ISC 29 (10) 19(6) 32(15)
RV/MSPH 37 (9.0) 36 (8) 33 (13)
PRV/MSPH 33 (2.0) 21 (3) 36(13)
Nasal Non-vaccinated 288 (95) 344 (265) 278(130)
LRV 522 (221) 646(171) 279 (250)
LK923 273 (62) 819 (790) 349 (78)
RV/CT 234(116) 418 (174) 651 (579)
RV/ISC 335(9) 447 (191) 328 (199)
PRV/ISC 772 (211) 718 (518) 1166 (683)
RV/MSPH 633 (596) 467 (229) 512 (456)
PRV/MSPH 800 (221) 1412(657) 1297 (909)
Results given as mean with (SD) and expressed in mg IgA/lOOmls; vaccinated vs
non-vaccinated
Individual IgG concentrations also varied markedly. No significant
differences were found in serum (range: 1484-13563 mg/lOOmls) and intestinal
scrapings (range: 0.1-1.3 mg/lOOmls) (data not shown) between the groups.
Significant increases were observed in nasal secretions (range: 28-225 mg/lOOmls)
(Table 5.6) in the PRV/ISC and PRV/MSPH groups 1-2 weeks after vaccination.
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Table 5.6: IgG concentrations in serum and nasal secretions
Sample Group/Weeks after vaccination 0 1 2
Serum Non-vaccinated 4190(1193) 4432(781) 5909(1537)
LRV 4901 (1926) 6725(1385) 6683(1272)
LK923 1846 (473) 1451(492) 1548(646)
RV/CT 6475 (1998) 6235(1427) 7583(1372)
RV/ISC 4650(1177) 6170(2766) 5548(1117)
PRV/ISC 3912 (856) 4631(3836) 4265(2556)
RV/MSPH 4879 (930) 5601(2521) 6546(2391)
PRV/MSPH 4586 (498) 2588(676) 3956(432)
Nasal Non-vaccinated 48(14) 29(14) 33 (4)
LRV 48(14) 54(19) 60 (20)
LK923 34(18) 48 (32) 37 (5)
RV/CT 65 (25) 32 (7) 43 (9)
RV/ISC 31 (62) 32(5) 47 (21)
PRV/ISC 35 (6.0) 217 (191)* 168 (77)*
RV/MSPH 40(11) 32 (9) 52 (29)
PRV/MSPH 41 (10) 234 (82)* 91 (29)
Results given as mean with (SD) and expressed in mg IgG/lOOmls; * p<0.05
(vaccinated vs non-vaccinated)
5.4 DISCUSSION
Oral vaccination was not successful in significantly boosting rotavirus-
specific antibodies and neutralising activity in serum, nasal secretions, and intestinal
scrapings. Significantly increased levels of total IgG were observed in nasal
secretions after vaccination with a high antigen dose either mixed with ISCOMs or
bound to microspheres and no response was observed with the low antigen dose.
No immune response was seen when animals received live rotavirus orally
either as a cell culture lysate or a lamb passaged strain. This finding is in accordance
with other studies where no antibody response occured after oral administration of
previously exposed humans with influenza and Salmonella typhi Ty21a respectively
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(Forrest, 1992; Moldoveanu et al, 1995). A low level of rotavirus-specific antibodies
was present before vaccination in serum, nasal secretions, and presumptively in
intestinal scrapings as nasal secretions are a good marker for the antibody status of
intestinal scrapings as described in chapter 3.
The reasons for the lack of detectable humoral immune response could be
that the rotavirus-specific antibodies present at mucosal surfaces particularly in the
intestinal lumen could be capable of preventing infection without a detectable
immune response to rotavirus. The antigenic structure of the virus could be changed
due to the harsh environment of enzymatic digestion and pH changes together with a
prolonged exposure of antigens to this environment especially in ruminants resulting
in a decreased immunogenicity (loss of critical epitopes) (Shalaby, 1995). The
dilution factor in ruminants compared to monogastric animals could influence the
concentration of antigens at the intestinal mucosa. The time of monitoring could be
critical and weekly sampling could miss an earlier humoral immune response or the
repeated exposure to rotavirus antigen could induce a state of unresponsiveness (oral
tolerance) (Mowat, 1994).
CT is reported to be a mucosal adjuvant inducing both mucosal and serum
antibodies after oral administration in naive animals (McGhee et al, 1992). The high-
affinity binding of CT, specifically the B subunits of CT to GM1 gangliosides on
intestinal epithelial cells and M cells, appears to contribute to its strong
immunogenicity (Lycke et al, 1985). CT has also the ability to serve as an adjuvant
for enhancement of mucosal and serum antibody responses to co-administered
antigens such as tetanus toxoid, bacterial proteins such as the surface fibrillar protein
of Streptococcus inutans, ovalbumin, influenza virus, sendai virus, and keyhole
limpet hemocyanin (KLH) (Lycke and Holmgren, 1986; Liang et al, 1988; Chen and
Quinnan, 1989; Dertzbaugh and Elson, 1991; Van der Heijden et al, 1991; Jackson et
al, 1993; Wu and Russell, 1994).
However, in this study CT had no effect on mucosal and serum antibody
responses after oral vaccination with inactivated rotavirus lysate. This lack of a
humoral immune response could be due to the same reasons as described when
animals were vaccinated with virus alone.
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ISCOMs have been demonstrated to be a mucosal adjuvant inducing strong
antibody responses and cellular immunity in naive animals (Lovgren, 1988; Fossum
et al, 1990). ISCOMs have successful been used intranasally in inducing protection
against influenza virus and generated high antibody levels in mice and horses
(Hannant et al, 1988; Sundquist et al, 1988; Lovgren et al, 1990). Ovalbumin given
with ISCOMs induced a wide spectrum of humoral and cellular immunity instead of
a state of oral tolerance when given alone (Mowat and Donachie, 1991; Mowat et al,
1991). However, no studies have been conducted if ISCOMs can enhance immune
responses in previously exposed animals by oral vaccination.
There was no evidence that ISCOMs had an effect on rotavirus-specific
antibody responses although a transient increase in rotavirus-specific IgA antibodies
in nasal secretions was observed. However, IgG concentrations were significantly
increased together with elevated IgA concentrations in nasal secretions when animals
were vaccinated with purified rotavirus and ISCOMs.
In this study the antigen was mixed with the ISCOMs, whereas incorporating
the antigen into the ISCOMs could improve the antigen uptake by the PP and
enhance the specific immune response (Ghazi et al, 1995). When mixed there is an
uncertainty as to whether the antigen is taken up by the PP together with the ISCOMs
or taken up by epithelial cells.
The increased levels of total IgA and IgG concentrations in nasal secretions
observed is probably stimulated by the presence of a high level of rotavirus protein
and not caused by the presence of ISCOMs as no increase was seen when ISCOMs
were given with the rotavirus lysate.
Biodegradable microspheres have been used as a mucosal adjuvant to
enhance mucosal responses to antigens such as ovalbumin and staphylococcal
enterotoxin B in naive animals (Eldridge et al, 1989; 1990; Challacombe et al, 1992).
No studies have been conducted in previously exposed animals.
Microspheres adsorbed with virus lysate or purified virus and given orally
had no significant effect on rotavirus-specific antibody responses in serum, nasal
secretions, and intestinal scrapings. However, a moderate increase in rotavirus-
specific IgA antibodies was observed in nasal secretions. A non-specific effect was
108
seen in animals vaccinated with purified virus and microspheres, they had a transient
increase in IgA concentrations together with significant increased IgG concentrations
in nasal secretions. A similar observation was noted with ISCOMs and purified virus.
This study demonstrates that it is difficult to enhance the virus-specific
immune response in previously exposed animals after oral vaccination possibly due
to reasons described earlier. An adjuvant effect was seen as ISCOMs and
microspheres vaccinated animals had a transient increase in rotavirus-specific IgA
antibodies in nasal secretions while CT vaccinated animals showed no response. The
small number of animals in each group was likely to influence the significance of the
outcome of the results. A dose effect was only observed in the total immunoglobulin
levels in nasal secretions in the ISCOMs and microspheres vaccinated animals.
These were increased in animals given the higher antigen dose. In conclusion, these
results show that there are particular difficulties in using oral vaccines to boost




CHARACTERISATION OF THE PRIMARY LOCAL AND
SYSTEMIC IMMUNE RESPONSE TO ROTAVIRUS IN
GNOTOBIOTIC LAMBS
6.1 INTRODUCTION
Natural infections of infants and young animals with rotavirus have been
correlated with protection against subsequent rotavirus disease. The immune
mechanisms responsible for resolution of the infection and protection against
subsequent challenge are not well understood. Several isolated mechanisms have
been described in chapter 1 but no clear picture has been established.
The importance of rotavirus-specific antibodies, cytotoxic T lymphocytes,
and T helper lymphocytes has been reported in several studies. The majority of these
have been conducted in mice and rabbits and some in lambs and calves (Offit and
Dudzik, 1988; 1989; Conner et al, 1991; Coulson et al, 1992; Oldham et al, 1993;
Bruce et al, 1995).
Mice inoculated with rotavirus had high antibody responses to rotavirus and
measurable cytotoxic T lymphocyte activity against syngeneic rotavirus-infected
target cells (Offit and Dudzik, 1988; 1989; McNeal and Ward, 1995; McNeal et al,
1995). These mechanisms have also been described in studies in which rotavirus-
specific antibodies passively transferred through breast milk, or passive
administration of cytotoxic T lymphocytes resulted in protection and resolution of
infection respectively (Offit and Clark, 1985; Offit et al, 1986; Dharakul et al, 1990;
Offit and Dudzik, 1990). In calves, similar observations of increased rotavirus-
specific antibodies and cytotoxic T lymphocytes after infection have been observed.
In CD8+ and CD4+ T cell-depleted gnotobiotic calves, increased levels of virus
excretion and reduced levels of faecal and serum antibody respectively were detected
(Oldham et al, 1993; Parsons et al, 1993). The importance of either effector arm in
active immunity against rotavirus has not been clarified.
This chapter aims to characterise the immune mechanisms involved after a
primary rotavirus infection in gnotobiotic lambs. Many studies on the mechanisms of
the primary immune response to rotavirus have been conducted in mice. To study
immunity to rotavirus in ruminants we used a lamb model. Gnotobiotic lambs were
used to get a clear picture of the primary immune mechanisms involved against
rotavirus and not influenced by other pathogens found in a normal environment.
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The reduced bacterial flora present in gnotobiotic lambs will affect the
immune response to orally administered antigens. Bacterial lipopolysaccharide (LPS)
affects the gut-associated lymphoid tissues resulting in enlargement of Peyer's
patches and significant expansion in the B cell zones of the follicle, with the
subsequent development of germinal centres, and thus influences the host response to
naturally encountered antigens (Pollard and Sharon, 1970, Ferguson and Parrott,
1972). Germ-free mice showed reduced humoral and cellular immune responses to
sheep erythrocytes given orally or parenterally compared to conventional mice
(MacDonald and Carter, 1979; Wannemuehler et al, 1982).
6.2 EXPERIMENTAL DESIGN
6.2.1 Animals
Gnotobiotic cross-Suffolk lambs were delivered aseptically by hysterectomy
and maintained in gnotobiotic isolator units. The lambs were divided into an infected
group and a control group.
The infected group (n=10) were infected orally at 5-6 days of age (day 0)
8 5with 1 gram of lamb faeces containing 10 ffu of a live lamb passaged ovine
rotavirus strain (K923) which was suspended in 5mls of PBS. The control group
(n=6) was given no treatment.
6.2.2 Samples
Blood and nasal secretions were sampled at regular intervals and faecal swabs
were taken daily. In the infected group, 2, 3, 2, and 3 lambs were killed at 3, 8, 10,
and 52 days after infection respectively. In the control group, 2 lambs were killed at
each of 3, 28, and 52 days after infection. At necropsy, MLNs, JPPs, IPPs, small
intestine, and intestinal scrapings were taken. Faeces were examined for the presence
of viral RNA. Blood, nasal secretions, and intestinal scrapings were tested for
rotavirus-specific antibodies and total IgA and IgG levels were measured by ELISA.
Rotavirus-specific antibody secreting cells were determined in PBLs by ELISPOT.
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Lymphocyte sub-populations and proliferation were determined in PBLs, MLNs,
JPPs, IPPs, EELs, and LPLs by FACS-analysis and lymphocyte stimulation tests
respectively. RT-PCR and hybridisation measured the expression of cytokines (IFNy,
IL-2, IL-4, and IL-6) in MLNs and JPPs.
6.3 RESULTS
6.3.1 Viral clearance
All lambs in the infected group excreted virus within 24-48 hours, cleared the
virus after 8-9 days, and showed no clinical signs of disease while in the control
group no viral RNA was detected at any stage.
6.3.2 Rotavirus-specific antibody secreting cells and antibodies
Increased numbers of rotavirus-specific IgA ASC were observed in blood
from 7 days after infection until the end of the experiment. Maximum levels were
reached 7 days after infection and declined slowly from 4 weeks after infection (Fig.
6.1). Rotavirus-specific IgA antibodies in serum were also detected from 7 days after
infection until the end of the experiment, reaching maximum levels 3-4 weeks after
infection (Fig. 6.2). In nasal secretions, rotavirus-specific IgA antibodies were seen
from 7 days after infection and showed a transient peak at 28-42 days after infection
(Fig. 6.3). In intestinal scrapings, no rotavirus-specific IgA antibodies were found in
the first 10 days after infection, however at 52 days after infection rotavirus-specific
IgA antibodies were observed in the infected group (Fig. 6.4). In the control group,
no rotavirus-specific IgA antibodies were found in serum, nasal secretions or
intestinal scrapings.
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Numbers of rotavirus-specific ASC in blood after rotavirus infection.
Results expressed in ASC/106 peripheral blood and given as mean with SD.


















Days after primary infection
42 52
Rotavirus-specific IgA antibody responses in serum after rotavirus infection.
Results expressed in units/mg IgA and given as mean with SD.
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Rotavirus-specific IgA antibody responses in nasal secretions after rotavirus
infection. Results expressed as units/mg IgA and given as mean with SD.














Days after primary infection
Rotavirus-specific IgA antibody responses in intestinal scrapings after
rotavirus infection. Results expressed in units/pg IgA and given as mean with
SD.
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Rotavirus-specific IgG ASC were detected in blood at maximum levels at 7
days after infection and remained at a constant level from 4 weeks after infection
until the end of the experiment (Fig. 6.5). Low levels of rotavirus-specific IgG
antibodies were found in serum from 14 days after infection and increased markedly
from 42 days after infection (Fig. 6.6). Rotavirus-specific IgG antibodies were
observed in nasal secretions from 14 days after infection, with a similar picture as
seen in serum (Fig. 6.7). In intestinal scrapings, no rotavirus-specific IgG antibodies
were found in the first 10 days after infection, however at 52 days after infection
rotavirus-specific IgG antibodies were present in the intestine (Fig. 6.8). The control
group had no detectable levels of rotavirus-specific IgG antibodies in serum, nasal
secretions, or intestinal scrapings.
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Days after primary infection
■ Infected
42 52
Numbers of rotavirus-specific IgG ASC in blood after rotavirus infection.
Results expressed as IgG ASC/106 peripheral blood lymphocytes and given
as mean with SD.



















Days after primary infection
42 52
Rotavirus-specific IgG antibody responses in serum after rotavirus infection.
Results expressed in units/mg IgG and given as mean with SD.
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Fig. 6.7: Mean rotavirus-specific IgG antibody responses in nasal secretions
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Days after primary infection
■ ■i.
42 52
Rotavirus-specific IgG antibody responses in nasal secretions after rotavirus
infection. Results expressed as units/mg IgG and given as mean with SD.














Days after primary infection
I Infected
Rotavirus-specific IgG antibody responses in intestinal scrapings after
rotavirus infection. Results expressed in units/pig IgG and given as mean with
SD.
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6.3.3 Neutralising titres against rotavirus
The infected group developed neutralising antibodies against rotavirus K923
in serum from 7 days post-infection while the control group had no detectable
neutralising antibodies (Fig. 6.9). Low heterotypic neutralising antibodies (maximum
VNT=10) were detected against the bovine rotavirus strain UK in the infected group
from 7 days after infection. In both groups, nasal secretions and intestinal scrapings
had no detectable neutralising antibodies against rotavirus K923 or rotavirus UK.














Days after primary infection
— Infected
42 52
Neutralising titres against K923 after rotavirus infection. Results given as
mean with SD.
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6.3.4 Total immunoglobulin A and G concentrations
No significant differences were found in total IgA concentrations in serum
after rotavirus infection between the infected (0.1 - 2.8 mg/100ml) and control
groups (0.1 - 3.1 mg/lOOml) (Fig. 6.10). In nasal secretions, the infected group (0.1 -
95 mg/100 ml) had significantly (p<0.05) increased total IgA concentrations from 21
days after infection compared to the control group (0.1 - 18 mg/100ml) (Fig. 6.11).
No significant differences were found in total IgA concentrations in intestinal
scrapings at 3 and 52 days after infection between the infected (0.1 - 3.2 mg/lOOmls)
and control groups (0.1 - 1.4 mg/lOOmls) (Fig. 6.12).
Fig. 6.10: IgA concentrations in serum
- Infected
—■- - Controls
IgA concentrations in serum after rotavirus infection. Results expressed in
mg/100ml and given as mean with SD.
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Fig. 6.11: IgA concentrations in nasal secretions
0 7 14 21 28 42 52
Days after primary infection
------ - Infected
— -Controls
IgA concentrations in nasal secretions after rotavirus infection. Results
expressed in mg/100 ml and given as mean with SD. (In control group day 42
missing).
Fig. 6.12: IgA concentrations in intestinal scrapings
4 T
3 8 10 28 52
Days after primary infection
IgA concentrations in intestinal scrapings after rotavirus infection. Results
expressed in mg/lOOmls and given as mean with SD.
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Total IgG concentrations in serum were significantly increased (p<0.05) after
rotavirus infection in the infected group (1.5-60 mg/lOOml) compared to the control
group (1.4 - 6.7 mg/100ml) (Fig. 6.13). No significant differences were found in IgG
concentrations in nasal secretions between the infected group (0.1 - 3.4 mg/ 100ml)
and control group (0.2 - 3.2 mg/lOOml) (Fig. 6.14). No significant differences were
found in intestinal scrapings at 3 and 52 days after infection between the infected
(0.01 - 0.1 mg/lOOmls) and control groups (0.01 - 0.4 mg/lOOmls) (Fig. 6.15).

















IgG concentrations in serum after rotavirus infection. Results expressed in
mg/100ml and given as mean with SD.
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Days after primary infection
42 52 — Infected
j—Controls
IgG concentrations in nasal secretions after rotavirus infection. Results
expressed in mg/100ml and given as mean with SD. (In control group day 42
missing).













Days after primary infection
52
IgG concentrations in intestinal scrapings after rotavirus infection. Results
expressed in mg/lOOmls and given as mean with SD.
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6.3.5 Proliferation of lymphocytes in blood and GALT
Peripheral blood lymphocytes from both groups responded to Con A (range
infected: 2971 ±2193 - 10041+8631; controls: 3144±808 - 13933+6955) and PWM
(range infected: 16341+11115 - 27982+6911; controls: 11664+1342 - 30694+1604)
but not to ovalbumin (data not shown) and rotavirus (Table 6.2). A moderate increase
in proliferation against rotavirus was seen in the infected group from 42 days after
infection.
Table 6.2: Rotavirus-specific lymphocyte proliferation in blood in the infected and
control group.
Day 0 7 14 21 28 42 52
Group
Infected 113+109 253+160 328+389 86+48 67+27 198+102 220+115
1.8 1.5 1.0 0.9 0.9 2.2 1.9
Controls 626+1089 297+166 141+133 296+313 67+25 527+298 ND
1.5 0.8 1.1 1.4 1.1 0.7
Results given in mean counts per minute +SD and stimulation index (stimulated
wells vs unstimulated wells); ND = not done
Lymphocytes isolated from MLNs and JPPs in both groups responded to Con
A (range MLNs: 8063+1081 - 15893+14401; JPPs: 3536+3731 - 23853+447) and
PWM (range MLNs: 13440+3818 - 24130+18248; JPPs: 9624+2586 - 31647+3823).
In both groups lymphocytes isolated from IPPs responded to Con A (range 64+23 -
454+557) or PWM (236+252 - 1264+1206). In the cultures of IELs and LPLs in both
groups no or a low response was observed to Con A (range IELs: 52+9 - 386+275;
LPLs: 55+8 - 417+456) and PWM (range IELs: 70+46 - 140+46; LPLs: 56+5 -
354+95).
Lymphocytes isolated from JPPs from the infected group responded
significantly to rotavirus at 52 days after infection, while a smaller non-significant
increase in proliferation was observed earlier at 10 days after infection (Table 6.3).
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Table 6.3: Rotavirus-specific lymphocyte proliferation in GALT in infected and
control group.
Days after 3 8 10 28 52
Group infection
Tissue












Infected JPP 794;387 314±87 1157;4367 ND 3001±2482
1.6 1.5 4.1 9.9*
Controls 291 ;364
1.3




Infected IPP 161 ;555 94±17 183;346 ND 160±6.0







Infected IEL 340; 119 123+14 107 ;317 ND 80±21
0.9 1.3 0.6 0.9
Controls 155; 130
0.7




Infected LPL 194;341 122±6.0 294;289 ND 124±55
2.3 1.3 0.8 0.8
Controls 167; 115
1.0




Results given in mean (n>2) counts per minute±SD or for each animal (n=2) and
stimulation index; * p<0.05; 1 one animal; ND = not done
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6.3.6 Phenotypic analysis of lymphocytes in blood and GALT
No significant changes in CD4+ or yS+ T cells were observed in blood between the
infected and control groups. No clear picture can be given about CD8+ T cells due to
missing values. No comparison can be made for CD45R+ cells between both groups,
but no change was observed in the infected group with time. A slight increase was
seen with time in the expression of light chain in both groups. (Table 6.4).
Table 6.4: Percentage of lymphocyte sub-populations in peripheral blood in the
infected and control group.
Days 0 7 14 21 28 42 52
after infection
Marker Groups
CD4 Infected 13 9.1 9.1 8.8 9.1 ND 9.1
(H) (4.3) (0.9) (1.5) (2.1) (0.8)
Controls 24 14 13 12 21 11.6;6.7 22.2;20.7
(12) (5.4) (2.1) (3.0) (9.4)
CD8 Infected 18 ND ND ND ND ND ND
(6.4)
Controls 16 ND ND ND ND 16.9; 10.8 14.6;11.9
(2.6)
y8TcR Infected 32 42 43 42 47 ND 26
(15) (13) (2.2) (6.5) (6.7) (0.9)
Controls 39 38 39 28 42 49.4;46.7 47.3;44.3
(5.3) (20) (13) (6.6) (16)
L chain Infected 20 19 13 7.7 24 ND 29
(3.2) (4.2) (2.5) (1.6) (5.4) (4.7)
Controls 17 16 21 27 35 41.1 ;40.1 43.7;33.0
(8.1) (6.0) (6.0) (5.9) (7.1)
CD45R Infected 19 23 14 16 23 ND ND
(14) (8.1) (0.3) (10) (5.3)
Controls 39 ND ND ND ND 40.5; 19.2 32.1;42.2
(1.3)
Results given as mean (n>2) with (SD) or from each animal (n=2); ND = not done
The CD4+ T cells decreased in MLNs and JPPs in both groups followed by
recovery. An increase was observed with time in IELs and LPLs in both groups. In
IPPs, CD4+ T cells showed a slight increase with time in both groups. No clear
picture can be drawn between both groups for the CD8+ T cells. The y8+ T cells
showed an increase in both groups in MLNs, JPPs, and IPPs with time. In the
infected group, these cells decreased with time in IELs with no changes in LPLs. An
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increase of y8+ T cells was observed in IELs and LPLs in the control group. The
expression of light chain increased with time in MLNs and IPPs in both groups while
similar levels with time were observed in IELs and LPLs for both groups. No
changes were observed in JPPs in the infected group while an increase was seen in
the control group. No clear picture is seen in CD45R+ cells in both groups due to
missing values (Table 6.5 and 6.6).
Table 6.5: Percentage of lymphocyte sub-populations in GALT in the infected group.
Days after 3 8 10 52
infection
Marker Tissue
CD4 MLN 59.2;62.5 16(1.0) 14.1 ;20.7 24(1.7)
JPP 24.0;29.7 4.8 (2.3) 4.4;6.0 18 (9.3)
IPP 2.3;1.5 2.2 (0.8) 3.6;2.7 13 (5.1)
IEL 7.5;5.8 43 (25) 75.9;62.1 63 (9.8)
LPL 51 24 (4.0) 42.1 ;28.4 38 (20)
CD8 MLN 18.3; 10.7 ND ND ND
JPP 5.9;3.2 ND ND ND
IPP 9.5;1.0 ND ND ND
IEL 17.5; 13.8 ND ND ND
LPL 141 ND ND ND
ySTcR MLN 9.3;9.6 6.2(2.1) 5.5;3.4 18 (1.2)
JPP 7.7;6.2 3.1 (1.2) 1.9;1.6 13 (3.3)
IPP 6.5;3.7 1.7 (1.2) 1.5;2.3 15 (3.5)
IEL 12.9;25.1 5.4(1.7) 10.7;9.0 5.9(1.7)
LPL 2.91 9.5 (5.6) 7.1 ;3.7 5.7 (2.7)
Light Ch. MLN 17.1;16.9 15 (4.2) 11.3; 16.5 30(1.3)
JPP 36.7;22.0 29 (8.7) 22.0;26.4 35 (8.8)
IPP 22.1; 17.2 36 (5.3) 41.5;31.2 46 (6.1)
IEL 17.1; 15.5 10(5.6) 3.8;7.7 21 (1.7)
LPL 351 18 (5.9) 17.7;11.4 23 (2.0)
CD45R MLN 23.3;46.2 43 (16) 32.7;50.5 ND
JPP 48.6;50.6 59 (20) 46.1;73.9 ND
IPP 92.9;88.3 88 (8.8) 86.1 ;91.9 ND
IEL 17.7 ;33.8 31 (6.2) 32.2;46.3 ND
LPL 311 13 (5.0) 21.1;15.9 ND
Results given as mean (n>2) with (SD) or from each animal (n=2); 'one animal;
ND = not done
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CD4 MLN 54.6;52.4 26.1; 19.7 16.5;27.3
JPP 39.9;44.4 4.0;9.2 4.4;23.7
IPP 2.3;3.2 1.3;3.7 5.3;7.5
IEL 9.5;8.0 66.6;57.8 49.3;50.8
LPL 14.7; 15.0 59.8;66.1 31.9:45.2
CD8 MLN 9.8; 15.7 ND 11.7;9.6
JPP 4.6;8.4 ND 1.8;2.3
IPP 2.3;1.5 ND 1.7;1.0
IEL 31.6; 19.5 ND 12.3;3.6
LPL 8.0;17.0 ND 4.0;5.8
y5TcR MLN 11.2;9.0 14.0; 19.8 24.4;24.6
JPP 3.0;5.1 2.8;3.0 6.8:11.6
IPP 1.8;2.1 4.1;5.7 6.0;8.4
IEL 6.5;15.4 13.4;16.4 28.8;16.7
LPL 6.2; 16.1 24.5;14.6 26.9;25.3
Light Ch. MLN 18.4;23.6 43.9;47.0 52.0;39.5
JPP 25.1 ;25.5 44.1;36.7 47.5;40.7
IPP 23.2;31.1 40.0;39.6 32.5;29.9
IEL 17.7;23.8 21.7;25.1 22.6;18.8
LPL 20.0;26.2 43.9;24.6 35.4;38.0
CD45R MLN 35.1 ;31.3 ND 65.6;57.6
JPP 51.0;35.3 ND 51.6;50.0
IPP 90.6;90.0 ND 83.2;68.0
IEL 29.3;19.5 ND 27.4;69.7
LPL 23.8;32.6 ND 33.9;36.6
Results given from each animal (n=2); ND = not done
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6.3.7 Cytokine expression of lymphocytes in JPPs and MLNs
Lymphocytes isolated from JPPs and MLNs in all animals except two
expressed GAPDH indicating a successful RT-PCR.
In JPPs, 2 of 5 infected lambs expressed mRNA for IFNy 8-10 days after
infection while in the control group, mRNA for IFNy was seen at 28 days in both
lambs. Transcripts for IL-2 were found in both groups at all time points, although no
clear bands are visible in the groups and the positive control. mRNA for IL-4 was
observed in both groups from 3 days after infection. The infected group had an
increased level compared to the control group at 3 and 52 days after infection. The
control group showed a high level of mRNA for IL-4 at 28 days. No mRNA for IL-6
was observed in either group (Plate 6.1).
In MLNs, 1 of 3 infected lambs showed mRNA for IFNy 8 days after
infection while in the control group no clear bands were observed, although 1 of 2
lambs had IFNy transcripts at 28 days. Transcripts for IL-2 were observed in both
groups, but at a lower level compared to the expression in JPPs. Transcripts for IL-4
were detected in both groups from 3 days after infection. The control group showed a
high level of expression 28 days after infection and declined at 52 days after
infection. The infected lambs showed mRNA at 8 and 10 days after infection with
high levels of IL-4 transcripts at 52 days after infection. This level of mRNA for IL-
4, 52 days after infection was higher in the infected group compared to the control
group. No clear picture can drawn for IL-6 as no clear bands are visible, however the
band intensity increased in the infected group with time (Plate 6.2).
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Plate 6.1: Cytokine expression in JPPs in the control and infected groups
Controls











£ mi• •Imm 4P •■
GAPDH and cytokine expression in lymphocytes isolated from JPPs from
infected lambs and control lambs. P = positive PCR control; N = negative
control; Controls: 1-6 (1-2, 3-4, 5-6 killed at 3, 28, and 52 days respectively);
Infected: 7-16 (7-8, 9-11, 12-13, and 14-16 killed at 3, 8, 10, and 52 days
respectively).
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Plate 6.2: Cytokine expression in MLNs in the control and infected groups
Controls Infected
P N 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
|| i JfcJI § It || AJl M. j| A a a &
GAPDH-> 4 4
GAPDH and cytokine expression in lymphocytes isolated from JPP from
infected lambs and control lambs. P = positive PCR control; N = negative
control; Controls: 1-6 (1-2, 3-4, 5-6 killed at 3, 28, and 52 days respectively);




In this study, lambs infected orally at 5-6 days of age with a live lamb
passaged ovine rotavirus strain K923 excreted rotavirus within 48 hours of infection.
The lambs showed no clinical signs (e.g., diarrhoea) and continued to excrete virus
for 6-7 days which was of a similar duration as described in a previous study
(Snodgrass et al, 1976b). However, in this study one-day-old lambs excreted virus
within a period of 24 hours. In similar studies, calves and lambs infected orally with
bovine rotavirus strains NCDV and UK respectively started virus excretion within 2-
3 and 2 days respectively. They continued to excrete virus for 5-6 and 6-7 days
respectively (Saif, 1987; Bruce et al, 1995). No virus was detected in the faeces of
the non-infected control lambs as expected.
The rotavirus-specific antibody response in serum seen in this study follows
the "classical" pattern with the appearance of specific IgA followed by specific IgG.
Similar observations have been described in humans and calves infected with
rotavirus (Hjelt et al, 1985a; 1986; Saif, 1987; Grimwood et al, 1988). In humans,
circulating rotavirus-specific IgA antibodies were detected at 1-2 weeks with the
peak recorded at 30 days after infection and these were detectable till 8 weeks after
infection (Grimwood et al, 1988; Offit et al, 1993). In the human intestine, rotavirus-
specific IgA antibodies were seen from 7 days after infection and persisted for 3-4
weeks (Davidson et al, 1983; Grimwood et al, 1988, Coulson et al, 1990). In calves,
rotavirus-specific IgA antibodies in serum were seen from 14 days after infection
with undetectable levels 5 weeks after infection (Saif, 1987). Faecal rotavirus-
specific IgA antibodies were seen from 8 days after infection (Oldham et al, 1993).
In humans, rotavirus-specific IgG antibodies were detectable from 30 days after
infection and continued to rise and were still detectable 6-12 months later. Rotavirus-
specific IgG antibodies were only occasionally detected in the intestine and may
derive from high serum antibody levels (Grimwood et al, 1988). In calves, serum
rotavirus-specific IgG antibodies were found from 14-21 days after infection in
calves and increased with time (Saif, 1987; Oldham et al, 1993).
131
The high numbers of rotavirus-specific IgG ASC observed in blood did not
correlate with high levels of circulating rotavirus-specific IgG antibodies while a
relative lower number of rotavirus-specific IgA ASC correlated with relatively
higher levels of circulating rotavirus-specific IgA antibodies. This could suggest that
the humoral immune response is dominated by a specific IgA response after an
intestinal infection.
These results demonstrate that a "classical" humoral immune response in
serum and nasal secretions is seen in lambs after infection but that other mechanisms
rather than antibodies in the intestinal lumen could be involved in viral clearance.
The finding of the common mucosal immune system described in man and various
animals is in contrast with the observation made in this study that rotavirus-specific
antibodies in nasal secretions preceded rotavirus-specific IgA antibodies in the
intestinal lumen. It is possible that these rotavirus-specific IgA antibodies reside in
the intestinal cell and were not detectable with the methods used in this study, as
described in a previous study in which mice were protected against a rotavirus
infection by intracellular intestinal non-neutralising VP6 specific antibodies (Burns
et al, 1996). The lack of rotavirus-specific IgA antibodies in the intestine could be
due to the immaturity of the IgA transport from the mucosal epithelium to the
intestinal lumen.
Homotypic neutralising titres in serum were seen from 7 days after infection
and remained at a constant level during the course of the study. Low heterotypic
neutralising antibodies against a bovine strain in serum were observed from 7 days
after infection. No neutralising antibodies were detected in nasal secretions and
intestinal scrapings during the course of the study. No neutralising antibodies were
detected in the non-infected control group as expected.
Similar observations have been made in rabbits, calves, and lambs infected
with rotavirus. A homotypic serum neutralising response was present from 7-9 days
after infection in older rabbits while in younger rabbits the presence of neutralising
titres was delayed but at 21 days after infection all rabbits had neutralising
antibodies. A heterotypic neutralising response was seen in some but not all rabbits
after primary infection (Conner et al, 1991). In calves and lambs, a homotypic
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neutralising response in serum was found from 7 days after infection (Saif, 1987;
Bruce et al, 1995). In rabbits, intestinal neutralising antibodies were detected from 5-
7 days after infection (Conner et al, 1991) which is in contrast with our finding of a
lack of neutralising antibodies at mucosal surfaces. This suggests that mechanisms
other than neutralising antibodies might be involved in virus protection as shown in
previous studies. Infection of mice with different rotavirus strains (serotype 3)
resulted in protection against subsequent challenge with EDIM, however no
neutralising antibodies against EDIM were present in the intestine (Ward et al,
1992b). Mice receiving hybridoma cells producing non-neutralising IgA VP6
specific antibodies through transplantation were protected against a rotavirus
infection. When directly administered into the lumen they were not effective (Burns
et al, 1996). These findings of previous studies and the lack of neutralising
antibodies found in this study support the hypothesis that in vivo intracellular viral
inactivation by secretory IgA during transcytosis is a possible mechanism of host
defence against rotavirus infection.
Low IgA concentrations were observed in serum, nasal secretions, and
intestinal scrapings in both groups from 3 days after infection. No IgA was detected
in serum, nasal secretions, and presumptively in intestinal scrapings at the start of the
study. In serum, total IgA concentrations increased in both groups with time with a
strong increase in the control group from 28 days after infection. In nasal secretions,
the infected group had significantly increased IgA concentrations compared to the
control group. In the infected group, a peak was observed at 42 days after infection
and correlated with the peak observed in rotavirus-specific IgA antibodies. IgA
concentrations in intestinal scrapings increased in both groups with time, however a
moderate, but insignificant, increased immunoglobulin concentration was seen in the
infected group 52 days after infection.
Low IgG concentrations were seen in serum in both groups at the start of the
study. In nasal secretions and presumptively in intestinal scrapings no IgG was
detected at the start of the experiment, but 3 days after infection low IgG
concentrations were observed in both groups. Serum IgG concentrations increased in
both groups with time but the infected group had significantly increased
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concentrations. In nasal secretions, IgG increased in both groups with time, however
the increase in the control group was delayed. IgG in intestinal secretions increased
in both groups with time.
The ELISA used in this study to determine the immunoglobulin
concentrations is more sensitive than single radial immunodiffusion (SRD) used in a
previous study (Smith, 1975; Smith et al, 1976). Using SRD, the limits of detection
were 1.2 mg/lOOmls and 2.4mg/100mls for IgG and IgA respectively while the limits
of detection for the ELISA were 0. lmg/lOOmls for both IgA and IgG.
The low immunoglobulin concentrations in serum, nasal secretions, and
intestinal scrapings in 6 day old gnotobiotic lambs are in contrast to concentrations
found in 10 day old specific pathogen free (SPF) lambs (Smith et al, 1976). These
SPF lambs had IgG concentrations 15-20xhigher in serum than observed in the
gnotobiotic lambs. The difference in concentrations could be due to the faster
colonisation of bacteria in SPF lambs compared to the limited bacterial flora with a
possible slower colonisation gnotobiotic lambs. The colonisation of bacteria might
stimulate immunoglobulin concentrations. This low or lack of total antibodies in
gnotobiotic lambs after birth confirms that no placental transfer of antibodies takes
place unlike humans (McLean and Holmes, 1980). This also suggests that the
humoral immune response has to mature after birth.
In a previous study in SPF lambs either infected intranasally with live
parainfluenza 3 virus (PI 3) or given no treatment, no serum IgA was detected (Smith
et al, 1976). Similar increases in serum IgA were observed in both the infected and
control gnotobiotic lambs, however the immunoglobulin concentrations observed
were lower or close to the detection limit of the method used with the SPF lambs.
This could explain why in the SPF lambs no serum IgA was observed. In nasal
secretions, SPF and gnotobiotic control lambs had a similar pattern of IgA
concentrations. Both infected groups had increased IgA concentrations compared to
the controls. The infected SPF lambs had an IgA level that was twice that of the
controls while the gnotobiotic lambs had a level 4-5 times that of the controls.
IgG concentrations in serum were higher in both infected groups compared to
the control groups. The two infected groups had a similar increase in IgG
concentrations in serum, however the increase in IgG in the SPF control lambs was
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higher than the one observed in the gnotobiotic control lambs probably due to the
faster colonisation of bacteria in the SPF lambs. In nasal secretions, the increase in
IgG concentrations was similar for all SPF and gnotobiotic lambs.
These results show that the measurement of immunoglobulin concentrations
by ELISA is more sensitive than SRD especially at low concentrations. The status of
the animal, gnotobiotic, SPF or conventional, or the presence of bacterial LPS, is an
important factor in the maturation of the humoral immune response. The
significantly increased IgA and IgG concentrations observed in nasal secretions and
serum respectively in the infected group could be due to the increased levels of
rotavirus-specific antibodies. The increases in IgA and IgG in the control group are
probably due to normal maturation in a gnotobiotic environment.
Peripheral blood lymphocytes from both groups responded to Con A and
PWM illustrating functional T and B cells. However, these lymphocytes did not
significantly respond to rotavirus antigen, although a moderate increase in
proliferation (stimulation index) was observed in the infected group 42 and 52 days
after infection. Cells were viable as seen in the responses to ConA and PWM. The
non-responsiveness of these PBLs to rotavirus could indicate that the number of
precursors to rotavirus is low. In contrast to this study, in gnotobiotic lambs infected
with bovine tissue culture lysate rotavirus-primed cells appeared in the blood 7-8
days after infection (Bruce et al, 1995).
In the GALT, lymphocytes from MLNs and JPPs all responded to Con A and
PWM while a lower response was observed in IPPs. The response to Con A was
lower than the response to PWM in IPPs. These results give evidence that functional
T and B cells are present in JPPs and MLNs and that IPPs have more functional B
cells than T cells as expected as PWM is mainly a B cell stimulant. No response or a
reduced response to Con A and PWM compared to MLNs was observed in IELs and
LPLs, reflecting similar observations seen in other studies (Mowat et al, 1989;
Mosley et al, 1991). This could suggest poor priming, effective suppressor
mechanisms, or activated and fully differentiated T and B cells in IELs and LPLs.
The cell viability of IELs and LPLs after culture was not examined. The lack of
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response to Con A, PWM, and rotavirus could be due to non-viable cells in these 5-
day-old cultures.
Only lymphocytes from JPPs responded to rotavirus antigen in the infected
groups. A response was seen at 10 days after infection, which was not significant, but
a significant proliferation was seen 52 days after infection. This illustrates the
development of specific effector, memory cells, and the presence of professional
APCs. No response to rotavirus was seen in the control group. The observation that
virus-primed cells were seen in JPPs was similar to a previous study in gnotobiotic
lambs infected with a bovine tissue culture lysate (Bruce et al, 1995). However, in
the previous study, virus-primed cells were seen in JPPs 7 days after infection while
in this study a response was observed 10 days after infection. This suggests that the
uptake and presentation of rotavirus via M cells seems possible (Landsverk et al,
1991) and that it is possible that the uptake and presentation of antigens takes longer
when infected with the homologous rotavirus strain. In the previous study, virus
primed cells were seen in MLNs and IPPs 7 days after infection this is in contrast
with the findings in this study. The lack of virus primed cells in MLNs could be due
to the delayed presentation of antigen in JPPs. It is likely that virus primed cells are
delayed in the MLNs and appear after 10 days. The observation of a lack of
proliferation in MLNs 52 days after infection suggests this is not the case or that
virus primed cells by-passed the MLNs and went into the circulation and no memory
cells reside within the MLNs. The non-responsiveness of MLNs to rotavirus could
also be explained due to a lack of professional APCs in these cultures. Addition of
autologous APCs and recombinant IL-2 could stimulate rotavirus antigen
presentation to lymphocytes resulting in proliferation to rotavirus (Bruce et al, 1994).
The response in IPPs observed in the previous study suggests that rotavirus-
specific memory cells have arisen at the site as a result of an unknown mode of
uptake and presentation as IPPs lack M cells. No response was seen in IPPs in this
study suggesting that IPPs are unlikely to participate in inducing a specific immune
response and that IPPs have a key function in B cell differentiation as a primary
lymphoid organ and do not participate in specific immune responses.
Few changes were observed in T and B cells in blood between the infected
and control group. No changes were seen in CD4+ and y5+ T cells with time in both
136
groups. A slight increase in the expression of light chain on B cells was seen in both
groups but this is probably due to a general increase in B cells and antibodies
observed in both groups. No clear picture can be drawn from the CD8+ T cells due to
missing data but in a previous study in lambs infected with a bovine rotavirus lysate
no changes were observed in CD8+ T cells in blood (Bruce et al, 1995). Due to
missing data, no comparison can be made from the CD45R+ cells between both
groups, however no changes were observed in the infected group with time. In the
previous study mentioned above, a significant increase in CD45R+ cells was seen 2-3
days after infection. If a similar change has occurred in this study, this change is
missed due to the weekly sampling.
In both groups, CD4+ T cells decreased in MLNs and JPPs followed by a
recovery while increases were seen in IELs and LPLs with time, this probably due to
the maturation of the immune system. Cytotoxic CD4+ T cells in humans have shown
to play a protective role against herpes simplex virus (Yasukawa and Zarling, 1984).
These cells could be involved in viral clearance. No clear picture can be drawn for
the CD8+ T cells as data is missing in both groups. This study did not examine the
activity of cytotoxic T lymphocytes so no conclusion can be made about the
involvement of CD8+cytotoxic T cells in viral clearance and protection in this study.
These cells have been shown to be important in viral clearance in infected animals
(Offit and Dudzik, 1988; London et al, 1989; Offit et al, 1991). However, these cells
are not necessary for a viral clearance as seen in several studies as (L-microglobulin
knockout mice resolve a primary infection. B-cell deficient mice, depleted of CD8+ T
cells before infection, gradually resolved a viral infection, suggesting different
mechanisms other than antibodies and CD8+ T cells could be involved (Franco and
Greenberg, 1995; McNeal and Ward, 1995). The y5+ T cells increased in MLNs,
JPPs, and IPPs in both groups while in IELs and LPLs these cells showed an increase
in the control group with time. In the infected group a decrease was observed in the
IELs with no change in LPLs with time. This decrease in the y8+ T cells in IELs in
the infected group could suggest that an increase in CD8+ T cells occurred in these
effector sites. Depletion of y8+ T cells in calves had no effect on rotavirus excretion,
suggesting that this mechanism is not important in viral clearance but the precise role
of y8+ T cells is still unclear (Oldham et al, 1993). The increased expression of light
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chain with time in MLNs in both groups, and in JPPs in the control group correlated
with the increased antibody levels found in serum and at mucosal surfaces. No
changes were observed in the JPPs in the infected group. Similar levels of expression
were found in IELs and LPLs between the groups. No conclusion can be drawn for
CD45R+ cells due to missing data but high levels were found in IPPs. The high
percentage of light chain and CD45R+ cells found in IELs could be due to
contamination by LPLs during the isolation process as B cells are relatively rare
(±10%) in IELs (Nagi and Babiuk, 1987).
In this study, no clear picture can be drawn concerning which lymphocyte
sub-population is involved in the cellular immune response after a primary rotavirus
infection. The decrease observed in the y8+ T cells in IELs in the infected groups
could suggest a possible increase in CD8+ T cells, however due to the missing values
and the lack of information of the cytotoxic activity, no conclusions can be made.
IFNy transcripts in JPPs were seen in two animals of the infected group 8-10
days after infection which could suggest a Thl-like response with the involvement of
CD8+ T cells, however no data is available in the control group at the same time
point. In MLNs, one animal of the control group had IFNy expression 28 days after
infection while one animal of the infected group had IFNy transcripts 8 days after
infection. The presence of IFNy in MLNs in the control group could be involved in
the maturation of the immune system. No clear comparison can be made between the
groups. IL-2 expression in JPPs was seen in both groups indicating activated T cells.
mRNA for IL-4 in JPPs was in greater quantities in the infected group 3 and 52 days
after infection compared to the control group suggesting a response directed towards
a Th2-like response after rotavirus infection. The increased expression of IL-4
observed in the infected group 3 days after infection is the first indication of an
immune response and preceded the rotavirus-specific ASC in serum and rotavirus-
specific antibodies in serum and nasal secretions. This high expression of IL-4 3 days
after infection could indicate an induction of B cells in the JPPs, for example a
switch from IgM+ to IgA+ B cells resulting in rotavirus-specific IgA antibodies in the
circulation from 7 days after infection. Homing to the intestinal surface probably
occurs as rotavirus-specific IgA antibodies were detected in the intestine 52 days
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after infection. Strong IL-4 mRNA expression was seen in the control group 28 days
after infection which correlates with the strong increase seen in IgA concentrations in
serum after 28 days of infection suggesting a maturation in the immune system. In
MLNs, the infected group expressed IL-4 mRNA in the first 10 days after infection
with a high expression 52 days after infection and this correlated with the rotavirus-
specific IgA antibodies observed in the intestine 52 days after infection. This
supports the hypothesis of an induction of a Th2-like immune response after
rotavirus infection. In the control group, IL-4 mRNA was expressed at all time points
but at 3 and 52 days after infection these were lower than observed in the infected
group. A similar high expression of IL-4 mRNA was seen at 28 days after infection
as in the JPPs. No expression of IL-6 mRNA was observed in JPPs and MLNs in
both groups. The data described here indicates that the primary immune response to
rotavirus is directed in favour of a Th2-like response as seen in the increased
expression of IL-4 in JPPs 3 days after infection rather than a Thl-like immune
response.
A similar observation of an immune response in favour of Th2-type activity
was seen in rats infected with Trichinella spiralis. Although cytokines of both the
Thl- and Th2-type were observed in the intestinal lymph in the first 8 days after
infection, the Th2-type cytokines were predominant. Worm expulsion was associated
with increased levels of IL-4 and IL-5 (Ramaswamy et al, 1996). In the present
study, viral clearance could not be associated with an increased level of cytokine,
although the levels of IL-4 in MLNs increased with time. Mice infected with
Heligmosomoides polygyrus showed increased expression of Th2-type cytokines
with no elevated levels of Thl-type cytokines (Svetic et al, 1993).
In the present study, the role of IFNy in a primary infection with rotavirus is
still unclear. The involvement of IFNy in a primary infection with Trichinella
spiralis in mice is also unclear due to contrasting results (Pond et al, 1989; 1991;
Grenciseta/, 1991).
This study describes the primary immune response to rotavirus in gnotobiotic
lambs. After infection, rotavirus-specific IgA ASC and antibodies preceded
rotavirus-specific IgG ASC and antibodies in blood and nasal secretions, however no
rotavirus-specific antibodies were detected in the intestinal lumen in the first 10 days
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after infection while viral clearance occurred within 8-9 days. IgA and IgG
concentrations in nasal secretions and serum respectively were significantly
increased compared to non-infected controls. Rotavirus-primed lymphocytes were
seen only in JPPs from 10 days after infection. No conclusion can be made about the
role of cytotoxic T lymphocytes in viral clearance as no data is available about CD8+
T cells and the activity of cytotoxicity was not examined. The expression of
cytokines does not indicate a role of cytotoxic T lymphocytes but favours a Th2-like
immune response. However, the mechanisms of viral clearance are still unclear.
Possible mechanisms could be: 1) intestinal intracellular rotavirus-specific IgA
antibodies as specific antibodies are detected in nasal secretions and with the
existence of a common mucosal immune system described in man and animals,
antibodies are expected in the intestine but they may reside within the cell; 2) natural
killer cell activity as NK cells have been reported to be responsible for the regulation
of cytomegalovirus infection in mice (Welsh et al, 1991); 3) CD4+ T cell cytotoxic
activity; 4) an unknown immunological method; or 5) a non-immunological method




INDUCTION OF THE MUCOSAL IMMUNE RESPONSE IN
GNOTOBIOTIC LAMBS BY VACCINATIONWITH
INACTIVATED ROTAVIRUS OR RECOMBINANT ROTAVIRUS
ANTIGENS MIXED WITH OR INCORPORATED INTO ISCOMS
7.1 INTRODUCTION
Oral rotavirus vaccines are being developed for children. The most promising
vaccines are a quadrivalent vaccine and a multivalent bovine reassortant vaccine
Bernstein et al, 1995; Clark et al, 1996a,b; Kapikian et al, 1996). In ruminants,
particularly cattle, rotavirus vaccination is based on maternal immunisation aimed at
a passive transfer of rotavirus neutralising antibodies via colostrum to the offspring
(Snodgrass et al, 1980).
Oral vaccination has the advantage that the antigen is delivered at the site of
infection and a specific immune response at mucosal surfaces is induced. ISCOMs
have successfully been used as a mucosal adjuvant with influenza virus subunits,
herpes simplex virus, measles virus fusion protein, feline leukemia virus, and
Epstein-Barr virus. Specific antibody responses or cell-mediated responses to the
viral components have been successfully induced (Osterhaus et al, 1985; Wahren et
al, 1987; Lovgren, 1988; DeVries et al, 1988; Jones et al, 1988; Morgan et al, 1988;
Sundquist et al, 1988).
Antigens used can either be incorporated into the ISCOM matrix or mixed
with the ISCOM matrix. In 1988, the first successful commercial ISCOM-based
vaccine (Iscovac Equi F, Iscotec) was available to induce protection in horses against
influenza. The vaccine was given intranasally and based on a mixture of antigens and
ISCOM matrix (Sundquist et al, 1988).
The aim of this study was to determine if one oral vaccination with
inactivated rotavirus mixed with ISCOMs or recombinant VP6 incorporated into
ISCOMs could induce immunological priming and protection against a subsequent
challenge, and to characterise the different immune mechanisms involved.
The VP6 protein was chosen to be incorporated into ISCOMs as it is the most
abundant protein of the virion, it carries antigenic determinants that are common to
all group A rotaviruses, and cross-reactivity between VP6 proteins of different
rotavirus strains has been shown in vitro in parenterally immunised mice with




Gnotobiotic cross-Suffolk lambs were maintained as described in chapter 2.
Lambs were divided into four groups. All lambs were vaccinated orally at 6-7 days
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of age, challenged 20-21 days later with 1 gram of faeces containing 10 ' ffu of live
lamb passaged ovine rotavirus strain K923 which was diluted in 5mls of PBS, and
killed 8-9 days later.
7.2.2 Vaccines
Group 1 (n=6) were vaccinated with 500|ig of ISCOM matrix (Iscotec,
Sweden) diluted in 5mls of PBS (PBS/ISC). Group 2 (n=5) received a mixture of
500flg of ISCOM matrix and 1ml of inactivated bovine rotavirus strain UK diluted in
PBS to a total volume of 5mls (RV/ISC). Group 3 (n=3) were vaccinated with 1ml of
inactivated bovine rotavirus (strain UK) diluted in 4mls of PBS (RV). The rotavirus
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given to groups 2 and 3 had a titre of 10 ffu/ml before inactivation with BEI (see
2.2.4). Group 4 (n=3) received 104p.g of recombinant VP6 (strain UK) (VP6)
(provided by Ms A. Wood and Ms. I. Campbell) incorporated into 519fig of Quil A
(kindly done by Ms A. Bellman, Iscotec, Sweden), and diluted in PBS to a total
volume of 4mls (VP6/ISC).
7.2.3 Samples
Blood and nasal secretions were taken at regular intervals and faecal swabs
were taken daily after vaccination and challenge. Lambs were killed eight or nine
days after challenge. At necropsy, MLNs, JPPs, IPPs, small intestine and intestinal
scrapings were taken.
Faeces were examined for the presence of viral RNA. Blood, nasal secretions,
and intestinal scrapings were tested for rotavirus-specific antibodies and total IgA
and IgG levels were measured by ELISA. Rotavirus-specific antibody secreting cells
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were determined in PBLs by ELISPOT. Lymphocyte sub-populations and
proliferation were determined in PBLs, MLNs, JPPs, IPPs, EELs, and LPLs by
FACS-analysis and lymphocyte stimulation tests respectively. The expression of
cytokine mRNA (IFNy, IL-2, IL-4, and IL-6) was measured in MLNs and JPPs by
RT-PCR and hybridisation.
7.3 RESULTS
7.3.1 Response after vaccination
7.3.1.1 Rotavirus-specific antibody secreting cells and antibodies
None of the groups had rotavirus-specific IgA ASC or antibodies in blood or
nasal secretions after vaccination.
Significantly (p<0.01) increased numbers of rotavirus-specific IgG ASC were
found in blood in all rotavirus vaccine groups (the RV/ISC, RV, and VP6/ISC
groups) from 7 days after vaccination (Fig. 7.1). The numbers of rotavirus-specific
IgG ASC were significantly (p<0.05) higher in the RV/ISC and RV groups than the
VP6/ISC group.
The RV/ISC and RV groups had significantly increased levels of rotavirus-
specific IgG antibodies in serum from 11 days after vaccination, but no such IgG
antibodies were found in the VP6/ISC group (Fig. 7.2). No rotavirus-specific IgG
antibodies were found in nasal secretion in any of the groups after vaccination.
No virus neutralising antibodies were found after vaccination in serum and
nasal secretions in any group.
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Numbers of rotavirus-specific IgG ASC in blood after vaccination. Results
expressed in ASC/1,000,000 peripheral blood lymphocytes and given as
mean with SD.
























Rotavirus-specific IgG antibody responses in serum after vaccination. Results
expressed in units/mg IgG and given as mean with SD.
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7.3.1.2 Total immunoglobulin A and G concentrations
IgA in serum was not detected in any lambs until 7 days after vaccination.
Thereafter all the ISCOM groups showed increases in IgA with no difference
between these groups. IgA concentrations were 2.0, 1.3, and 0.3 mg/lOOmls for the
PBS/ISC, RV/ISC, and VP6/ISC groups respectively 21 days after vaccination. The
RV group did not show any increase in IgA at any stage and had an IgA
concentration of 0.1 mg/lOOmls 21 days after vaccination (Fig. 7.3a).
In nasal secretions, IgA was not detected in any lambs until 7 days after
vaccination. Thereafter all the ISCOM groups had increased IgA concentrations with
no difference between the groups. IgA concentrations were 13.4, 22.9, and 22.4
mg/lOOmls for the PBS/ISC, RV/ISC, and VP6/ISC groups respectively 21 days after
vaccination. The RV group showed no similar increase in IgA concentration after
vaccination. An IgA concentration of 0.5 mg/lOOmls was found 21 days after
vaccination (Fig. 7.3b).
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Fig. 7.3: IgA concentrations in serum (a) and nasal secretions (b)
a)
—♦— PBS/ISC
- - -■— RV/ISC
- - * - - RV
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- - X- - VP6/ISC
IgA concentrations in serum (a) and nasal secretions (b) after vaccination.
Results expressed in mg/lOOmls and given as mean with SD.
All lambs had low IgG concentrations in serum at the start of the experiment
and showed increases in IgG in serum with time with significant (p<0.01) increases
observed in the VP6/ISC compared to the other groups. The VP6/ISC group had an
IgG concentration of 97 mg/lOOmls 21 days after vaccination while the PBS/ISC,
RV/ISC, and RV groups had IgG concentrations of 6.0, 6.3, and 8.2 mg/lOOmls
respectively (Fig. 7.4a).
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In nasal secretions, IgG was not detectable in the rotavirus vaccine groups
until 7 days after vaccination while detectable IgG in the PBS/ISC group was found
from lldays after vaccination. No differences in IgG concentrations were observed
between the groups from 11 days after vaccination. IgG concentrations were 0.5, 0.6,
0.2, and 0.4 mg/lOOmls for the PBS/ISC, RV/ISC, RV, and VP6/ISC groups
respectively 21 days after vaccination (Fig. 7.4b).














■ - * - RV/ISC
- -A- - RV



















- - * - - RV/ISC
— -A- - RV
— -X — VP6/ISC
IgG concentrations in serum (a) and nasal secretions (b) after vaccination.
Results expressed in mg/lOOmls and given as mean with SD.
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7.3.2 Responses after challenge
7.3.2.1 Viral clearance
No significant difference was observed between the groups in the time to
onset of viral excretion. The PBS/ISC group commenced excreting virus 72 hours
after challenge while the rotavirus vaccine groups started excreting virus between 48-
72 hours after challenge. The number of positive tested days was reduced to 4.0, 5.0,
and 4.7 for the RV/ISC, RV, and VP6/ISC groups respectively. However, in the
RV/ISC group the number of positive days was significantly (p<0.05) reduced than
the number of positive days (5.7) found in the PBS/ISC group, although both RV and
VP6/ISC groups had p-values of 0.11 and 0.10 respectively. The rotavirus vaccine
groups together cleared the virus in a significantly (p<0.05) reduced number of days
(7.0 days vs 9.0 days in the PBS/ISC group) (Fig. 7.4).
Fig. 7.4: Mean viral excretion in days after challenge
0123456789 10
Days after challenge
Viral excretion after vaccination and subsequent challenge. Results
expressed in days and given as mean with SD
148
7.3.2.2 Rotavirus-specific antibody secreting cells and antibodies
After challenge, rotavirus-specific IgA ASC were observed in all groups. The
RV/ISC and VP6/ISC groups had significantly (p<0.05) higher numbers of
circulating rotavirus-specific IgA ASC than the PBS/ISC group 7 days after
challenge (Fig 7.5). After challenge, rotavirus-specific IgA antibodies were detected
in serum in all groups, however no significant differences were found between the
groups (Fig. 7.6). Rotavirus-specific IgA antibodies were found in nasal secretions in
all groups and all rotavirus vaccine groups had significantly (p<0.05) higher levels 7
days after challenge than the PBS/ISC group (Fig. 7.7). After challenge, rotavirus-
specific IgA antibodies were detected in gut scrapings in all groups but at
significantly (p<0.01) higher levels in the RV/ISC and RV groups. The levels of
rotavirus-specific IgA antibodies in intestinal scrapings were much lower then
observed in serum and nasal secretions (Fig. 7.8).
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Numbers of rotavirus-specific IgA ASC in blood after challenge. Results
expressed in ASC/1,000,000 peripheral blood lymphocytes and given as
mean with SD.


















Rotavirus-specific IgA antibody responses in serum after challenge. Results
expressed in units/mg IgA and given as mean with SD.
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Fig 7.7: Mean rotavirus-specific IgA antibody responses in nasal secretions
Days after challenge
Rotavirus-specific IgA antibody responses in nasal secretions after challenge.
Results expressed in units/mg IgA and given as mean with SD.




Rotavirus-specific IgA antibody responses in gut scrapings after challenge.
Results expressed in units/(lg IgA and given as mean with SD. The intestinal
scrapings were collected at necropsy 1-2 weeks after challenge.
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All groups had increased numbers of rotavirus-specific IgG ASC in blood
after challenge with significantly (p<0.05) increased numbers in the RV/ISC and
VP6/ISC groups compared to the PBS/ISC and RV groups 7 days after challenge
(Fig. 7.9). Significantly (p<0.05) increased rotavirus-specific IgG antibodies were
detected in serum in the RV/ISC and RV groups 4 days after challenge (Fig. 7.10). In
the RV/ISC and RV groups, these rotavirus-specific IgG antibodies significantly
(p<0.05) declined afterwards while detectable levels of rotavirus-specific IgG
antibodies were observed in the PBS/ISC and VP6/ISC groups 7 days after challenge
(Fig. 7.10). In nasal secretions, significantly increased rotavirus-specific IgG
antibodies were observed in the RV/ISC and RV groups 4 days after challenge.
Detectable levels of rotavirus-specific IgG antibodies were seen in the PBS/ISC and
VP6/ISC groups 7 days after challenge (Fig 7.11). Rotavirus-specific IgG antibodies
in intestinal scrapings were only seen in the RV/ISC and RV groups with no
detectable levels found in the PBS/ISC and VP6/ISC groups (Fig. 7.12).
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Numbers of rotavirus-specific IgG ASC in blood after challenge. Results
expressed in ASC/1,000,000 cells and given as mean with SD.













Rotavirus-specific IgG antibody titres in serum after challenge. Results
expressed in units/mg IgG and given as mean with SD.
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Rotavirus-specific IgG antibody responses in nasal secretions after challenge.
Results expressed in units/mg IgG and given as mean with SD.
Fig. 7.12: Mean rotavirus-specific IgG antibody responses in gut scrapings
PBS/ISC RV/ISC RV VP6/ISC
Vaccine group
Rotavirus-specific IgG antibody responses in gut scrapings after challenge.
Results expressed in units/p,g IgG and given as mean with SD. The intestinal
scrapings were collected at necropsy 1-2 weeks after challenge.
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7.3.2.3 Neutralising titres against rotavirus
All lambs developed circulating rotavirus neutralising antibodies against
K923 7 days after challenge. The PBS/ISC, RV/ISC, RV, and the VP6/ISC groups
had mean neutralising titres (range) of 160 (80-160), 80 (20-160), 80 (40-160), and
160 (80-160) respectively, with no significant differences between the groups. A low
heterotypic response (VNT=10) was observed in serum in all groups against bovine
rotavirus (UK) No neutralising antibodies were detected in nasal secretions and
intestinal scrapings.
7.3.2.4 Total immunoglobulin A and G concentrations
All groups showed increased IgA concentrations in serum 4 days after
challenge. IgA concentrations increased to 6.3, 5.6, 7.8, and 2.1 mg/lOOmls for the
PBS/ISC, RV/ISC, RV, and VP6/ISC groups respectively 7 days after challenge (Fig.
7.13).
IgA was detected in nasal secretions before vaccination in all ISCOM groups.
All groups showed increases in IgA by 4 days after challenge, but there was no
increase thereafter. IgA concentrations were 32.1, 24.4, 5.9, and 31.2 mg/lOOmls for
the PBS/ISC, RV/ISC, RV, and VP6/ISC groups respectively 7 days after challenge
(Fig. 7.14). Individual animal concentrations varied widely in serum and nasal
secretions. No significant differences were seen between any groups at 4 and 7 days
after challenge, or between day 0 and day 4 and 7 within a group.
No significant differences in IgA concentrations in intestinal scrapings were
observed between the groups (Fig. 7.15).
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IgA concentrations in serum after challenge. Results expressed in mg/lOOmls
and given as mean with SD.



















IgA concentrations in nasal secretions after challenge. Results expressed in
mg/lOOmls and given as mean with SD.
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PBS/ISC RV/ISC RV VP6/ISC
Vaccine group
IgA concentrations in intestinal scrapings. Results expressed in mg/lOOmls
and given as mean with SD. The intestinal scrapings were collected at
necropsy 1-2 weeks after challenge.
IgG was detected before vaccination in all groups. All groups showed
increases in IgG concentrations from 4 to 7 days after challenge. The VP6/ISC group
had significantly (p<0.01) increased levels in serum compared to the other groups.
IgG concentrations were 14.3, 37.3, 32.1, and 261 mg/lOOmls for the PBS/ISC,
RV/ISC, RV, and VP6/ISC groups respectively 7 days after challenge (Fig 7.16).
In nasal secretions, IgG was detected before vaccination in all groups. No
clear increases were seen in all groups after challenge. IgG concentrations were 0.7,
1.7, 0.5, and 0.4 mg/lOOmls for the PBS/ISC, RV/ISC, RV, and VP6/ISC groups
respectively 7 days after challenge (Fig. 7.17). Individual animal concentrations
varied widely.
IgG was found in intestinal scrapings in all groups. A higher IgG
concentration was seen in the VP6/ISC group, but this was not significant (Fig. 7.18).
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IgG concentrations in serum after challenge. Results expressed in mg/lOOmls
and given as mean with SD.






IgG concentrations in nasal secretions after challenge. Results expressed in
mg/lOOmls and given as mean with SD.
158
Fig 7.18: IgG concentrations in intestinal scrapings
IgG concentrations in intestinal scrapings after challenge. Results expressed
in mg/lOOmls and given as mean with SD. The intestinal scrapings were
collected at necropsy 1-2 weeks after challenge.
7.3.2.5 Proliferation of lymphocytes in blood and GALT
Peripheral blood lymphocytes responded to Con A (range PBS/ISC:
1514± 1855 - 8183± 11353; RV/ISC: 6219±6200 - 11800±8452; RV: 1527± 1332 -
10200+13873; VP6/ISC: 5593±5894 - 13266±5037) and PWM (range PBS/ISC:
5463±5925 - 19167± 15737; RV/ISC: 8091 ±5990 - 32739±8014; RV: 7730±2568 -
33942±8119; VP6/ISC: 17685±3517 - 34078±3311) at each time point in each
group. No response was seen to ovalbumin in all groups. No response was observed
to UK in any group after vaccination, but the VP6/ISC group showed a significant
(p<0.05) proliferation 1 week after challenge compared to the other groups (Table
7.1).
159
Table 7.1: Peripheral blood lymphocyte proliferation in response to UK in vitro.
Days after 0 7 14 211 28
vaccination
Group
PBS/ISC 61 ±41 37±28 111±62 35± 14 81 ±77
0.9 0.6 0.8 0.6 1.0
RV/ISC 123 ±98 101 ± 101 383±477 40±43 100±31
0.9 1.1 0.8 1.0 0.6
RV 408±558 242±358 447±584 52±38 37± 11
1.1 1.1 0.7 1.2 0.9
VP6/ISC 607±749 164±119 54±32 77±53 605±151
1.1 1.4 1.0 1.2 2.7*
Results expressed in mean counts per minute±SD and stimulation index (stimulated
wells vs unstimulated wells); 1 = day of challenge; *=p<0.05.
GALT lymphocytes were obtained 1-2 weeks after challenge. Lymphocytes
isolated from MLNs and JPPs in all responded to Con A (range in MLNs for all
groups: 5782±472 - 25339±7839; JPPs: 2459±1841 - 13345±5205) and PWM (range
in MLNs for all groups: 10929±1890 - 25339±7839; JPPs: 10251 ±4873 -
25186± 10474). IPP lymphocytes in all groups responded to Con A (range for all
groups: 154±95 - 2202±4764) or PWM (range for all groups: 2209± 1511 -
4150±8312). IELs and LPLs from the all groups showed no response either to Con A
(range in IEL for all groups: 139±20 - 159±113;LPL: 131 ±51 - 241 ±157) or PWM
(range in IELs for all groups: 63±28 - 128±34; LPLs: 111 ±31 - 212± 134). No
response was seen to ovalbumin in all groups irrespective of tissue.
Lymphocytes isolated from JPPs from all groups responded to UK. Due to
high animal to animal variations, this was only significant in the RV/ISC and RV
groups. An increased proliferation to UK was seen in the lymphocytes isolated from
MLNs in the RV/ISC and RV groups, but this was not significant (Table 7.2).
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Table 7.2: GALT lymphocyte proliferation in response to UK in vitro 1-2 weeks
after challenge.
Tissue MLN JPP IPP IEL LPL
Group
PBS/ISC 97±50 744±1126 103±128 77±34 110±113
0.4 6.4 1.0 0.9 0.6
RV/ISC 497±794 415+164* 79±46 51 ± 19 66±32
1.7 2.0 0.7 1.0 0.6
RV 869±1035 1433±182* 169±106 86±36 90±62
5.0 12 2.5 1.5 0.3
VP6/ISC 120+76 4121±5154 86±26 84±43 79±14
0.7 6.4 1.7 1.1 0.6
Results given in mean counts per minute±SD and stimulation index; * = p<0.05.
7.3.2.6 Phenotypic analysis of lymphocytes in blood and GALT
Results are summarised in Table 7.3 and 7.4 with FACS profiles shown in the
appendix. The PBS/ISC group had significantly (p<0.05) increased CD4+ T cells in
blood after challenge compared to pre-vaccination levels while no changes were
observed in the percentage of CD8+ T cells in blood. The y8+ T cells were
significantly increased 1-3 weeks after vaccination and remained elevated after
challenge. A significantly (p<0.05 and p<0.01) increased expression of light chain
and CD45R+ cells in blood was observed after challenge. The RV/ISC group showed
a similar increase in CD4+ T cells after challenge as observed in the PBS/ISC group.
No changes were seen in the percentage CD8+ T cells. The y8+ T cells were
significantly (p<0.05) increased 2 weeks after vaccination but declined 21 days after
vaccination. After challenge, an increase was observed in the percentage of these
cells. The expression of light chain showed increases after vaccination with a
significant (p<0.05) increase compared to pre-vaccination level after challenge. The
percentage of CD45R+ cells was significantly (p<0.01) increased at 21 days after
vaccination compared to pre-vaccination levels. After challenge, similar levels were
seen between the PBS/ISC and RV/SC groups. The RV group showed a similar
pattern in CD4+ T cells as the PBS/ISC and RV/ISC groups. No changes were seen
in the percentage of CD8+ T cells compared to pre-vaccination levels. The y8+ T cells
were significantly increased 2 weeks after vaccination but declined 21 days after
vaccination. After challenge, an increase was observed in the percentage of these
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cells. The expression of light chain increased after vaccination with a significant
(p<0.05) increase compared to pre-vaccination levels seen 2 weeks after vaccination
and 1 week after challenge. The percentage of CD45R+ T cells increased
significantly (p<0.05) to similar percentages as seen in the PBS/ISC group after
challenge. The VP6/ISC group showed no changes in CD4+ and CD8+ T cells in
blood after vaccination or challenge. A significant (p<0.05) decrease in y8+ T cells
was seen 2-3 weeks after vaccination. No changes were found in the expression of
light chain. This is in contrast with the increases observed in the PBS/ISC, RV/ISC,
and RV groups. The percentage of CD45R+ cells showed no changes after
vaccination or challenge compared to pre-vaccination levels. Pre-vaccination levels
of CD45R+ cells in the VP6/ISC group were significantly (p<0.05) higher compared
to the PBS/ISC, RV/ISC, and RV groups.
Table 7.3: Mean percentage of lymphocyte sub-populations in peripheral blood in
vaccinated groups.
Days after 0 7 14 21 28
vaccination
Marker Groups
CD4 PBS/ISC 13 (6.0) 14(10) 23 (12) 16(3.9) 32 (9.5)**
RV/ISC 12(5.9) 14 (8.3) 22 (6.9) 22 (4.4) 34 (6.1)**
RV 21 (1.9) 25 (3.8) 27 (3.7) 23 (0.6) 33 (5.2)*
VP6/ISC 36 (4.9) 34(14) 35 (6.4) 36 (9.0) 37 (9.5)
CD8 PBS/ISC 24;20 30;27 14; 14 23;20 24; 19
RV/ISC 17; 15 25 ;25 17; 17 12;21 20;28
RV 27 (2.9) 28 (4.2) 15 (6.3) 14(4.0) 24(1.3)
VP6/ISC 19(4.9) 16(6.6) 17 (5.9) 16 (4.1) 18 (3.4)
ySTcR PBS/ISC 41 (8.8) 67 (10)* 69 (3.6)* 61 (5.9)* 53 (4.0)
RV/ISC 44(13) 61(13) 65 (4.3)* 45 (9.1) 62 (6.2)
RV 45 (8.8) 51 (2.7) 64 (8.6)* 51 (10) 57 (3.7)
VP6/ISC 40 (6.2) 24(15) 26 (5.4)* 24 (7.5)* 23 (11)
L chain PBS/ISC 19(5.8) 18(4.6) 24 (6.3) 26 (5.8) 41(12)*
RV/ISC 17 (6.4) 18 (5.7) 27 (9.4) 30 (9.6) 43 (7.8)*
RV 19 (2.0) 21 (2.1) 34 (4.9)* 31 (9.5) 30 (2.6)*
VP6/ISC 17(3.5) 15 (5.5) 18 (4.0) 22 (6.1) 22 (6.3)
CD45R PBS/ISC 22(12) 19(11) 17 (5.3) 21 (3.4) 42 (4.1)**
RV/ISC 21 (12) 23 (9.1) 25(11) 42 (4.9)** 42 (5.0)**
RV 27 (3.9) 36 (7.0) 33 (2.7) 26 (6.7) 44 (7.9)*
VP6/ISC 44 (5.9) 40(15) 40 (5.3) 46 (0.3) 42 (4.1)
Results given as mean (n>2) with (SD) or from each animal (n<2); * = p<0.05; ** =
p<0.01 (vaccination/challenge levels vs pre-vaccination (baseline) levels within one
group)
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The percentage of CD4+ T cells was significantly (p<0.05) higher in MLNs in
both the RV and VP6/ISC groups and in JPPs in the VP6/ISC group compared to the
PBS/ISC group. The VP6/ISC group had a significantly (p<0.01) lower percentage of
CD4+ T cells in IELs and LPLs compared to the PBS/ISC group. Similar percentages
were observed in IPPs between the groups. No differences were seen in the
percentage of CD8+ T cells in MLNs, JPPs, and IPPs while in IELs and LPLs the
VP6/ISC group had a significantly (p<0.05) higher percentage compered to the
PBS/ISC group. The percentage of yb+ T cells was significantly (p<0.05) lower in
MLNs, JPPs, IPPs, IELs and LPLs in the VP6/ISC group than the PBS/ISC group.
The expression of light chain was similar in MLNs, JPPs, and IELs in all groups,
however in IPPs and LPLs the VP6/ISC group had a significantly (p<0.05) lower
percentage compared to the PBS/ISC group. The VP6/ISC group had a significantly
(p<0.05) higher percentage of CD45R+ cells in MLNs than the PBS/ISC group while
a significantly (p<0.05) lower percentage was seen in IELs. No differences in the
percentage of CD45R+ cells were seen in JPPs, IPPs, and LPLs between the groups
(Table 7.4).
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Table 7.4: Mean percentage of lymphocyte sub-populations in GALT in vaccinated
and challenged groups 1-2 weeks after challenge.
Marker CD4 CD8 y5TcR L Chain CD45R
Tissue Groups
MLN PBS/ISC 24 (6.6) 33;33 19 (4.6) 32(12) 42 (13)
RV/ISC 24(14) 17;32 15 (6.8) 35 (4.8) 52 (8.6)
RV 40 (4.5)* 43 (4.6) 21 (8.4) 29 (5.2) 54 (4.3)
VP6/ISC 48 (8.5)* 37(11) 4.6(1.2)* 24 (3.4) 66 (5.2)*
JPP PBS/ISC 19(11) 13; 15 17 (6.0) 44 (20) 58 (16)
RV/ISC 23 (8.1) 22;22 14 (7.4) 37(12) 64(11)
RV 20 (4.1) 12(3.1) 8.4 (4.0) 34(10) 43 (13)
VP6/ISC 42 (4.1)* 24(18) 2.7 (0.6)* 20 (6.5) 62(12)
IPP PBS/ISC 16(11) 8.1;19 14(5.2) 57 (19) 85 (6.1)
RV/ISC 13 (6.5) 17;6.2 13 (7.4) 51 (8.9) 81 (9.9)
RV 23 (5.5) 9.0 (4.1) 18 (6.0) 62 (3.7) 92 (4.0)
VP6/ISC 10(11) 7.0 (7.6) 2.6 (0.5)* 28 (5.0)* 85 (13)
IEL PBS/ISC 46 (20) 30;27 21 (4.6) 26(13) 42 (9.1)
RV/ISC 50(15) 25;22 21 (7.6) 19(4.6) 45 (4.1)
RV 54 (32) 30 (2.5) 19(15) 18(1.1) 44 (0.9)
VP6/ISC 4.1 (2.0)** 48 (12)* 7.3 (2.7)* 14(3.0) 30 (2.7)*
LPL PBS/ISC 36(12) 34;34 20 (7.7) 28 (7.0) 32 (7.3)
RV/ISC 38 (4.8) 25;32 20 (5.4) 28 (5.7) 30 (8.4)
RV 44 (14) 19(9.7) 22 (7.2) 24 (2.4) 28 (6.2)
VP6/ISC 7.6 (4.8)** 46 (7.2)* 9.2 (4.4)* 14(5.9)* 30 (9.5)
Results given as mean (n>2) with (SD) or from each animal (n<2); * = p<0.05;
** = p<0.01 (rotavirus vaccinated groups vs PBS/ISC group)
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7.3.2.7 Cytokine expression of lymphocytes in JPPs and MLNs
GAPDH expression was seen in all JPPs. In MLNs, GADPH expression was
seen in all animals except in animal no. 10. GAPDH expression indicates a valid RT-
PCR and if no GAPDH expression was seen, animals were excluded from results.
In JPPs, IFNy transcripts were seen in 4 of 6 animals from the PBS/ISC
group, 1 of 5 animals from the RV/ISC group and in all animals from the RV and
VP6/ISC groups. The RV/ISC group had a significant (p<0.05) suppression of IFNy.
Transcripts for IL-2 were found in the ISCOM-vaccinated groups while no clear
expression was observed in the RV group. IL-4 and IL-6 transcripts were seen in 4 of
5 animals from the RV/ISC group and in all animals from the PBS/ISC, RV, and
VP6/ISC groups (Plate 7.1).
In MLNs, no clear picture can be drawn about the expression of IFNy as no
clear bands are visible in test samples as seen in JPPs. Faint IL-2 transcripts were
seen in all groups although no clear bands were visible in both test and positive
samples. No transcripts for IL-4 were seen in any group. IL-6 expression was seen in
all groups, although the PBS/ISC group had a significant (p<0.05) lower expression
of IL-6 than the other groups (Plate 7.2).
165
Plate 7.1: Cytokine expression in JPPs in the vaccinated and challenged groups
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GAPDH and cytokine expression in lymphocytes isolated from JPPs from
vaccinated and challenged groups. P = positive PCR control; N = negative
control; PBS/ISC: 1-6; RV/ISC: 7-11; RV: 12-14; VP6/ISC: 15-17.
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Plate 7.2: Cytokine expression in MLNs in the vaccinated and challenged groups
PBS/ISC RV/ISC RV VP6/ISC
P N 1 23456 789 10 11 12 13 14 15 16 17






. It ' - «
IL-4 ►
IL-6 -► » i» it ill
GAPDH and cytokine expression in lymphocytes isolated from MLNs from
vaccinated and challenged groups. P = positive PCR control; N = negative
control; PBS/ISC: 1-6; RV/ISC: 7-11; RV: 12-14; VP6/ISC: 15-17.
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7.4 DISCUSSION
In this study, lambs were vaccinated orally at 6-7 days of age either with a
single dose of PBS mixed with ISCOMs, RV mixed with ISCOMs, RV alone or
recombinant VP6 incorporated into ISCOMs. The PBS/ISC group showed no
specific response. Rotavirus-specific IgG ASC in blood were observed in the
RV/ISC, RV, and VP6/ISC groups 7 days after vaccination with declining numbers
from 14 days. The RV/ISC and RV groups had three times more rotavirus-specific
IgG ASC than the VP6/ISC group. Circulating rotavirus-specific IgG antibodies were
detected in the RV/ISC and RV groups from 11 days after vaccination. No rotavirus-
specific IgG antibodies were seen in the VP6/ISC group reflecting the lower numbers
of IgG ASC. No vaccination regime induced any rotavirus-specific IgA ASC or
antibodies. All 3 viral and subunits vaccines primed the immune system as observed
in increases in rotavirus-specific IgG ASC and antibodies. Rotavirus-specific IgG
ASC preceded rotavirus-specific IgG antibodies in blood indicating that cell
trafficking occurred after mucosal priming from the intestine to the circulation
compartment.
In previous studies, mice given a single oral dose of lOOpg ovalbumin
incorporated into ISCOMs showed a specific IgG response, although the levels were
generally low. No specific IgA response was observed after one dose, however when
given 3 or 6 doses, a specific IgA response was seen. The most critical factor in
inducing a specific IgA response was the number and/or frequency of vaccinations
rather than the antigen dose. This may reflect the need for repeated stimulation of a
relatively small number of specific-precursors to obtain and/or maintain a specific
mucosal IgA response (Mowat et al, 1991; 1993).
A rotavirus-specific IgG response was seen in serum in mice vaccinated
orally with inactivated whole rotavirus incorporated into microspheres. No rotavirus-
specific IgA was found in serum and intestinal scrapings after vaccination. No
response was seen in mice vaccinated with the same amount of free rotavirus
(Khoury et al, 1995). This is in contrast with the observation seen in the present
study.
The lack of virus-specific IgA after one vaccination was similar to the
observation seen in mice vaccinated orally with influenza subunits incorporated into
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ISCOMs (Ghazi et al, 1995). No specific IgA antibodies in the intestine or serum
were seen in mice vaccinated orally with tetanus toxoid and cholera toxin. A similar
specific IgG response was seen in serum after one oral dose (Jackson et al, 1993).
In a previous study in which horses were vaccinated intranasally with whole
inactivated influenza virus incorporated into ISCOMs or virus alone, a significantly
higher antibody response was seen in the horses vaccinated with the incorporated
antigen (Mumford et al, 1994). In contrast to the present study the group given
recombinant VP6 incorporated into ISCOMs had a lower antibody response than the
given rotavirus mixed with ISCOMs or rotavirus alone. In the present study the
major inner core protein (VP6), a non-neutralising antigen, was incorporated and not
the whole virus including the neutralising antigens. The presence of neutralising
antigens in a vaccine could explain the higher antibody response after vaccination
compared to a vaccine composed of non-neutralising antigens.
No IgA was detected in serum and nasal secretions in any group at the start of
the study. Low detectable immunoglobulin levels were observed in nasal secretions
and serum in all groups from 3 and 7 days after vaccination respectively. IgA
concentrations increased in all groups after vaccination. The ISCOM vaccinated
groups had higher IgA concentrations in serum and nasal secretions 21 days after
vaccination compared to the RV group, but this difference was not significant. IgA
concentrations in serum in any vaccinated group were similar to those observed in
the infected and control groups (see chapter 6) in the first 21 days after
vaccination/infection. In nasal secretions, the ISCOM vaccinated groups had IgA
concentrations which were 2-3 times lower as seen in the infected group. The RV
group had similar levels than the control group, which were lower than the ISCOM
vaccinated and infected groups.
Low detectable IgG concentrations were observed in all groups at the start of
the study. No IgG was found in nasal secretions and presumptively in intestinal
scrapings at the start of the study but low detectable levels were seen from 7 days
after vaccination. In serum, the VP6/ISC groups had significantly increased IgG
concentrations compared to the other groups. In nasal secretions, no differences in
IgG concentrations were seen between the groups after vaccination. IgG
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concentrations found in serum in the PBS/ISC, RV/ISC, and RV vaccinated group
were 2-3 times lower than observed in the infected group 21 days after
vaccination/infection. The control group had concentrations, which were 2-3 times
lower than observed in these three vaccinated groups. The VP6/ISC group had levels
5 times higher than observed in the infected group. A similar observation of
significantly increased concentrations was seen in sheep vaccinated orally with
ISCOMs and a high antigen dose as observed in chapter 5. In nasal secretions, the
infected group had increased IgG compared to the vaccinated and control groups 21
days after vaccination/infection.
After birth, total IgA and IgG increased with time in serum and at mucosal
surfaces due to the maturation of the immune system and the bacterial colonisation of
the gut as described for the control group in chapter 6.
ISCOMs have a non-specific effect on total IgA concentrations in nasal
secretions. Vaccination of the animal, especially when the antigen is incorporated
into ISCOMs has an enhancing effect on total IgG concentrations in serum.
Vaccinated lambs were challenged with a live Iamb passaged ovine strain
K923, 3 weeks after vaccination. All vaccinated lambs commenced excreting virus
between 48-72 hours after challenge which was 48 hours later than observed in a
study in which one-day-old lambs were infected (Snodgrass et al, 1976b). The
PBS/ISC, RV/ISC, RV, and VP6/ISC groups excreted virus for an average of 5.7,
4.0, 5.0, and 4.7 days respectively. Lambs given the rotavirus vaccines were partially
protected after one single dose as seen in a reduced period of virus excretion
compared to the PBS/ISC group. A significant reduction in the virus excretion period
was seen only in the RV/ISC group. The small number of animals in the RV and
VP6/ISC groups influenced the outcome of the results as seen in the low p-values. It
is possible that bigger groups could show a significantly reduced period of virus
excretion and that multiple vaccine doses could induce full protection. However,
multiple doses of a vaccine comprising antigen (rotavirus) alone could induce oral
tolerance (Mowat, 1994).
In a previous study, no protection was seen in mice vaccinated intranasally
with a single dose of influenza subunits incorporated into ISCOMs and challenged 3
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weeks later with live influenza virus. All mice had detectable live virus in the lungs.
No clear picture could be given about the excretion period as mice were killed 3 days
after challenge (Ben Ahmeida et al, 1993).
Age resistance has been shown in 12 day-old lambs which excreted virus for
only 1-2 days following a primary infection (Snodgrass et al, 1976b). A similar age
resistance was not seen in the present study in the PBS/ISC vaccinated group maybe
due to a different breed of lambs or a different antigen dose.
Rotavirus-specific IgA ASC and antibodies were detected in blood and
rotavirus-specific IgA antibodies in nasal secretions in all groups after challenge. The
RV/ISC and VP6/ISC groups had a significantly increased number of ASC in blood
with differences observed in rotavirus-specific IgA antibodies in serum. In nasal
secretions, the RV/ISC, RV, VP6/ISC groups had significantly higher levels of
rotavirus-specific IgA antibodies. Rotavirus-specific IgA antibodies appeared first in
serum followed by nasal secretions. In the intestine, the RV/ISC and RV groups had
significantly higher levels of rotavirus-specific IgA antibodies. Virus-specific IgA
ASC and antibodies were seen only after infection/challenge with a live virulent
virus strain.
Rotavirus-specific IgG ASC were boosted after challenge with significantly
higher numbers found in the RV/ISC and VP6/ISC groups. Rotavirus-specific IgG
antibodies were seen in all groups but the RV/ISC and RV groups had significantly
higher levels at 4 days after challenge. In nasal secretions, all groups had rotavirus-
specific IgG antibodies but the RV/ISC and the RV group had significantly higher
levels. Rotavirus-specific IgG antibodies in the intestine were only seen in the
RV/ISC and RV groups. The RV/ISC and RV groups showed a secondary IgG
response as seen in rapidly increased levels at 4 days while the PBS/ISC and
VP6/ISC groups had a slower humoral immune response with detectable levels 7
days after challenge.
The high numbers of rotavirus-specific IgG ASC did not correlate with high
levels of rotavirus-specific IgG antibodies in blood. However, high numbers of
rotavirus-specific IgA ASC correlated with high levels of rotavirus-specific IgA
antibodies in blood. This could suggest that an IgA response is dominant after a
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mucosal infection with live virus despite mucosal priming after vaccination. A
similar observation was reported in chapter 6 in lambs after a primary infection with
live rotavirus.
The presence of rotavirus-specific antibodies in the intestine 1-2 weeks after
challenge is in contrast to the lack of rotavirus-specific antibodies in lambs infected
with rotavirus (see chapter 6). The presence of rotavirus-specific antibodies in the
intestine in the rotavirus vaccine groups is probably due to maturation of the immune
system.
The significantly increased rotavirus-specific IgA antibodies in the intestine
and rotavirus-specific IgG antibodies in serum, nasal secretions, and intestine
observed in the RV/ISC and RV groups after challenge is probably due to
immunological priming after vaccination. B cells are absolutely necessary for the
development of immunity to rotavirus as specific antibodies are essential in viral
clearance when reinfected (Franco and Greenberg, 1995; Franco et al, 1997a). The
significantly increased specific antibody response observed in the RV/ISC and RV
groups could suggest a similar finding as these groups are reinfected with rotavirus.
Priming also occurred in the VP6/ISC group, although to a lesser degree. The fact
that whole rotavirus was used in the RV/ISC and RV groups rather than the VP6
protein could explain this difference in priming.
No rotavirus-neutralising antibodies in serum and nasal secretions were seen
in any group after vaccination. After challenge, all groups developed neutralising
antibodies against the challenge strain K923 1 week after challenge but no significant
differences were found between the groups. Low heterotypic neutralising antibodies
were seen against the bovine rotavirus strain UK.
No neutralising antibodies were detected in nasal secretions and gut scrapings
1 week after challenge while rotavirus-specific antibodies were present at mucosal
surfaces. This could indicate that the neutralising activity might be effected during
transport of these secretory IgA antibodies by epithelial cells or the secretory
component of these antibodies could influence the neutralising activity in the lumen.
Mice primed parenterally with the same recombinant VP6 antigen emulsified
with Freunds complete adjuvant (CFA) and boosted with rotavirus strain UK
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emulsified in IFA, showed significantly increased neutralising antibodies 1-2 weeks
after boosting compared to mice primed with PBS in CFA and boosted as above
(Bruce et al, unpublished data). In the present study, lambs were killed 1-2 weeks
after challenge with the last sampling 7 days after challenge. It is possible that we
missed this boosted neutralising response in the primed groups due to either the time
of killing, a different immune response in sheep compared to mice, or that CFA
might be better in inducing serum neutralising antibodies than ISCOMs.
The lack of neutralising antibodies in the intestine indicates that a mechanism
other than neutralising antibodies is responsible for viral clearance.
IgA concentrations in serum and nasal secretions increased in all groups after
challenge with no significant differences seen between the groups. No significant
differences were seen in intestinal scrapings. All vaccinated groups had boosted IgA
concentrations in serum 1 week after challenge compared to the infected and control
groups at the same point in the experiment (28 days after infection/vaccination) (see
chapter 6). In nasal secretions, the RV group had similar concentrations of IgA to the
control group while in the PBS/ISC, RV/ISC, and VP6/ISC groups, concentrations
were 2-3 times lower as seen in the infected group.
IgG concentrations increased in all groups in serum after challenge but
significantly increased IgG concentrations were only seen in the VP6/ISC group. In
nasal secretions, no increase in IgG concentrations was observed in all groups after
challenge. No differences in IgG concentrations were seen in intestinal scrapings
between the groups after challenge. In serum, IgG concentrations in the PBS/ISC,
RV/ISC, and RV groups were similar as observed in the infected group, however the
VP6/ISC group had a level 7-10 times higher. In nasal secretions, all vaccinated
groups had similar concentrations to the infected and control groups. The observation
that the significantly higher IgG concentrations in serum in the VP6/ISC group did
not correlate with significantly higher IgG concentrations in nasal secretions and
intestinal scrapings might suggest that IgG antibodies at mucosal surfaces are
produced locally and not by transudation from serum.
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Rotavirus-primed lymphocytes were not detected in blood in any group after
vaccination, but were seen in the VP6/ISC group 1 week after challenge. Mice fed
single doses of 50-lOOp.g ovalbumin in ISCOMs were able to generate systemic T
cell immunity (Mowat et al, 1991). The lack of response in the PBS/ISC, RV/ISC,
and RV groups together with the response seen in the VP6/ISC group could suggest
that vaccines comprising a mixture of antigens and ISCOMs are taken up within
different cells at different sites within the intestine. In the VP6/ISC group, uptake of
antigens and ISCOMs is likely to occur at the same place due to the incorporation of
the antigen into the ISCOMs. This could suggest that different mechanisms of
antigen presentation and priming are taking place in the VP6/ISC group compared to
the PBS/ISC, RV/ISC, and RV groups. Epithelial cells could play an important role
in antigen presentation and the priming of T and B lymphocytes when the vaccine is
a mixture of antigen and adjuvant. When antigen incorporated vaccines are used, M
cells in the JPPs could play an essential role in antigen presentation and priming.
Lymphocytes from MLNs and JPPs from all groups responded to Con A and
PWM indicating the presence of functional T and B cells. In IPP, lymphocytes in all
groups responded less to Con A than PWM, which was expected, as PWM is mainly
a B cell stimulant and IPP consists of mainly B cells. No response to Con A and
PWM was observed in IELs and LPLs and this was consistent with the observation
reported in chapter 6 in which a similar lack of response was seen to Con A and
PWM in IELs and LPLs. The lack of response in the IEL and LPL population to any
antigen could be due to the lack of viable cells in these cultures.
Lymphocytes from JPPs from all groups responded to UK. This was only
significant in the RV/ISC and RV groups. No significance response was observed in
the other two groups due to high animal-to-animal variations within a group. In
MLNs, an increased proliferation was seen in the RV/ISC and RV groups, however
this was not significant. This together with the finding of increased rotavirus-specific
antibodies in these two groups could suggest that a Th2-like immune response was
induced after vaccination.
In the PBS/ISC, RV/ISC, and RV groups, the proportion of CD4+ T cells
significantly increased in blood after challenge, but no clear picture of the VP6/ISC
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group was evident due to a high percentage observed at the start the study. This
increase in CD4+ T cells in blood correlates with the big increase in rotavirus-
specific antibodies in serum after challenge. No changes were seen in CD8+ T cells
in all groups after vaccination or challenge. y8+ T cells significantly increased in the
PBS/ISC after vaccination and remained elevated after challenge. In the RV/ISC and
RV groups, yS+ T cells significantly increased after vaccination but a decline was
observed in the percentage of y8+ T cells 21 days after vaccination. After challenge,
the percentage of these cells increased in both groups. This decline in y8+ T cells in
the RV/ISC and RV groups could be a result of homing. The percentage of y8+ T
cells were significantly decreased in the VP6/ISC group after vaccination and
remained at a similar level after challenge. The precise role of y8+ T cells is still
unclear but they may be involved with the maturation of the immune system or they
could have a cytotoxic role as an increase in these cells was observed in the RV/ISC
and RV groups after challenge (Goodman and Lefrancois, 1988). In a previous study,
depletion of y8+ T cells had no effect on the virus excretion in calves infected with
rotavirus suggesting that these cells are not important in viral excretion (Oldham et
al, 1993). However, in another study in calves infected with rotavirus, y8+ T cells
were involved in a rotavirus-specific immune response (Parsons et al, 1993). The
expression of light chain increased in the PBS/ISC, RV/ISC, and RV groups after
vaccination with significant increases in all three groups after challenge compared to
pre-vaccination levels. This is probably due to a general increase in B cells and
antibodies. No increase was seen in the VP6/ISC group and this was in contrast with
the significantly increased IgG antibodies in serum observed in this group. The
RV/ISC group had significant increases in CD45R+ cells after vaccination whilst in
the PBS/ISC and RV groups increases were seen after challenge. No changes were
seen in CD45R+ cells in the VP6/ISC group as a high percentage was observed at the
start of the experiment.
In this study, the total percentage of the different lymphocyte markers in
blood usually exceeded 100%. A possible explanation could be the fact that
lymphocytes can express more cell surface markers. It has been shown that naive
ovine CD4+ T cells also express CD45R. This could influence the total percentage of
cells, as these CD4+ T cells will be analysed twice. The percentage of these cells in
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these lambs will be high at the start of the experiment, as they have not been exposed
to antigens. However, after antigen stimulation in vitro naive CD4+ T cells showed a
decreased expression of CD45R; a phenotypic change that also occurs when naive T
cells undergo transition to memory cells in vivo (MacKay et al, 1990). It had been
shown in sheep that y8+ T cells also can express CD8 however at a lower level than
aP+ T cells (MacKay et al, 1990). When bronchoalveolar lavage fluid lymphocytes
obtained from sheep were stimulated in vitro with Con A, the co-expression of CD4
and CD8 increased (Begara, 1994). In this study, a clear answer about double-
positives in the lambs used in this experiment can not be given as no two-colour
immunofluorescence analyses were done. However double-positives have been
shown in sheep so they could have had an influence on the total percentage of
lymphocytes or technical reasons could have been the cause of total percentages
exceeding 100%.
The percentage of CD4+ T cells was significantly higher in MLNs in the RV
and VP6/ISC groups and in JPPs in the VP6/ISC group, whilst in EELs and LPLs a
significantly lower percentage was observed in the VP6/ISC group than in the
PBS/ISC group. No changes were found in IPPs between the groups. The percentage
of CD8+ T cells in MLNs, JPPs, and IPPs was similar for all groups. In IELs and
LPLs, the VP6/ISC group had a significantly higher percentage than the PBS/ISC
group. This observation correlates with the lower percentage of CD4+ T cells
observed in IELs and LPLs in this group suggesting a bigger involvement of CD8+ T
cells in this group. The VP6/ISC group had significantly lower y8+ T cells in MLNs,
JPPs, IPPs, IELs, and LPLs than the PBS/ISC group, which correlates with the lower
levels seen in blood. No differences were observed in IELs and LPLs between the
groups. The expression of light chain was similar in MLNs, JPPs, and IELs for all
groups. In IPPs and LPLs, the VP6/ISC group had a significantly lower percentage.
The lower expression of light chain in LPLs reflects the lower expression observed in
blood in this group. The percentage for CD45R+ cells was similar in all tissues for all
groups, although the VP6/ISC group had a significantly higher percentage in MLNs
and a significantly lower percentage in IELs.
In this study, the lymphocyte sub-populations in each group could suggest
that different mechanisms were involved in viral clearance. The immune response in
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the VP6/ISC group is in favour of Th 1 -like response with the involvement of CD8+ T
cells in IELs. In the PBS/ISC, RV/ISC, and RV groups there was no clear indication
of a Th 1 - or Th2-like immune response.
IFNy transcripts in JPPs were seen in the PBS/ISC, RV, and VP6/ISC groups.
In the RV/ISC group, a significant down-regulation of IFNy was seen, as 4 of 5
samples showed no expression. In MLNs, no distinct bands were visible for IFNy.
This could suggest that in the RV/ISC group viral clearance is not dependent on a
Thl-like response. The observation of IFNy expression in the VP6/ISC group
correlates with the increased percentage of CD8+ T cells observed in IELs. The
ISCOM groups had mRNA for IL-2 in JPPs whilst faint bands were observed in
MLNs. This could suggest that ISCOMs are a stimulant for IL-2 expression.
Transcripts for IL-4 were seen JPPs without any clear differences and no expression
of IL-4 was seen in MLNs. All groups had IL-6 expression in JPPs. In MLNs, the
PBS/ISC group had a significantly lower expression of IL-6 than the other groups
that could indicate that rotavirus vaccination induces increased expression of IL-6.
A down-regulation of IFNy as in the RV/ISC groups was also seen in mice
infected with Shistosoma mansoni. These mice also showed elevated Th2-type
responses (Pearce et al, 1991). Mice vaccinated either with inactivated respiratory
syncytial virus (RSV) or live RSV showed different cytokine profiles after a
subsequent challenge. Vaccination with inactivated RSV resulted in a predominantly
Th2- type response while vaccination with live virus gave a predominantly Thl-type
response after challenge (Tang et al, 1997). In a previous study, feeding mice
ovalbumin in ISCOMs primed CD4+ T cell responses in JPPs of both the Thl- and
Th2-type (Maloy et al, 1995). A similar observation was seen in the present study.
The cytokine expression could suggest that both Thl- and Th2-like immune
responses were involved in the PBS/ISC, RV, and VP6/ISC groups while a Th2-like
immune response is involved in the RV/ISC groups.
This study describes the effect of vaccination with a single oral dose of
PBS/ISC, RV/ISC, RV, and VP6/ISC on the immune response in lambs against a
subsequent challenge. Quantitative differences in response between the VP6/ISC
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group and other groups are difficult to interpret due to the impossibility of comparing
the different vaccine doses. However, qualitative differences are apparent.
After vaccination, priming occurred in the RV/ISC, RV, and VP6/ISC groups
resulting in partial protection against a subsequent challenge as seen in a reduced
period of viral clearance. Immunological priming was adequate without ISCOMs.
Different mechanisms were likely to be induced when different vaccines were used
as seen in the tested parameters. No clear picture is available for the PBS/ISC group
as evidence for both Thl- and Th2-like responses were seen. The RV/ISC group
favours a Th2-like response as a down-regulation of IFNy and increased rotavirus-
specific antibodies were observed. The RV group showed both Thl- and Th2-like
responses and no clear conclusion can be made. A Thl-like response was seen in the
VP6/ISC group as seen in the expression of IFNy together with a significantly higher
percentage of CD8+ T cells in IELs, although no information is available about the
cytotoxic activity of these cells.
The study shows that the VP6 protein is a good inducer of both Thl- and
Th2-cells as seen in increased CD4+ T cells in MLNs and JPPs together with the
presence of mRNA for IFNy and IL-4 in lymphocytes isolated from these tissues. Th
cell responses against the VP6 protein have also been observed in spleen cells from
mice, parenterally inoculated with a bovine rotavirus strain and/or a porcine rotavirus
strain (Bruce et al, 1994; Banos et al, 1997).
Several immune mechanisms could be induced after vaccination with the
VP6 protein. A cytotoxic immune response could be involved, and may be related to
the increased percentage of CD8+ T cells found in IELs. Mice vaccinated with
plasmid DNA encoding the VP6 protein showed virus-specific cytotoxic T cell
responses (Chen et al, 1997). Mice given hybridomas excreting VP6 specific
antibodies were protected against rotavirus infection by blocking virus replication in
the intestinal epithelium; these antibodies were not active in the intestinal lumen
(Burns et al, 1996). The protective mechanism induced in this study could be
intracellular non-neutralising rotavirus VP6 specific IgA antibodies as no
neutralising antibodies were present at mucosal surfaces. A similar mechanism was
also suggested in mice vaccinated with plasmid DNA encoding the VP6 protein
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which had significant reductions in viral excretion after a subsequent rotavirus
infection (Chen et al, 1997).
Vaccination with VP6 was partially protective as a reduced virus excretion
(p=0.10) was observed. In this study, a single dose was given. It is possible that when
multiple doses are given, full protection could be achieved. The small number of
animals used in this study could have influenced the results.
The VP6 protein has the potential to be used in a subunit vaccine, as it is the
most abundant protein of the virion and it carriers antigenic determinants that are
common to all group A rotaviruses. Cross-reactivity between VP6 proteins of
different rotavirus strains has been shown in vitro in parenterally immunised mice
with rotavirus (Bruce et al, 1994; Banos et al, 1997).
In this study, ISCOMs were used as a mucosal adjuvant although
immunological priming was adequate without ISCOMs. A significant reduction in
viral excretion that was only observed in the group given whole virus mixed with
ISCOMs. However, the groups given the subunit vaccine or inert rotavirus alone
showed a reduced virus excretion but the small number in the group influenced the





Diarrhoeal diseases have a world-wide impact on both human and animal
health and are a major cause of morbidity and mortality. Rotavirus is the most
important agent of viral gastroenteritis in children and young animals, accounting for
approximately 870,000 human deaths annually and substantial economic losses in the
agricultural business. Rotavirus infects the gastrointestinal tract, a mucosal surface.
Mucosal surfaces are the main entry port of infections and the gut associated
lymphoid tissues play an important role in mucosal immunity.
Induction or boosting of mucosal immunity is crucial for protection against
these mucosal infections or reinfections and the local immune response can be
mediated by different components. The humoral specific effector mechanisms could
involve locally produced secretory IgA, or IgG derived from serum or possibly
locally produced. The cellular effector mechanisms could involve cytotoxic T
lymphocytes, helper T lymphocytes or natural killer cells.
This study concerns parenteral and oral vaccination against rotavirus in adult
sheep using different antigen doses and adjuvants, oral vaccination in gnotobiotic
lambs to induce immunological priming and protection against a subsequent
challenge, and the characterisation of the primary immune response against rotavirus
in lambs.
Parenteral vaccines are not very effective at inducing a mucosal immune
response in naive animals. However, in previously exposed humans and animals
parenteral vaccination can induce or boost an immune response at mucosal surfaces
(Saif and Bohl, 1980; Svennerholm, 1980). Oral vaccines have the advantage that
antigen is delivered to the site of infection and may induce specific mucosal immune
responses in naive animals and could boost mucosal immune responses in previously
exposed animals.
A detailed characterisation of the mucosal immune response against rotavirus
is not available although several mechanisms have been shown to be involved, such
as cytotoxic T lymphocytes, T helper lymphocytes, and rotavirus-specific antibodies
(Offit and Dudzik, 1988; 1989; Conner et al, 1991; Coulson et al, 1992; Oldham et
al, 1993).
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A commercial rotavirus dam vaccine for ruminants is available based on
rotavirus lysate emulsified with an oil-based adjuvant such as IFA (Wells et al, 1978;
Snodgrass et al, 1980; Castrucci et al, 1984; Saif et al, 1984; Archambault et al,
1988; Mostl and Burke, 1988; Bellinzoni et al, 1989). This vaccination relies on the
passive transfer of maternal rotavirus neutralising antibodies via colostrum and milk
to the offspring. These maternal antibodies absorbed into the circulation but mainly
present in the lumen of the neonatal intestine are an effective mediator of protection.
Parenteral vaccination could also be useful in boosting mucosal immune responses in
the elderly for protection against reinfection.
A parenteral vaccine based on the commercial rotavirus dam vaccine, a
mixture of rotavirus lysate and IFA, was able to stimulate rotavirus-specific secretory
IgA responses at mucosal surfaces in adult sheep, although they were short-lived,
and systemic rotavirus-specific antibody responses. In humans, specific ASC induced
by parenteral vaccination with Salmonella typhi Ty21a were mostly directed to the
systemic compartment although a part of the specific ASC had mucosal homing
attitudes (Kantele et al, 1997). A similar observation was observed in this study in
which the majority of rotavirus-specific antibodies were associated with the systemic
compartment. The response seen in nasal secretions could reflect the response seen
at the intestinal surface. Stimulation of IgA antibodies in the intestine and other
mucosal surfaces such as the respiratory tract could increase protection against
reinfection by a mucosal pathogen.
Parenteral vaccines could be used against endemic enteric infections. Firstly,
aimed at a passive transfer of immunity from the adult to the offspring. Secondly
aimed at an increased level of specific IgA antibodies at mucosal surfaces to protect
against those infections which are clinically important in adults such as bovine
coronavirus in cows and Escherichia coli in Traveller's diarrhoea in humans.
Parenteral vaccines could be a potential alternative to oral vaccines especially in
adults.
Parenteral vaccination with different antigen doses could influence the
immune response while the use of other adjuvants could be more favourable as IFA
has known side effects. At a low rotavirus antigen dose, ISCOMs and IFA were
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successful as adjuvants in inducing antibody responses while at a high rotavirus
antigen dose, ISCOMs and microspheres induced antibody responses. Increases were
seen in rotavirus-specific IgA antibodies in nasal secretions although no differences
were observed in rotavirus-specific antibodies in intestinal scrapings. A dose effect
was observed in rotavirus-specific IgG antibodies in serum and nasal secretions,
however this was not significant. The small numbers in each group may have
influenced the outcome of results. Further research with larger groups should be
conducted to test if these preparations can stimulate rotavirus-specific IgA antibodies
at mucosal surfaces and if rotavirus vaccines can be improved using a higher antigen
load.
Oral vaccination of adult sheep using different antigen doses and adjuvants
had no significant effect on the immune response although transient increases in
rotavirus-specific IgA antibodies were observed in nasal secretions in animals
vaccinated either with ISCOMs or microspheres. The possibility exists that the
response was short-lived and this was missed in this study due the time of sampling.
Oral vaccination in sheep was not effective with the vaccines used although
different types of vaccines and antigen presentations could be more successful. For
example incorporating the antigen into the adjuvant could have a more significant
effect on the immune response. In this circumstance antigens are more protected
against the environment and both antigens and adjuvant are taken up at the same
place. This might not be the case when antigens and adjuvants are mixed, with the
possibility of different routes of uptake being used.
Protection of the young ruminant against natural rotavirus infection is based
on passively derived maternal neutralising antibodies mainly present in the intestinal
lumen through the feeding of colostrum and milk. Increased maternal neutralising
antibodies in colostrum is achieved by parenterally vaccinating the dam (Snodgrass
et al, 1980; Castrucci et al, 1984; Bellinzoni et al, 1989).
Parenteral priming of the young could induce a suppression of the specific
humoral immune response when subsequently challenged. This was observed in a
previous study in which mice and piglets showed a lack of intestinal specific F4
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antibodies upon challenge with live F4+ Escherichia coli after parenteral priming
with killed Escherichia coli F4 bacteria (Bianchi et al, 1996).
Oral vaccinations have the advantage that antigens are delivered to the site of
infection and induce an active local immunity. Several mucosal adjuvants such as
ISCOMs, cholera toxin, and microspheres have been shown to enhance the immune
response as antigens given alone are often poorly immunogenic and may provoke
oral tolerance when given as multiple doses (Mowat, 1994).
ISCOMs were used as a mucosal adjuvant to induce immunological priming
and protective immunity in gnotobiotic lambs against a subsequent challenge with
live virulent rotavirus. Rotavirus antigens were given orally either mixed with or
incorporated into the ISCOMs. Vaccines comprised either rotavirus lysate mixed
with ISCOMs, rotavirus alone, or a recombinant VP6 protein incorporated into
ISCOMs and resulted in immunological priming and partial protection against a
subsequent challenge. The only significant reduction in viral clearance was seen in
the group vaccinated with rotavirus mixed with ISCOMs. Reductions in viral
clearance were also seen in the group given rotavirus alone and in the group given a
vaccine comprising recombinant VP6 incorporated into ISCOMs. The small numbers
in the last two groups influenced the outcome of the results.
Different protective immunological mechanisms were induced when the
different vaccines were used. In the non-vaccinated group both Thl- and Th2-like
responses were seen. Similar observations were seen in the group given rotavirus
alone. Rotavirus mixed with ISCOMs induced a Th2-like response while the group
given recombinant VP6 protein incorporated into ISCOMs induced mainly a Thl-
like response.
All groups had rotavirus-specific IgA antibodies present in the intestine at
necropsy however; these were non-neutralising while neutralising antibodies were
seen in circulation. Several hypotheses can be made about the lack of neutralising
activity of these intestinal secretory antibodies. The neutralising activity might be
affected during transport of these secretory IgA antibodies by epithelial cells or the
secretory component of these antibodies could influence the neutralising activity in
the lumen.
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Lambs were given a single oral dose of vaccine although multiple doses have
been reported to induce greater protection. Mice given two doses of an intranasal
influenza/ISCOM vaccine were relatively more protected against challenge than
mice given one dose (Ghazi et al, 1995). It is unclear if multiple doses would induce
full protection in lambs and this should be investigated further.
The reduced viral clearance observed when recombinant VP6 was used in the
vaccine could be of great importance as all group A rotaviruses share common VP6
epitopes and this could have potential for a future vaccine. Mice parenterally
immunised with a bovine or porcine rotavirus strain had Th cells in the spleen which
showed responses against the VP6 proteins of other rotavirus strains (Bruce et al,
1994; Banos et al, 1997). Similar cross-reactivity was seen here as the recombinant
VP6 antigen was based on the bovine rotavirus UK strain while the challenge virus
was an ovine rotavirus strain K923. Mice vaccinated with plasmid DNA encoding for
VP6 showed significant reductions in viral excretion (Chen et al, 1997).
To complete this study more groups should be included. Groups given whole
rotavirus antigen incorporated into ISCOMs, VP6 given as a mixture with ISCOMs,
and groups given multiple doses of the vaccines used with the emphasis on the VP6
vaccines. Although, the potential of inert rotavirus as a vaccine should also be further
examined. The observation of neutralising activity in circulation with a lack of
neutralising activity in the gut should be further investigated.
Characterisation of the primary immune response in gnotobiotic lambs after a
rotavirus infection showed a "classical" primary humoral immune response.
Rotavirus-specific IgA antibodies preceded rotavirus-specific IgG antibodies. These
antibodies were seen in serum and nasal secretions after infection while rotavirus-
specific antibodies were not detected in the gut in the first 10 days after infection.
The virus was cleared within 8-9 days. Infection with rotavirus increased IgA and
IgG concentrations in nasal secretions and serum respectively. The predicted
involvement of cytotoxic T cells was not investigated due to technical reasons.
However, the cytokine expression results did not indicate a Thl-like immune
response involved in viral clearance but favoured a Th2-like immune response as
rotavirus-specific antibodies were present in the intestine after the first 10 days of
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infection. Antibodies are essential in protection against reinfection (Franco and
Greenberg, 1995; Franco et al, 1997a).
The precise mechanisms of viral clearance are still unclear although several
mechanisms could be involved. Intestinal intracellular non-neutralising rotavirus-
specific IgA antibodies have been suggested by recent studies but the relevance to
this case is not known (Burns et al, 1996; Chen et al, 1997). Further research has to
determine the role of these intracellular IgA antibodies. The role of cytotoxic T cells
is still unclear as tests are difficult to perform because of a lack of available target
cells, but the effectiveness of cytotoxic T cells has been reported in mice (Dharakul,
1990; Offit and Dudzik, 1990). Other cells such as natural killer cells or cytotoxic
CD4+ T cells could play a role in viral clearance.
This study tried to characterise the primary immune response in lambs against
rotavirus. A few mechanisms are suggested but more research has to be done to
determine the importance of each mechanism involved in viral clearance. Viral
clearance is very likely to be the result of several specific mechanisms. More animals
should be included to determine when rotavirus-specific antibodies appear in the
intestinal lumen.
In summary, parenteral vaccination in previously exposed sheep with
RV/IFA induced significantly increased systemic immune responses and of more
importance significantly boosted rotavirus-specific IgA antibodies at mucosal
surfaces.
A clear adjuvant effect was observed in humoral immune response between
the adjuvants used at each antigen dose. IFA and ISCOMs were more successful at a
low antigen dose then microspheres, while at the high antigen dose ISCOMs and
microspheres proved to be more successful. No significant effect was observed on
rotavirus-specific IgA antibodies at mucosal surfaces and no significant dose effect
was seen on the level of rotavirus-specific antibodies but these could be due to the
small numbers in each group.
Oral vaccination in previously-exposed sheep was not successful in
increasing rotavirus-specific antibodies either in circulation or at mucosal surfaces,
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however a single oral vaccination with inactivated virus in gnotobiotic lambs resulted
in partial protection against subsequent challenge. Partial protection was seen in the
groups given rotavirus lysate mixed with ISCOMs, rotavirus lysate alone, or
recombinant VP6 incorporated into ISCOMs, however this was only significant in
the rotavirus/ISCOM group. Different immune mechanisms were induced when
different vaccines were used each resulting in partial protection although the small
number in each group influenced the outcome of the results. Partial protection was
not a result of neutralising antibodies as no neutralising activity was detected in the
gut. Vaccination with recombinant VP6 incorporated into ISCOMs could be
important in the future for vaccine development as all group A rotaviruses have the
same epitopes on the VP6 antigen.
In laboratory animals (e.g., SCID and knockout mice), several immune
mechanisms have been identified but the role of each component in the primary
immune response is still unclear. The primary immune response to rotavirus in
gnotobiotic lambs is more complex as a clear mechanism was not characterised and
protection is probably a result of multiple immune mechanisms acting together.
Several possible mechanisms are being suggested but the role of each should be
further investigated especially in an out-bred population.
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199 M/M: 5mls 10% Yeast extract, 5mls 0.1M glutamine, 5mls amphotericin B,
7mls 8% sodium carbonate, 3.75mls 0.1M sodium hydroxide, 5mls 2.5M hepes,
50mls lactalbumin hydrolysate, 50mls 5% bovine serum albumin, 50mls 199 lOx
medium with Earle's Salts (Gibco, UK), and made till 500mls with distilled water.
PBS lOx: 800g NaCl, 115g Na2HP04, 20g KC1, and 20g KH2P04 are dissolved in 10
litres of distilled water and diluted 1/10 in distilled water before use.
OPD-SUBSTRATE: 60mg of G-phenylenediamine dihydrochloride (Sigma, UK) is
dissolved 75mls in OPD-buffer (OPD-buffer: 4.64g (w/v) of citric acid and 7.33g
(w/v) disodium hydrogen ortophosphate anhydrous is dissolved in lOOOmls of
distilled water), prior to use 60pl of a 30% (w/w) hydrogen peroxidase (H202) is
added.
AEC-SUBSTRATE: 1 tablet of 3-amino-9-ethylcarbazole (AEC) (Sigma, UK) is
dissolved in 2.5mls of N,N-dimethyl-formamide (Sigma, UK) and added to 47.5mls
of AEC-buffer (AEC-buffer: 14.8mls of a 0.2M acetic acid solution and 35.2mls of a
0.2M sodium acetate solution was added to 50mls of distilled water). The substrate
suspension is filtered twice through two 0.45]um filters. Prior to use 35pl of 30%
H202 was added to suspension.
SDS-EXTRACTION BUFFER: l%(w/v) sodium dodecyl sulphate (SDS) (BDH,
UK) is dissolved in lxextraction buffer (lOxextraction buffer: 11.69g of sodium
chloride, 2.42g Tris, and 0.74g EDTA is dissolved in 200mls of distilled water).
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RNA-EXTRACTION BUFFER: 5mls of a sterile 250mM sodium citrate solution
(pH 7.0) was added to 23.6g guanidine isothiocynate (Sigma, UK) and made up to
47mls of distilled water and mixed well before addition of 2.5mls of a 10% (w/v)
sodium lauroyl sarcosine solution (Sigma, UK) and 0.36ml of a 14.2M stock of £-
mercaptoethanol (Sigma, UK).
IOxMOPS BUFFER: buffer containing 0.2M MOPS [3-(N-morpholino)
propanesulfonic acid], 50mM sodium acetate, and lOmM EDTA, this was brought to
pH 7.0 and autoclaved.
RNA-UOADING BUFFER: buffer containing 0.75ml of formamide, 0.15ml of
10XMOPS buffer, 0.24ml of 37% (w/v) formaldehyde solution, 0.1ml of glycerol,
0.1ml of a 10% (w/v) bromophenol blue solution, 0.01ml of a lOmg/ml stock
solution of ethidium bromide, and 0.1ml of distilled water.
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FACS PROFILES
FACS profiles of the different monoclonal antibodies on PBLs.
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PBLs from lamb W1153 (PBS/ISC group) 1 week after challenge.
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FACS PROFILES
FACS profiles of the different monoclonal antibodies on JPPs.
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JPPs from lamb W1154 (RV/ISC group) 1-2 weeks after challenge.
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FACS PROFILES
FACS profiles of the different monoclonal antibodies on IELs.
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FACS PROFILES
FACS profiles of the different monoclonal antibodies on LPLs.
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